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SUMMARY
1. The effects of endothelin-1 (ET-1), a novel 21 amino acid peptide, were examined 
on isolated tracheal smooth muscle. Tracheal chains, prepared from the trachea of both 
rat and guinea-pig, were cumulatively dosed with ET-1 (0.01-1|J,M) following 
construction of a cumulative concentration response curve to the reference contractile 
agonist, carbachol (CCh, 0.1-100pM). The mechanism of action and modulation of the 
ET-1 induced response on tracheal smooth muscle, by various agents has been 
examined.
2. On rat tracheal smooth muscle cumulative dosing with ET-1 (0.01-IjiM), induced 
a consistent contractile response with a calculated EC^Q value of 0.22 ± 0.085|iM and a
maximum contractile tension induced by IgM ET-1 of 0.67 ± 0.090g. In contrast, the 
response of guinea-pig tracheal smooth muscle to cumulative dosing with ET-1 was 
variable. ET-1 induced a biphasic response, a transient relaxation which was followed 
by a contractile response. Calculation of EC50 values (1.59 ±  0.37|liM) was only 
possible in those tissues which displayed concentration response curves >50% M  
whereas in others, the response achieved only 25-30% of the maximum contractile 
tension induced by CCh and in these tissues the relaxation responses were more 
prevalent.
3. Incubation of both rat and guinea-pig tracheal smooth muscle with 10|iM of 
bestatin, captopril, phosphoramidon or thiorphan failed to affect the ET-1 induced 
response, indicating that ET-1 is not a substrate for the aminopeptidase, angiotensin 
converting and neutral endopepddase enzymes on tracheal smooth muscle.
4. Incubation of both rat and guinea-pig tracheal smooth muscle in a reduced Ca%+ 
containing buffer had no effect on the ET-1 induced contractile responses in either
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preparation, but did potentiate the relaxation responses induced by 0.05|iM, 0.5jiM and 
l(iM ET-1 on guinea-pig tracheal smooth muscle.
5. In the presence of IOjiM nicardipine, the ET-1 induced response on rat tracheal 
smooth muscle was attenuated, demonstrating that influx of extracellular Ca^+ via the 
dihydropyridine Ca^+ channels is necessary for the full expression of constrictor 
activity. On guinea-pig tracheal smooth muscle however, preincubation with 
nicardipine had no effect on the ET-1 induced relaxant and contractile responses, 
suggesting that influx of extracellular Ca^+ via the dihydropyridine sensitive Ca^+ 
channels is not essential for the constrictor activity of ET-1 in this tissue preparation.
6. Incubation of rat tracheal smooth muscle with 25|iM indomethacin prior to 
exposure to ET-1, had no effect on the ET-1 induced response, indicating that the 
cyclooxygenase metabolites of arachidonic acid have no part in the response induced by 
the peptide. In contrast, in the presence of 25fiM indomethacin, the ET-1 induced 
relaxation responses observed on guinea-pig tracheal smooth muscle were abolished 
and the contractile response potentiated. It is therefore suggested that the ET-1 induced 
relaxation responses are mediated by the ET-1 induced release of the relaxant products 
of the cyclooxygenase enzyme which limit the constrictor activity of the peptide in this 
tissue preparation.
7. Removal of the tracheal epithelium from the tracheal smooth muscle of the rat and 
guinea-pig had no effect on the subsequent response to the peptide, indicating that the 
tracheal epithelium does not modulate the ET-1 induced effects. However, 
preincubation of epithelium denuded guinea-pig tracheal tissues with indomethacin 
abolished the ET-1 induced relaxation responses and produced a concentration response 
curve with a much steeper relationship than that observed on epithelium intact tissues in 
the presence of indomethacin. These observations suggest that 5 the tracheal smooth
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muscle releases indomethacin sensitive and the epithelium indomethacin insensitive!
relaxant factors ijin response to ET-1, which then limit the constrictor action of the peptide.
8. The response of rat tracheal smooth muscle to ET-1 was unaffected by 
preincubation with the lipoxygenase enzyme inhibitor nordihydroguaiaretic acid 
(NDGA) (10|iM), indicating the non-involvement of the lipoxygenase metabolites of 
arachidonic acid in the ET-1 induced response, whereas, preincubation of guinea-pig 
tracheal smooth muscle with NDGA resulted in a marked inhibition of the ET-1 induced 
contractile response, indicating that the lipoxygenase metabolites of arachidonic acid are 
intimately involved in the contractile response.
9. Rat tracheal smooth muscle was insensitive to the actions of platelet activating 
factor (PAF) and therefore the effects of the PAF antagonist [ 1 -O-Hexadecyl-2-acetyl- 
sn-glycero-3phospho(N,N,N-trimethyl)hexanolamine] were not evaluated. On guinea- 
pig tracheal smooth muscle, PAF induced relaxation responses which were sensitive to 
the actions of InM PAF antagonist. The contractile responses induced by ET-1 were 
unaffected by preincubation with the PAF antagonist (InM) indicating the non­
involvement of PAF. In contrast, the ET-1 induced relaxation responses were 
potentiated at the higher concentrations of the peptide.
10. Repeat cumulative dosing with ET-1 (0.01-l|iM) on both rat and guinea-pig 
tracheal smooth muscle resulted in a marked attenuation of the contractile response, 
indicating that ET-1 induces tachyphylaxis on repeat dosing. On guinea-pig tracheal 
tissues however, the degree of tachyphylaxis was dependent on the initial response to 
the peptide; those tissues where the initial response ET-1 was less than 50% of the 
maximum contractile tension induced by CCh, displayed no tachyphylaxis, whereas 
those tissues which displayed good contractile responses on the initial exposure to the 
peptide, exhibited marked tachyphylaxis upon repeat dosing.
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11. Repeat single dosing with ET-1 (0.05, 0.5 and IgM) on rat tracheal smooth 
muscle showed tachyphylaxis, the degree of tachyphylaxis was greatest at the higher 
concentrations of the peptide. Repeat single dosing with ET-1 (0.05, 0.5 and IgM) on 
guinea-pig tracheal smooth muscle induced variable responses. At 0.05gM ET-1 no 
tachyphylaxis was observed; at 0.5gM ET-1 tachyphylaxis to the ET-1 induced 
relaxation responses only was observed; at IgM ET-1 tachyphylaxis to the ET-1 
induced contractile responses was observed. In the presence of indomethacin the 
relaxant responses were abolished and the potentiated contractile responses displayed 
marked tachyphylaxis, the higher the concentration of ET-1, the greater the degree of 
tachyphylaxis.
12. Binding studies performed with [125i]ET-l indicated the presence of saturable 
binding sites for the peptide on the tracheal smooth muscle of both the rat and the 
guinea-pig, however, such studies were limited by the high degree of non-specific 
binding. Increasing the concentration of protein used potentiated the saturable binding 
and reduced the non-specific binding to an acceptable level in rat tissues, whereas only 
a slight potentiation of saturablebinding was observed with the guinea-pig.
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CHAPTER 1 
INTRODUCTION
17
1.1 GENERAL INTRODUCTION
It has long been recognised that the vascular endothelium plays an important role in the 
regulation of vascular smooth muscle tone, by releasing various vasoactive substances. 
The discovery of prostacyclin by Moncada and Vane (1979) followed by the 
identification of an endothelium derived relaxing factor (EDRF) involved in the 
endothelium dependent vasodilatation induced by acetylcholine, by Furchgott and 
Zawadski (1980), resulted in much attention being attributed to the importance of such 
vasoactive substances produced within the vessel wall.
However, there is now available substantial data which indicates that the vascular 
endothelium is not only a source of vasodilatory substances, but is also capable of 
facilitating contractions of the vascular smooth muscle. A number of substances have 
been shown to cause vasoconstriction dependent on, or enhanced by an intact 
endothelium, thereby indicating that the vascular endothelium is capable of secreting 
under various stimuli, vasoconstrictor as well as vasodilator substances. It was this 
observation, that vascular endothelial cells were capable of secreting contractile factors, 
which led Yanagisawa and colleagues to fully investigate the exact nature of such a 
substance, and in doing so, discovered endothelin.
In 1988, Yanagisawa and coworkers isolated a potent vasoconstrictor substance from 
cultured porcine aortic endothelial cells, determined its amino acid sequence and 
subsequently molecularly cloned the peptide precursor. The peptide, subsequently 
named endothelin, does not belong to any previously reported peptide family and is the 
only endothelium-derived vasoconstrictor substance convincingly identified to date.
Porcine endothelin is a twenty one amino acid residue peptide with free amino and 
carboxy termini (Figure 1). Within the twenty one amino acid structure are contained
18
Figure 1: Structure of the Three Endothelin Isoforms
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Endothelin-1
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Amino acid sequences of the Endothelin isoforms and Sarafotoxin S6b. 
Filled circles represent amino acid residues different from those in ET-1
19
four cysteine (Cys) residues at positions 1,3,11 and 15, between which are situated 
two disulphide bridges, Cys 1-Cys 15 and Cys3-Cysll.
Endothelin arises from a precursor polypeptide, preproendothelin, consisting of 203 
amino acids. The existence of mRNA encoding the prepro form of endothelin in the 
vascular endothelium, indicates that this peptide is produced by de novo synthesis and 
is processed in a manner similar to that of many peptide hormones and neuropeptides. 
The proposed biosynthetic pathway for endothelin involves cleavage of the 
preproendothelin at the paired basic amino acid residues L ys^ l-A rg^  recognised by 
processing endopeptidases (Figure 2). Further cleavage occurs between Arg92-Arg93, 
the next paired basic amino acids within the chain, resulting in the generation of a 39 
amino acid residue peptide known as proendothelin or big endothelin (Yanagisawa et 
al., 1988a). One more key proteolytic cleavage is required for the generation of mature 
endothelin from big endothelin. This step occurs between the amino acids Trp73_ 
Val74, resulting in the formation of the 21 amino acid peptide endothelin. It is 
interesting to note that the final cleavage step is not a previously recognised specific 
proteolysis and this rather unusual processing of big endothelin to endothelin is 
performed by a putative endothelin converting enzyme (Yanagisawa et al, 1988a).
1.2 MULTIPLE FORMS OF ENDOTHELIN.
Following the identification and subsequent synthesis of porcine endothelin from 
cultured vascular endothelial cells, the cDNA encoding the human endothelial cell 
derived vasoconstrictor peptide endothelin, was isolated from a human placenta cDNA 
library (Itoh et a l, 1988). Human preproendothelin contains 212 amino acid residues 
and is highly homologous to porcine preproendothelin displaying 69% sequence 
homology, the sequence differences including both substitutions and 
insertions/deletions. Following removal of the signal peptide, the 22478 dalton (Da)
2 0
Figure 2 : Pathway of Endothelin-1 Biosynthesis
N
Lys-Arg_________ Arg-Arg
20
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53 74 92 203
Preproendothelin
dibasic pair specific endopeptidase(s)
t
Tip-Val
N
53 74 92
Big endothelin
putative endothelin converting enzyme
▼
53 74
Endothelin
Schematic representation of the pathway of endothelin biosynthesis 
(Yanagisawa et a l, 1988)
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putative human preproendothelin might be processed to the mature endothelin in a 
manner similar to that of porcine endothelin, namely dibasic pair specific proteolysis 
and an unusual proteolytic processing step between Trp73 . Val'74. The predicted 
amino acid sequence of human mature endothelin is identical to that of porcine 
endothelin, suggesting that the preproendothelin gene has evolved under strong 
pressure to conserve the structure and hence the function, of the mature peptide.
In the search of the possible existence of endothelin related peptide(s) at the DNA level, 
an endothelin related gene was cloned and sequenced in the rat (Yanagisawa et a i, 
1988b). Despite the tissues which express the gene being unknown, the peptide was 
termed rat endothelin and as porcine and human endothelin, possesses vasoconstrictor 
properties. The rat endothelin precursor is similar to, but distinct from the porcine 
precursor. However, the positions of the four Cys residues, which may be an 
important determinant of the higher structure of the mature peptide, are perfectly 
conserved. The paired basic amino acids Arg-Arg directly preceed the rat endothelin 
sequence, and as for porcine (Yanagisawa et a i, 1988a) and human (Itoh et a i, 1988) 
forms of endothelin, no dibasic pair of amino acids is found at the carboxyl terminus, 
thereby suggesting, as an analogy to porcine endothelin, that the carboxyl terminus of 
rat endothelin is the amino acid tryptophan (Trp), with cleavage at the T rp^-H e^ bond 
occurring via the putative endothelin converting enzyme. Therefore, rat endothelin like 
both porcine and human endothelin, is a twenty one amino acid residue peptide with 
two intra chain disulphide bridges. The amino acid sequence of porcine and rat 
endothelin differs chiefly in the amino region of the peptide, rat endothelin being more 
polar due to the charged lyseine residue at position 7 instead of the more hydrophobic 
methionine residue of porcine endothelin. In contrast, however, the carboxy termini of 
both porcine and rat endothelin are perfectly conserved, the carboxyl terminal fragment 
(CTF) 16-21, being common to both (Yanagisawa et aL, 1988b).
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Further studies looking for the existence of multiple forms of endothelin resulted in the 
discovery of human genes encoding three isopeptides of endothelin, identified by 
screening a human genomic DNA library (Inoue et al., 1989). The nucleotide 
sequences of the three human genes display high sequence homology within the 
regions encoding the mature 21 amino acid peptides, whilst the immediately "upstream" 
sequence and the putative introns encoding the precursor forms of the peptide are 
poorly conserved. Each of the human genes identified, encoded a 21 amino acid 
peptide, similar to but distinct from each other, and were accordingly termed 
endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) (Inoue et al., 1989). 
The amino acid sequence of ET-1 was shown to be identical to that of porcine 
endothelin; ET-2 differed from ET-1 in positions 6 and 7 of the amino acid sequence, 
whereas ET-3 differed in positions 2,4,5,6,7 and 14 (Figure 1). Many of the amino 
acid variations in the sequences of the three peptides are substitutions with chemically 
similar amino acid residues, however, the four Cys residues which form the two 
intrachain disulphide bridges, are perfectly conserved between all three, as is the 
CTF(16-21). Complete structural homology was also observed between ET-3 and the 
previously isolated peptide, rat endothelin, thereby suggesting that rat endothelin rather 
than being a species variant of ET-1, is in fact an isopeptide of ET-1, possessing 
distinct structural and pharmacological properties.
The mature peptides ET-2 and ET-3, like ET-1, are generated from precursor peptides. 
The encoded amino acid sequences of ET-2 and ET-3 are preceeded by paired basic 
amino acid residues, Lys/Arg-Arg, the site of cleavage, but no dibasic pair of amino 
acids is found in the carboxyl terminal region (Inoue et al., 1989), thereby indicating 
that ET-2 and ET-3 are, as in the case of ET-1, generated via an unusual proteolytic 
processing step between Trp-Val/De by the putative endothelin converting enzyme.
The observation that the nucleotide sequence encoding the three isopeptides is highly 
conserved despite little similarity in the nucleotide sequence of the remainder of the
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prepro form of the three peptides, suggest that although the three genes are evolutionary 
distinct from each other, the genes evolved from the common ancestral gene under 
strong pressure to preserve the mature endothelin sequence (Landan et al., 1991). The 
number of endothelin related genes is also highly conserved amongst mammalian 
species examined (Inoue etal., 1989).
Despite the endothelins not belonging to any previously reported peptide family, the 
amino acid sequence of endothelin bears structural homology to a group of peptide 
neurotoxins, known as the sarafotoxins (STRX), isolated from the venom of the snake 
Actractaspis Engaddensis (for review see Bdolah et al., 1988). The SRTX's are highly 
toxic peptides having powerful effects on the heart and strong vasoconstrictor 
properties (Bdolah et a l, 1989 & Wollberg et ai, 1989). Four sarafotoxins, SRTX -a, 
-b, -c and -d have been isolated, all of them from snake venom (for review see Bdolah 
et a l, 1989). Like the endothelins the SRTX's contain 21 amino acids and members of 
each class of peptide display considerable sequence homology; they each possess four 
Cys residues, the positions of which are perfectly conserved, and 52-67% of their 
amino acid residues are identical (Landan et a l, 1991).The major differences between 
the various peptides are found within the amino acid sequence of the inner loop, 
between Cys^-Cys^, the sequences at positions 4-7 representing the major variable 
region with only minor substitutions elsewhere (Sokolovsky, 1991). It is interesting to 
note that the amino acid in position 2 is Ser in ET-1, ET-2, SRTX-a and SRTX-b and 
Thr in ET-3, SRTX-c and SRTX-d, it has been suggested that the amino acid in 
position 2 is crucial to the activity of these peptides and may account for their activity 
differences (Landan et al, 1991).
1.2.1 Structure Activity Relationships of the Endothelins
The endothelins, ET-1, ET-2 and ET-3 are all potent constrictors of vascular smooth 
muscle in vitro and strong pressor agents in vivo, however, the characteristics of their
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pharmacological activities are quantitatively different. Rat endothelin is less potent than 
porcine endothelin in constricting rat aortic strips (Yanagisawa et al., 1988b). 
Vasoconstrictor activity, expressed in terms of maximum tension generated, has 
indicated a rank order of potency ET-2 > ET-1 > ET-3 and this order also corresponds 
to the time required for the recovery of arterial pressure followng an intravenous (i.v.) 
bolus of the peptide in anaesthetized cats (Inoue et ai, 1989). Although the peptides are 
overall structurally very similar, the intra chain amino acids at positions 4-7 are 
variable. In contrast however, the four Cys residues, the CTF( 16-21) and the cluster of 
charged residues Asp^-Lys^-Glu^O are perfectly conserved, suggesting the importance 
of these residues for full biological activity (Yanagisawa and Masaki, 1989b). Many 
hypotheses have been put forward to explain the discrepancy in potency between the 
three structurally similar endothelin peptides. Inoue et al., (1989), argued that the 
activity of ET-1, ET-2 and ET-3 is correlated to the hydrophobicity of the entire 
peptide; ET-2 being the most hydrophobic with an additional tryptophan residue at 
position 6 and ET-3 the most polar, with a charged lyseine residue at position 7, instead 
of the hydrophobic methionine residue of ET-1. Kloog and Sokolovsky (1989), 
suggested a possible effect of net charge of the peptides on their activity. Graur et a l, 
(1988), however, suggested that a comparison between the activity of the peptides (the 
endothelins and the STRX's), point to the amino acid in position 2 being most 
important to their biological activity. Both ET-1 and ET-2 have a Ser residue in position 
2, whereas ET-3 possesses a Thr residue. It is also pointed out that the STRX's all 
have the same degree of hydrophobicity yet they exhibit different levels of activity, 
STRX-a and STRX-b being less hydrophobic than ET-3 but generally as active as ET- 
1.
Alteration of the peptide chain length also affects its potency. Removal of the C- 
terminal Trp^l results in a 1000 fold decrease in potency (Kimura et al., 1988). 
Alterations in the sequence of amino acids of ET-1 by either substitution or deletion 
results in derivatives of ET-1 which display different kinetics of constriction to the
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parent peptide, responses developing and decaying much more rapidly than those of 
ET-1 itself. Oxidation of the methionine residue of ET-1 to produce [Met^(0)]ET-l 
however, did not result in a change in biological activity compared with the native 
peptide, whereas amidation of the terminal carboxyl group reduces the activity to 1/15 
the activity of ET-1 (Nakajima et a l, 1989).The CTF(16-21) has variable activity 
depending upon the assay system utilized, on rat thoracic aorta and rat pulmonary 
preparations the CTF has little or no activity (Maggi et al., 1989a & Nakajima et a i, 
1989), whereas on guinea-pig bronchus CTF( 16-21) displayed full agonist properties 
(Maggi et a i, 1989a), but nonetheless, was far less potent, in terms of activity, than 
ET-1 itself.
Destruction of the intra chain disulphide bridges of ET-1 results in a marked decrease in 
potency. The linear structural analogues of ET-1, Cysl-11, Cys3-15 and Cys 1-3 
Cys 11-15 exhibit a markedly lower potency than the parent molecule (Nakajima et a i, 
1989). Reduction and alkylation of the four Cys residues results in a reduction in 
potency of ET-1 by a factor of 100. Substitution of Cys^ and C y s  15 with Ala residues, 
results in a potency decrease of 200, whereas a similar substitution of Cys^ and Cysl 1 
decreases the potency by a factor of 20 only (Miller et ai, 1989), thereby indicating that 
the maintenance of the disulphide bridge Cys 1 -Cys 15 is the more important of the two 
bridges for expression of the full vasoconstrictor activity of ET-1.
For the expression of full, potent vasoconstrictor activity of ET-1 the complete peptide 
structure is required, substitution or deletion of the amino acids or opening of the 
disulphide bridges results in a considerable decrease in potency. Each individual part of 
the peptide plays an important role in maintaining its potency, Kimura et al., (1988), 
suggests that the disulphide loop structure and the C-terminal Trp are essential for the 
vasoconstrictor action of ET-1.
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1.3 THE ENDOTHELIN CONVERTING ENZYME
The fact that the proteolytic processing of big endothelin at the Trp21-Val22 bond 
increases the activity of the mature peptide by a factor of more than 100, illustrates the 
physiological importance of the conversion of bET(i-39) into ET-l(i_21) (McMahon et 
aL, 1991). Analysis of the culture supernatant of porcine aortic endothelial cells has 
indicated the presence of the CTF big ET-1(22-39) including its N-terminal truncated 
form big ET-1(23-39) at approximately equimolar concentrations with the mature 
peptide ET-l(i_21) and its oxidised form [Met?(0)]ET-1(1-21) (Sawamura et aL, 
1989). Big ET-l(i_39) was also isolated but its total concentration was only 2% of the 
ET-l(i-21) content, thereby suggesting that ET-l(i-21) and CTF bigET-1(22-39) are 
generated from big ET-l(t-39) by specific processing between Trp^l and Val22.
Since its discovery, this rather unusual processing of big ET-1 has been a matter of 
intense investigation. Hitherto, a cathepsin-D-like apartic protease, which generates ET- 
1 from big ET-1 at an acidic pH has been characterised in bovine adrenal medullary 
cells (Sawamura et ai, 1990a), bovine aortic endothelial cells (Matsumura et a i, 1990; 
Sawamura et a i, 1990b) and rat lung (Wu-Wong et al., 1990). However, further 
research has indicated that the endothelin converting enzyme (ECE) activity resides with 
a novel metal dependent neutral protease and not cathepsin-D as originally thought 
(Ikegawa et a l, 1990; Ohnaka et al., 1990; McMahon et al., 1991; Sawamura et al., 
1991 & Takada et al., 1991). Much controversy has surrounded identity of the ECE 
(see Table 1 for summary), and many researchers have identified ECE activity at both 
acidic and neutral pH (Ohnaka et al., 1990; Takaoka et al., 1990 & Hioki et al., 1991). 
The possibilty of the conversion of big ET-1 to ET-1 being mediated in vivo by at least 
two types of enzymes has been investigated (Matsumura et al., 1990). Analysis of 
cultured bovine aortic endothelial cells revealed ECE activity at both pH 3 and pH 7, the 
activity at pH 3 inhibited by Pestatin A, suggesting the enzyme to be an acidic aspartic 
protease, and activity at pH 7 inhibited by EDTA and EGTA suggesting a metal
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dependent neutral protease is responsible for the ECE activity (Ohnaka et a i, 1990). 
However analysis of the products formed from big ET-1 in the absence of the enzyme 
inhibitors revealed that only ET-1 was detected at pH 7, whilst at pH 3, various ET-like 
immunoreactivities only were detected. The appearance of various ET-like 
immunoreactivities at pH 3 suggests that either big ET-1 was nonspecifically cleaved or 
that the ET-1 so formed, was subjected to further enzymatic degradation. Further 
research has demonstrated that the membrane fraction of cultured aortic endothelial cells 
produce substantial conversion of big ET-1 to ET-1 at neutral pH, furthermore, this 
effect was blocked by the metal chelators EDTA and 1,10 phenanthroline, as was the 
cytosolic conversion of big ET-1. Phosphoramidon, a metalloproteinase inhibitor, 
specifically suppressed only the membrane fraction induced increase in big ET-1 
conversion, whilst other metalloproteinase inhibitors, e.g. thiorphan, were without 
effect (Matsumura et al., 1990).
Recently however, it has been suggested that the cytosolic fraction of endothelial cells 
possess phosphoramidon sensitive converting activity, thereby contradicting work 
reported by Matsumura et a i, (1990). Takada et a i, (1991), demonstrated that the 
cytosolic enzyme, like the membraneous enzyme is phosphoramidon-sensitive, but 
differs in a number of parameters. Big ET-1 was suggested as a physiologically more 
important substrate for the cytosolic than the membraneous enzyme the km of the 
cytosolic enzyme being considerably lower. It was also demonstrated that the molecular 
weight of the cytosolic enzyme (540k Da), is greater than the membraneous enzyme 
(100k Da), thereby suggesting at least two types of phosphoramidon sensitive neutral 
metalloproteinase ECE exist in vascular endothelial cells. Such an apparent discrepancy 
in results is difficult to explain, but it is possible that the inhibitory effects of 
phosphoramidon on the cytosolic fraction were masked by the nonspecific degradation 
of big ET-1 and/or the ET-1 generated, thereby suggesting that the metalloprotease 
inhibitor was without effect (Matsumura et a i, 1990). Furthermore, in cultured bovine 
endothelial cells, the acid proteinase inhibitor pepstatin, serine proteinase inhibitors
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PMSF and pAPMSF, thiol protease inhibitor E64 and other protease inhibitors 
leupeptin and bacitracin failed to inhibit the conversion of big ET-1 to ET-1, whereas 
the metal protease inhibitor phosphoramidon dose dependently inhibited the formation 
of ET-1 from big ET-1 (Sawamura et al., 1990b). Phosphoramidon has also been 
shown to completely inhibit the pressor response to big ET-1 in anaesthetized, ganglion 
blocked rats, whilst having no effect on the ET-1 induced response itself (Matsumura et 
al., 1990; McMahon et al .,1991). McMahon et al., (1991), also demonstrated that 
leupeptin, E64, captopril and kelatorphan were ineffective in blocking the pressor 
response to big ET-1. Interestingly, a further metalloprotease inhibitor, thiorphan, also 
blocked the pressor response to big ET-1, but with a much lower potency than that of 
phosphoramidon.
Phosphoramidon was originally identified as a potent inhibitor of the bacterial 
metalloprotease thermolysin, although it does inhibit other metalloprotease enzymes, 
most noteably neutral endopeptidase 24.11 (Mumford et ai, 1981). Phosphoramidon, 
thiorphan and kelatorphan however, are all equipotent as inhibitors of neutral 
endopeptidase 24.11 (NEP 24.11) (Olins et al., 1989 ), however the lack of effect of 
kelatorphan on the conversion of big ET-1 to ET-1, suggests that the ECE is not NEP 
24.11,but rather a novel phosphoramidon-sensitive metalloprotease (McMahon et al., 
1991). The full expression of pharmacological activity of ET-1 in vivo, is dependent 
upon its generation from its precursor, big ET-1, the conversion step being undertaken 
by an endothelin converting enzyme which is now recognised to be a phosphoramidon- 
sensitive neutral metalloprotease. Such an enzyme may therefore represent an important 
therapeutic target for pharmacological intervention in vascular diseases
2 9
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1.4 MODE OF ACTION OF ENDOTHELIN-1
The purpose of this study was to look at the effects of endothelin-1 (ET-1) only, 
therefore the mode of action of ET-1 is covered in detail, however, it is beyond the 
scope of this thesis to fully evaluate the mechanism of action of both ET-2 and ET-3.
1.4.1 Involvement of Calcium Channels in the Endothelin-1 Induced 
Response
Yanagisawa et al., (1988a), reported ET-1 to be an endogenous agonist for the 
dihydropyridine sensitive L-type calcium (Ca^+) channel, the hypothesis for such a 
mode of action based on :
(i) the structural homology of ET-1 with a group of peptide neurotoxins which act 
directly on voltage dependent ion channels, and
(ii) the vasoconstrictor action of ET-1 on porcine coronary artery strips, which was 
shown to be critically dependent on extracellular Ca^+ and attenuated in the presence of 
the dihydropyridine sensitive Ca^+ channel blocker, nicardipine.
However, the direct involvement of the Ca2+ channel in the ET-1 induced response is 
subject to controversy. Since the initial mode of action of ET-1 was outlined by 
Yanagisawa et a l, (1988a), reports have indicated equivocal results concerning the 
action of the voltage dependent Ca^4- channel in the ET-1 induced response. In some 
systems, the action of ET-1 has been demonstrated to be independent of the voltage 
dependent Ca^4" channel (Chabrier et a/.,1989; D'Orleans-Juste et a l, 1989a & 
1989b), whilst in others, the action of ET-1 has been shown to be closely involved 
with activation of the Ca^4* channel (Goto et a l, 1989 & Brooks et a l, 1991). 
Furthermore, some researchers have indicated that only part of the ET-1 induced 
constrictor response is sensitive to the action of Ca^4* antagonists (Maggi et a l, 1989a;
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Stasch et a i, 1989 & Watanabe et ai, 1989), thereby suggesting a dual mode of action 
of ET-1.
Binding studies using [ ^ I ]  labelled ET-1 have demonstrated the existence of a single 
class of high affinity receptor sites in cultured rat vascular smooth muscle cells (VSMC) 
(Hirata et aL, 1988a & Chabrier et al., 1989), which were unaffected by Ca2+ 
antagonists such as nifedipine, diltizem and verapamil up to a concentration of IfiM. 
Conversely, unlabelled ET-1 did not displace radioactive dihydropyridines from their 
binding sites on rat cardiac membrane fragments (Gu et a i, 1989), or to the skeletal 
muscle T-tubule membrane (Van Renterghem et ai, 1989), thereby suggesting that the 
binding sites of both ET-1 and the dihydropyridines differ, and that the dihydropyridine 
channels are not the primary site of action of ET-1.
It may be speculated that ET-1 induces Ca^+ influx via a route other than the 
dihydropyridine sensitive Ca^+ channels. However, the possibilty that ET-1 indirectly 
activates such channels cannot be excluded. Van Renterghem et a i, (1989), proposed 
that the vasoconstrictor action of ET-1 is indirectly mediated via the L-type Ca^+ 
channel, ET-1 causing the opening of a non-selective cation channel in the plasma 
membrane resulting in a membrane depolarization, which in turn activates the L-type 
Ca2+ channel, thereby explaining in some cases why only part of the ET-1 induced 
contractile response is inhibited by dihydropyridine sensitive Ca^+ antagonists.
The finding that the ET-1 induced contraction can be inhibited by a potassium (K+) 
channel opener BRL 34915 in rat trachea (Turner et al .,1989a) and rat thoracic aorta 
(Kim et a i, 1989), in a Ca2+ containing medium, lends further support to the 
involvement of other voltage dependent channels in the action of ET-1. BRL 34915 
increases membrane K+ conductance and the resulting hyperpolarisation of the cell 
membrane inhibits the influx of Ca^+ from the extracellular space. In a Csfl+ free 
medium however, BRL 34915 has no inhibitory effect on the ET-1 induced
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contraction, thereby indicating that the contractile activity of ET-1 is not critically 
dependent on the presence of extracellular Ca2 + and occurs via a mechanism 
independent of influx of extracellular Ca2+.
1.4.2 Intracellular Calcium
It has been demonstrated that ET-1 induces an increase in intracellular Ca^ + 
concentration ([Ca^+]i), in VSMC determined by quin-2 and fura-2 microfluorimetry 
(Hirata et al., 1988a, 1988b; Van Renterghem et ai, 1988; Kai et al., 1989 & Marsden 
et a l, 1989). In the absence of extracellular Ca^+, ET-1 contrary to previous reports 
(Yanagisawa et al., 1988a & Borges et ai, 1989a ), was still able to induce an increase 
in [Ca2+]i (Kai et al., 1989; Marsden et a i, 1989 & Kishino et a/.,1991), thereby 
suggesting the mobilization of intracellular Ca^+ stores. In the presence of extracellular 
Ca2+, ET-1 induces a rapid, sustained elevation of [Ca^+]i in vascular smooth muscle 
cells (VSMC), (Danthuluri et a i, 1990), the latter component of which has been 
shown to be sensitive to the Ca^+ channel blocker diltiazem (Kai et al., 1989). 
However, in the absence of extracellular Ca^+, ET-1 induces a rapid, but transient 
increase in [Ca^+]i5 which returns to basal levels faster than when in the presence of 
extracellular Ca^+ (Danthuluri et al., 1990) and is insensitive to the action of Ca^+ 
antagonists. Therefore, it is suggested that the contractile response evoked by ET-1 is 
composed of two phases, an initial component insensitive to the action of Ca^+ channel 
antagonists indicating mobilization of intracellular Ca^+ stores, and a latter component 
sensitive to the action of Ca^+ antagonists suggesting the influx of Ca^+ via these 
channels (Hirata et a i, 1988b; Kozuka et al„ 1989 & Maggi et a i, 1989a). The 
intracellular Ca2+ store activated by ET-1 has been suggested to overlap with the 
caffeine sensitive intracellular Ca2+ store in cultured rat VSMC (Kai et a l, 1989 & 
Kasuya et a l, 1989). Following depletion of the caffeine sensitive stores by repeated 
application of caffeine in a Ca^+ free medium, the subsequent application of ET-1 
failed to increase [Ca^+Jj (Kai et a i, 1989), and also inhibited the ET-1 induced
3 6
contractile response in porcine coronary artery (Kasuya et al., 1989). However,
contrary to such results, Kodama et ai, (1989), reported that following depletion by
of —
caffeine and histamine^intracellular Ca^+ stores, ET-1 induced a transient and dose
dependent contraction with no increase in [Ca^+]i observed. It was also suggested that
at lower concentrations of ET-1 (< InM), contraction occurs mainly in a Ca^+
dependent manner via Ca2+ influx, whilst at higher concentrations (>10nM), the ET-1
induced contraction is mediated via the release of intracellular Ca^+ (Muldoon et al.,
1991), and also in a Csfi+ independent manner. In the presence of extracellular Ca^+,
ET-1 (0. InM) increased intracellular Ca2+ levels (Muldoon et a l ., 1991), however,
such an increase can be considered to be the result of Ca^+ influx stimulated by low
doses of ET-1, since a lack of extracellular Ca^+ abolished this effect.
The caffeine sensitive intracellular Ca2+ store is known to overlap with the inositol
1,4,5 trisphosphate (IP3) sensitive pool in intact vascular smooth muscle, and it is 
possible that the initial development of the ET-1 induced contraction in a Ca^+ free 
medium is mediated via IP3 induced intracellular Ca^+ release (Kasuya et a i, 1989).
1.4.3 Hydrolysis of Phosphatidylinositol 4,5 bisphosphate
A characteristic of some vasoconstrictor agonists is their ability to induce phospholipase 
C (PLC) mediated degradation of phosphatidylinositol 4,5, bisphosphate (PI) and at 
least two catabolic products of this process, namely inositol 1,4,5 trisphosphate (IP3) 
and diacylglycerol (DAG), are involved in mediating the complex action essential for 
contraction. Measurement of inositol phosphates in VSMC has confirmed that ET-1 
stimulates the formation of IP3 (Resink et a i, 1988; Araki et al., 1989; Muldoon et a i, 
1989; Simonson et ai, 1989; Van Renterghem et a i, 1989 & Danthuluri et a i, 1990), 
and labelling of cells with [^HJ-arachidonic acid or [^H]-glycerol, has confirmed the 
formation of [^H]-DAG (Resink et ai, 1988; Griendling et a i, 1989; Lee et al., 1989 
& Sunako et al., 1989). Inositol trisphosphate mediates the intracellular mobilization of
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Ca2+ (early phase of vasoconstriction), whereas DAG activates protein kinase C 
(PKC) (sustained phase of vasoconstriction) (Araki et al, 1989 ).
1.4.4 Inositol Phosphate Accumulation
Endothelin-1 increases [Ca^+Ji by activating the phosphoinositide cascade, however, 
the kinetics of such increases depend ultimately on the concentration of ET-1 used. 
Simonson et al., (1989), demonstrated that at low concentrations of ET-1 (O.l-lOpM), 
a slow sustained increase in [Ca^+Jj occurred, whereas at higher concentrations 
(>0.1nM), a rapid transient increase in [Ca^+]i was observed. It was suggested that the 
transient increase in [Ca^+]i was due to activation of phosphoinositide specific PLC 
resulting in the formation of IP3 , which in turn causes an increase in [Ca^+]i, evidence 
for which was provided by the dose response curve of PI hydrolysis being parallel to 
the transient increase in [Ca^+]i in cultured glomerular mesangial cells, thereby 
suggesting that PI hydrolysis is an early membrane event.
Contrary to the observations made by Hirata et al., (1988b), most research has 
indicated ET-1 to stimulate the accumulation of inositol phosphates resulting from 
hydrolysis of PI. ET-1 stimulates a rapid formation of inositol monophosphate (IPl), 
inositol bisphosphate (IP2 ) and IP3 (Araki et al., 1989 & Sugiura et al., 1989). The 
formation of IP3 is reported to attain peak levels within 30-60 seconds of stimulation 
by ET-1 in VSMC and NG 108-15 cells (Kasuya et al., 1989; Resink et a i, 1989 & 
Yue et al., 1991). Varying reports exist concerning the effect on IP3 formation in the 
absence of extacellular Ca^+. In VSMC the absence of extracellular Ca^+ did not 
inhibit the formation of IP3 , indicating the process to be independent of influx of 
extracellular Ca^+ (Kasuya et al., 1989 & Muldoon et al., 1989), whereas, in 
cerebellar granule cells, PI hydrolysis was shown to be dependent upon influx'of
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extracellular Ca^+ (Lin et a i, 1991). However, in both cases, the stimulatory effect of 
ET-1 on PI hydrolysis was insensitive to the action of Ca^+ channel blockers.
The finding that the ET-1 induced vasoconstriction can be reversed by the PKC 
inhibitor l-(5-isoquinolynylsulfonyl)-2-methyl piperazine (H-7), provided further 
evidence for the involvement of PKC (Sugiura et a i, 1989). However, it was also 
observed that PKC activating phorbol esters 12-O-tetradecanoylphorbol-13-acetate 
(TPA) and phorbol-12,13-dibutyrate (PDBu), inhibited the ET-1 induced PI hydrolysis 
(Araki et a l, 1989; Lin et al., 1990 & Yue et a l, 1991), suggesting that PKC 
modulates the signalling mechanism of ET-1 to PLC and that the ET receptor system is 
sensitive to the PKC mediated desensitization mechanism. It is possible however, that 
such an effect depends upon the tissue preparation used. Vigne et al., (1989), 
demonstrated that isolated rat atria stimulated by ET-1, induced the formation of inositol 
phosphates. Contrary to previous reports however, the action of ET-1 was not 
mediated by PKC, the PKC activating phorbol esters failing to desensitize cells to the 
effect of ET-1.
Lin et al., (1990), demonstrated that PLC coupled ET-1 receptors are expressed in both 
neurons and glial cells evidenced by an observed increase in PI hydrolysis in cerebellar 
astrocytes, C^-glioma cells and cerebellar granule cells upon stimulation with ET-1. 
However, it was also observed that these cells differ in their pharmacological selectivity 
and signal transduction mechanisms in stimulating PI hydrolysis. It has been suggested 
that different pools of PI are involved in mediating the response induced by a variety of 
agonists. In cerebellar granule cells the responses to ET-1 and SRTX-b were found to 
be non additive on PI hydrolysis (Lin et al., 1991), whereas the ET-1 induced effect 
was demonstrated to be additive to the response induced by carbachol (CCh), ATP and 
angiotensin II (Lin et al., 1990), thereby suggesting that the receptors are linked to 
different PI pools. The ET-1 induced PI turnover has been shown to be insensitive to 
the action of pertussis toxin (PTX), in cerebellar granule cells (Lin et al., 1990 &
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1991), NG 108-15 cells (Yue etal., 1991) and VSMC (Araki et al.t 1989). However, 
in rat mesangial cells, PTX inhibited the PI hydrolysis in intact cells stimulated with 
ET-1 (Thomas et al., 1991). It is probable therefore, that the GTP binding protein 
linking to the endothelin receptor differs between cell type and therefore requires further 
investigation to determine the nature of such a mechanism.
1.4.5 Diacylglycerol Formation and Activation of Protein Kinase C
Diacylglycerol (DAG), is the only well characterized metabolite for PKC, and is formed 
by the PLC mediated degradation of PI. In VSMC ET-1 stimulates a biphasic formation 
of DAG, peak accumulation observed at 15-30 seconds and again 2-5 minutes later and 
remains elevated above control levels for 10-20 minutes (Griendling et al., 1989; 
Sunako et al., 1989 & Danthuluri et al., 1990), leading to the possibility that PI is not 
the only source of DAG , and it is possible that hydrolysis of different phospholipids 
occurs. The concomitant production of IPg, (peak 30 seconds) and IPl, (peak 5 
minutes) suggests that the early formation of DAG is derived from PI hydrolysis 
despite the similarity in the time course of production of IPl with DAG (Sunako et al., 
1989). Labelling VSMC with differing radioligands, incubating for different time 
periods and stimulating with ET-1 resulted in a pattern of DAG formation which 
indicated that DAG could originate from different phospholipid pools (Lee et al., 
1989), e.g. by the hydrolysis of phosphatidylcholine or glycolipid (Griendling et al.,
1989).
As well as the PLC mediated degradation of PI, ET-1 has been suggested to be 
involved in mediating the phospholipase A2 (PLA2 ), déacylation of phospholipids 
(Resink et al., 1989 & 1990). Phospholipase A2 plays an essential role in the sequence 
of events leading to constriction by the synthesis of biologically active metabolites of 
arachidonic acid, by liberating arachidonic acid from various membrane phospholipids. 
Treatment of cells with phorbol, 12-myristate, 13-acetate (PMA) failed to completely
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down regulate ET receptors indicating a population of ET receptors which are 
insensitive to PKC and the inhibitory effects of PMA may be exerted via differential 
effects on the PLC and PLA% signalling pathways utilised by ET-1 (Resink et al.,
1990).
The activity of PKC is regulated by DAG, and the time course of activation of PKC 
correlates with [^H] DAG production observed in ET-1 stimulated VSMC (Lee et al., 
1989). ET-1 caused a prolonged phosphorylation of an acidic protein Mr 76000 Da, the 
effects detectable after 30 seconds and sustained for 20 minutes (Griendling et al., 
1989). The effects were mimicked by phorbol esters but not by ionomycin, and was 
markedly reduced following treatment with PDBu, thereby indcating the protein to be a 
specific substrate for PKC. Phorbol ester induced contraction of vascular smooth 
muscle is Ca^+ dependent, and the lag time in onset of contraction can be reduced by 
increasing influx of Ca^+ (Griendling et al., 1989). This factor may have important 
implications for the action of ET-1, if ET-1 causes an influx of Ca^+, then the 
combination of DAG production from the hydrolysis of PI, with Ca^+ may be 
sufficient to initiate a PKC dependent contraction (Griendling et al., 1989 & Danthuluri 
et al., 1990). The DAG induced activation of PKC may play a role in mediating Ca^+ 
influx stimulated by ET-1 and this implies a feedback loop for supplying the Ca^+ 
required to activate PKC, i.e. an increase in [Ca^+]i combined with DAG activates 
PKC, which in turn stimulates Ca^+ influx which would then serve to maintain PKC 
activation and therefore contraction (Griendling et ai, 1989 & Danthuluri et al., 1990).
A variety of agonists linked to PLC activation and Ca^+ mobilization have been shown 
to increase the intracellular pH of VSMC via the PKC activation of Na+/H+ exchange, 
ET-1 is no exception (Danthuluri et al., 1990). Stimulation of VSMC with ET-1 
resulted in an alkaline pH shift, the time course of which is demonstrated to be similar 
to DAG production. A lack of effect in PKC down regulated cells and the inhibition of 
effect observed in the presence of PKC inhibitors, indicated that alkalinization is indeed
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a consequence of PKC activation (Danthuluri et a i, 1990). The maximum pH change 
induced by ET-1 was shown to occur at a dose submaximal for an increase in [Ca^+ji 
and DAG production, and yet induce a maximum PKC stimulation. The nature of the 
ET-1 induced contractile response in vascular smooth muscle may be due to its unique 
ability to activate PKC with extreme potency.
1.4.6 Multiple Endothelin Receptors
The identification of the endothelin isopeptides raised the question as to whether 
multiple endothelin receptors exist. ET-3 is in general a much less potent constrictor 
than ET-1 in vitro, its relative potency varying from equiactive to a 20 fold difference in 
magnitude when compared with the effects of ET-1 on the rat stomach strip and aortic 
strip and guinea-pig ileum and trachea (Spokes et al., 1989). Such variability in 
response lends further support to the concept of multiple receptors.
Binding studies using [125i] labelled endothelins have demonstrated the ET-1 binding 
site to be distinct from those of the dihydropyridine sensitive voltage dependent Ca^+ 
channels, indicating that ET-1 has its own distinct binding site (Miyazaki et a l, 1989). 
Initial studies demonstrating the existence of multiple forms of the endothelin receptor 
involved competitive displacement experiments using [125i]_et-1 and unlabelled 
endothelins. The presence of at least two types of endothelin receptor were identified on 
chick cardiac membranes (Watanabe et ai, 1989) and rat lung membranes (Miyazaki et 
aL, 1991), one with equal affinity for ET-1 and ET-2, the other ET-3 preferring. 
Affinity cross-linking experiments, to examine the molecular characteristics of the 
putative receptors, revealed one major labelled protein band Mr 53000 Da at the ET- 
l/ET-2 preferring receptor, whereas the ET-3 preferring receptor was shown to contain 
one minor band Mr 53000 Da and two major bands Mr 46000 and 34000 Da (Watanabe 
et al., 1989). Different laboratories obtained proteins with different molecular mass, 
ranging from 32 kDa to 110 kDa for the ET-1 labelled protein, and 30 kDa to 70 kDa
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for the ET-3 labelled protein, depending upon the tissue and/or experimental procedure 
employed. Ambar et aL, (1990), also reported the existence of discrete and diffuse 
protein bands of Mr 80000 and 90000 Da, which may represent various carbohydrate 
substituents of membrane proteins. However, the possibility of partial proteolysis of 
the Mr 90000 Da band being responsible for the lower Mr bands cannot be ruled out. 
Indeed, studies on rat brain membrane and bovine atrial membrane revealed that the 
protein bands Mr 30000 and 52000 Da, have an identical peptide map, indicating a 
similarity in the primary structure of the two bands suggesting that the Mr 30000 Da 
band is a product of proteolytic degradation of the Mr 52000 Da band (Schvartz et aL, 
1990 & 1991). Furthermore, the protein bands identified in bovine atrial membranes 
which bind ET-1 and ET-3 with distinct potency differences, despite having the same 
molecular mass, differ in their peptide maps suggesting minor differences in their 
primary structure (Schvartz etaL, 1991).
1.4.7 Cloning of the Endothelin Receptors
In 1990, two reports appeared which revealed the cloning of two endothelin receptors 
(Arai et aL, 1990 & Sakurai et al .,1990). Aral et aL, (1990), constructed a bovine lung 
cDNA library from which an endothelin receptor of Mr 48516 Da and consisting of 427 
amino acid residues was isolated. The cloned cDNA was shown to encode a functional 
receptor in the Xenopus oocyte assay system and folowing transfection of the cloned 
cDNA into monkey kidney COS cells, affinities for the endothelins were determined. 
Binding of [I^Sqet-I was saturable and displacement experiments demonstrated ET-1 
to be the most potent inhibitor of radioligand binding to this receptor, with order of 
potency ET -1 >ET-2»ET -3 >sarafotoxin S6b. Subsequently, this receptor, the ET-1 
selective, was termed ETa (Masaki, 1991), and may be considered to be the smooth 
muscle receptor.
A non-selective endothelin receptor was isolated by Sakurai and coworkers (Sakurai et 
aL, 1990), a cDNA library from poly(A)+RNA from rat lung was constructed and 
COS-7 cells transfected with the cDNA were shown to express specific, high affinity 
binding sites for endothelins, to have a Mr 46901 Da and to consist of 415 amino acids. 
The three isopeptides of endothelin were shown to be equipotent in displacing 
[125i]ET-l binding, indicating a different receptor to that isolated by Arai and 
colleagues. The receptor was demonstrated to be functional by responding to binding 
by the production of IP3 accompanied by a transient increase in [Ca^+jj. A mRNA 
corresponding to the cDNA has been detected in many rat tissues, including the brain, 
kidney and lung but not in vascular smooth muscle (Sakurai et a i, 1990). Therefore, 
the cDNA, so isolated, encodes a non-selective subtype of the endothelin receptor 
which differs from the vascular smooth muscle receptor, and accordingly is termed the 
ETb receptor (Masaki, 1991).
Following the reports concerning the cloning of the ETa and the ETg receptor, 
endothelin receptors were cloned in both human placenta (Ogawa et aL, 1991) and rat 
A10 vascular smooth muscle cells (Lin et aL, 1991). Furthermore, the mRNA encoding 
the receptor in human placenta was found to be expressed on a variety of human 
tissues, including the brain and cultured endothelial cells (Ogawa et aL, 1991). A high 
degree of sequence homology exists between the human cloned receptor and rat ETb 
indicating that the receptor is in fact the human ETb receptor. The receptor cloned from 
rat A10 vascular smooth muscle cells was demonstrated to be ET-1 selective and RNA 
analysis exhibited a high expression of the receptor in rat lung and heart and a lower 
expression in rat liver, brain muscle and kidney (Lin et aL, 1991). The selectivity of the 
cloned receptor for ET-1 suggests that it is an isoform of the ETa receptor. 
Furthermore, endothelin receptors have been characterized on neuronal cells; an ETa 
receptor on a human neuroblastoma cell line (Wilkes & Boarder, 1991a) and an ETb 
receptor on chromaffin cells (Wilkes & Boarder, 1991b). It is therefore evident that
4 4
there exists heterogeneity of endothelin receptors on neuronal type cells in culture, even 
though they are both of peripheral origin.
The non-selective ETb receptor has also been detected in membranes from the 
endothelium of porcine thoracic aorta and rat thoracic aorta (Takayanagi et aL, 1991). 
Using the specific ligand [Glu^]-sarafotoxin S6b, the ETg receptor was shown to be 
located on vascular endothelium and to be linked to vasodilation, whereas the ETa 
receptor is localised to the smooth muscle and mediates vasoconstriction (Takayanagi et 
a/., 1991). Sarafotoxin S6c is an agonist which distinguishes between the endothelin 
receptor subtypes, being more selective for the ETb receptor (Williams et aL, 1991). 
Using S6c as a subtype selective ligand, certain tissues were found to possess both 
receptor subtypes. In rat kidney S6c produced a biphasic shallow competition curve, 
the high and low affinity components of the binding curve indicating the presence of 
ETb and ETa sites respectively, a similar profile was also demonstrated in the rat 
hippocampus (Williams et aL, 1991).
Despite the fact that the cloned receptors differ in the number of amino acids (see Table 
2), this probably represents a consequence of tissue differences. In spite of this 
difference, the receptors display distinct structural homology; they all contain seven 
hydrophobic transmembrane domains, a relatively long N-terminus and a cytoplasmic 
C terminal tail which together with a cytoplasmic loop containing several serine 
residues is potentially able to be phosphorylated by serine/threonine protein kinases, 
suggesting that receptor function may be regulated by protein kinases (Arai et aL, 1990; 
Sakurai et aL, 1990; Lin et aL, 1991 & Ogawa et aL, 1991). Each cloned receptor also 
exhibits significant sequence and topographical similarity with the photoreceptor 
rhodopsin and other G protein coupled receptors. Confirmation of the endothelin 
receptor situated on endothelial cells being coupled to a G protein was provided by 
Eguchi et aL, (1991), who demonstrated that the GTP analogue GTPyS inhibited 
binding of ^^I^ET -l and [^5j]ET-3 to the endothelial cells.
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As yet the ET-3 specific receptor, putatively termed ETc (Masaki, 1991), has not been 
cloned. However, binding studies have revealed, in addition to the low affinity ET-3 
receptor, a high affinity ET-3 receptor subtype on brain capillary endothelial cells 
(Frelin et al., 1991 & Vigne et al., 1991) and on brain astrocytes (Frelin et aL, 1991). 
Furthermore, ET-3 is the major isoform of the endothelins found in the brain, in 
particular the pituitary gland (Emori et ai, 1989; Matsumoto et aL, 1989 & Samson et 
al., 1991), and has been shown to inhibit, in a dose dependent manner, prolactin 
release from cultured anterior pituitary cells (Samson et al., 1990), an effect not 
observed upon the addition of ET-1 nor due to the activation of dopamine receptors. It 
has therefore been postulated that, the ET-3 specific receptor subtype is localized within 
the pituitary gland and is involved in the inhibition of prolactin release (Masaki, 1991), 
however, this has yet to be fully clarified.
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1.5 THE RESPIRATORY EFFECTS OF ENDOTHELIN-1
ET-1 was originally identified as a potent vasoconstrictor peptide in the culture medium 
of porcine aortic endothelial cells (Yanagisawa et aL, 1988a). The release of ET-1 from 
cultured canine and porcine tracheal epithelial cells (Black et aL, 1989) and airway 
epithelia of rats and mice (Rozengurt et aL, 1990), has been reported and its production 
within close proximity to the lungs and bronchus as well as tracheal smooth muscle 
itself, suggests that ET-1 could affect airway smooth muscle. Indeed, studies with 
airway smooth muscle both in vitro and in vivo have demonstrated that ET-1 exerts a 
potent contractile effect on the airway smooth muscle of the guinea-pig (Uchida et aL, 
1988; Maggi et aL, 1989c; Hay 1990 & Henry et aL, 1990), rat (Henry et aL, 1990), 
rabbit (Grunstein et aL, 1991a &1991b) and human (McKay et aL, 1991b) and that 
aerosol or intravenous (i.v.) administration of ET-1 to anaesthetized animals results in a 
sustained bronchoconstrictor response (Lagente et aL, 1989; Whittle et aL, 1989; 
Touvay et aL, 1990 & Dyson et aL, 1991).
The airway response to ET-1, as for the vascular response, is slow in onset, 
characteristically long lasting and very difficult to wash out. The ET-1 induced 
response is unaffected by blockers of histamine, 5-HT, acetylcholine and a  
adrenoceptors (Cardell et aL, 1990 & Hay, 1990), indicating a direct action of ET-1 on 
smooth muscle. However, in some preparations, propranolol has been shown to 
potentiate the airway effects of ET-1 when administered i.v. to anaesthetized animals 
(Braquet et aL, 1989 & Touvay et aL, 1990), but has no effect when ET-1 is given via 
aerosol (Braquet et aL, 1989), suggesting that propranolol has a systemic effect rather 
than local bronchial activity and further demonstrates that both phenomena i.e. 
respiratory and vascular, are in part, dissociated (Macquin-Mavier et aL, 1989 & 
Touvay et aL, 1990). The action of dihydropyridine Ca^+ antagonists demonstrate that 
in the airways, the involvement of voltage sensitive Ca^+ channels in the ET-1 induced 
response is as equivocal as that observed in the vascular system. Ca^+ channel
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blocking agents have been shown to attenuate the effects of ET-1 in some airway 
preparations (Uchida et a l, 1988 & Bolger et a l, 1990a), and to have no effect in 
others (Turner et a l, 1989a; Hay, 1990 & McKay et a l, 1991a). The role of 
eicosanoids in the ET-1 induced airway response is also heavily disputed, the action of 
ET-1 in some preparations being limited by the formation of eicosanoids (Hay, 1990 & 
Henry et a l, 1990), whilst in others, inhibition of cyclooxygenase results in an 
attenuation of response (Sarria et a l, 1990).
Marked interspecies and intertissue variations in the potency of ET-1 on airway smooth 
muscle have further complicated the overall picture of ET-1 activity. The potency of 
ET-1 within airway smooth muscle has been shown to be directly comparable with that 
observed in the vascular system i.e. EC50  0.53nM in guinea-pig tracheal smooth 
muscle (Uchida et a l, 1988) compared with 0.4nM, observed in porcine coronary 
artery strips (Yanagisawa et al, 1988a), although in some cases it has been shown to 
be remarkably less potent (Turner et a l, 1989a). Furthermore, it is possible that the 
potency of ET-1 is heterogenous within the respiratory tract, with different potency 
values found in the trachea and the lung parenchyma (Bolger et al., 1990a).
1.5.1 Activity of the Endothelins and Analogues
The three endothelin isoforms ET-1, ET-2 and ET-3, have all been demonstrated to be 
potent constrictors of airway smooth muscle (Maggi et a l, 1990; Advenier et a l, 1990 
& Dyson et a l, 1991). However, the pharmacological profile of each of the three 
isoforms is qualitatively different and moreover, reports of rank orders of potency are 
equivocal. Maggi and coworkers showed ET-3 to be the more potent peptide in 
constricting guinea-pig bronchus in vitro, and indicated a rank order of potency of ET- 
3>ET-2>ET-1 (Maggi et al., 1990), whereas, in human isolated bronchus the rank 
order of potency and efficacy was ET-l>ET-2=ET-3 (Advenier et a l, 1990). It is 
possible that species differences could be considered to be responsible for such variable
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findings and analysis of the airway responses to i.v. ET-1, ET-2, ET-3 and sarafotoxin 
S6b in the anaesthetized cat have demonstrated a rank order of potency ET-2=S6t»ET- 
l=ET-3 (Dyson et al., 1991), again illustrating the variability in the action of the 
peptides.
Despite the disulphide bridge Cysl-15 being considered to be the more important of the 
two bridges for expression of the full vasoconstrictor activity of ET-1 (Miller et a l, 
1989), the monocyclic ET-1 analogue containing the disulphide bridge Cysl-15 and an 
amidated C terminus, up to a concentration of 30nmol/kg i.v. had little or no effect on 
the pulmonary mechanics of the anaesthetized cat (Dyson et aL, 1991), perhaps 
indicating that in the airways the activity of ET-1 depends more on the presence of the 
Cys3-ll disulphide bridge. The carboxyl terminal fragment 16-21 (CTF( 16-21)) is 
common to all the endothelin peptides, however its activity is tissue dependent. In the 
guinea-pig bronchus CTF(16-21) has been shown to be a full agonist with an EC50 of
0.23|iM (Maggi et a l, 1989a & Rovero et a i, 1990), whereas in vascular or other 
nonvascular tissue preparations, CTF has little or no effect (Maggi et al., 1989a & 
Nakajima et al., 1989). Amidation of the CTF to produce CTF(16-21)NH2 results in a 
dramatic decrease in activity (EC50  >0.1 mM) (Maggi et al., 1989b), thereby 
suggesting that the Trp^COOH function plays a crucial role in the activation of the ET 
receptors in airway smooth muscle. Further studies with the analogues of the CTF(16- 
21) have demonstrated that the contractile activity of the CTF depends upon its 
structural configuration. Indeed, the analogues of E T -l(i6-21 )> E T -l^ 7 -2 l) and 
[Vall9]ET(i6 -21 ) were the only structural variations which resulted in a comparable 
maximum response to the parent CTF( 16-21) (Rovero et a i, 1990). It is interesting to 
note that despite the sarafotoxins being full agonists in the guinea-pig bronchus, 
sarafotoxin(i6 -21 ) and sarafotoxin S6d (i6 -21 ) displayed only very weak agonist 
properties (Rovero et a l, 1990). As the only structural variation between ET(i6 -2 1 ) 
and S6d (i6 -21 ) is the replacement of L eu^  with Gin, it is possible that this is the 
crucial feature for the differential activity. The possibility of cross reactivity between
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endothelin CTF and unrelated receptors cannot be excluded, however the structural 
requirements for full endothelin activity are similar to those required by the CTF(i6 - 
21), which makes this more unlikely.
In vivo however, the response to CTF( 16-21) is inconsistent with that observed in 
vitro. Aerosol administration of CTF(16-21) up to a concentration of ImM, to 
anaesthetized, spontaneously breathing rats, failed to affect pulmonary mechanics, 
whereas ET-1 itself resulted in bronchoconstriction (Di Maria et al., 1991), thereby 
suggesting that the bronchoconstrictor activities of ET-1 in vivo are not dependent on 
its C terminal sequence. Similarly, CTF( 16-21) up to a concentration of 300nmol/kg 
administered i.v. to the anaesthetized cat had little or no activity on pulmonary 
mechanics (Dyson et al., 1991). Route of drug administration may be considered to be 
a feature responsible for variations in results, but aerosol administration may be 
regarded as a more physiological route, when considering respiratory responses, than
i.v. administration where the drug is exposed to circulating factors. However, the 
failure of CTF(16-21) to elicit a response in the above systems occurred on both 
aerosol and i.v. administration, and may therefore be considered to be a consequence of 
in vivo studies.
1.5.2 Mechanism of Action
The precise mechanism of action of ET-1 within the respiratory system is unclear and 
controversial. Reports concerning the involvement of Ca^+ channels and metabolites of 
arachidonic acid in the ET-1 induced response are equivocal, possibly related to the 
region of the respiratory tract studied e.g. tracheal smooth muscle, bronchi or the lungs 
themselves, resulting in intersystem as well as interspecies variations, thereby further 
complicating the overall picture.
1.5.2.1 Involvement o f Calcium Channels
ET-1 was originally postulated to be an endogenous agonist of the dihydropyridine 
sensitive Ca^+ channels (Yanagisawa et ai, 1988a). Confirmation of such an action of 
ET-1 in the respiratory system was provided by Uchida and coworkers who 
demonstrated the contractile action of ET-1 in guinea-pig tracheal smooth muscle to be 
inhibited in the presence of the Ca^+ channel blocking agent nicardipine (Uchida et al., 
1988). However, further studies into the role of Ca2+ channels in the ET-1 induced 
respiratory response have showed variability in the effects of Ca^+ channel antagonists 
(see Table 3). Maggi et a i, (1989c), indicated that L-type voltage sensitive Ca^+ 
channels play a role in the ET-1 induced respiratory response in both isolated guinea- 
pig trachea and bronchi. Nifedipine was shown to partially inhibit the ET-1 induced 
contraction, whilst NiCl2 and to conotoxin were ineffective, suggesting that neither T 
nor N type voltage sensitive Ca^+ channels are involved. Despite partial inhibition of 
the response however, a large component of the response remained nifedipine resistant, 
thereby suggesting the possible involvement of other Ca^+ channels or perhaps the 
mobilization of intracellular Ca^+ (Maggi et a i, 1989c). Preincubation of rat tracheal 
smooth muscle with nicardipine has been shown to both inhibit (Borges et a i, 1989b) 
and to have no effect (Turner et a i, 1989a), on the ET-1 induced contraction. 
Furthermore, Hay, (1990), observed that nicardipine had very little or no effect on the 
ET-1 induced contraction of guinea-pig tracheal smooth muscle, suggesting that ET-1 
acts largely via a mechanism other than activation of the dihydropyridine sensitive Ca^+ 
channels. Indeed, the inhibition of the contractile response to ET-1 in rat tracheal 
smooth muscle by the K+ channel opener BRL 34915 lends further support to such a 
hypothesis (Turner et a i, 1989a).
The contractile response of the human isolated bronchial smooth muscle to ET-1, is 
composed of two phases (Advenier et al., 1990). The initial phase, in response to low 
concentrations of ET-1, has low intrinsic activity but is potentiated by the action of the
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Csfi+ channel agonist Bay K8644 and inhibited by nicardipine. The second phase 
however, has higher intrinsic activity but is not significantly modified by either Bay 
K8644 or nicardipine. Therefore, it is suggested that at low concentrations of ET-1, 
Ca2 + influx via dihydropyridine sensitive channels occurs, whereas at higher 
concentrations, some other mechanism comes into operation. Support for the two phase 
mode of action of ET-1 was provided by Sarria et a i, (1990), in a study on guinea-pig 
tracheal rings and moreover indicated that the response to high concentrations of ET-1 
involved the action of non-specific Ca^+ channnels, evidenced by the inhibitory action 
of the inorganic Ca^+ channel antagonists La^+ and Cd^+. It has therefore been 
demonstrated that, although a large portion of the response to ET-1 involves stimulation 
of influx of extracellular Ca^+, the relative contribution of such channels may be tissue 
dependent. This factor may therefore account for the reported variability of the action of 
the dihydropyridine Ca^+ channel blockers on the ET-1 induced response in respiratory 
smooth muscle, although offering no explanation for differential activity of the 
antagonists in the same tissue. Ontogenetic studies looking at the action of ET-1 on the 
tracheal smooth muscle of adult and 2 week old rabbits, have revealed however, a 
difference not only in the potency of ET-1 itself, but also in the efficacy of nifedipine 
(Grunstein et al.t 1991b). A greater role for involvement of voltage dependent Ca^+ 
channels in immature tracheal smooth muscle was suggested, evidence for which was 
provided by the enhanced effect of the Ca^+ channel antagonist in attenuating the ET-1 
induced contraction. The relative contribution of Ca^+ from other stores and possibly 
channels, was shown to increase with age, demonstrated by the reduced effect of 
nifedipine in adult tracheal smooth muscle.
In vivo, the bronchoconstrictor action of ET-1 appears not to be mediated via the 
activation of voltage dependent Ca^+ channels (Braquet et a i, 1989; Lagente et al., 
1989 & Macquin-Mavier et a l, 1989). Pretreatment with i.v. nicardipine (30mg/kg) 
(Macquin-Mavier et a i, 1989), intra peritoneal (i.p.) nifedipine (50mg/kg) and i.v. 
verapamil (0.3mg/kg) (Braquet et ai, 1989 & Lagente et al., 1989), failed to inhibit the
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bronchopulmonary response to both i.v. (Macquin-Mavier et al., 1989) and aerosol 
(Braquet et a l, 1989 & Lagente et al., 1989) administration of ET-1 to anaesthetized, 
mechanically ventilated guinea-pigs.
1.5.2.2 A Role fo r  Calcium
The dependence of the ET-1 induced response on extracellular Ca^+, is as the 
involvement of Ca2+ channels, controversial. Yanagisawa et al., (1988a), proposed 
that contraction of isolated porcine coronary arteries to ET-1 was due, in part, to the 
influx of extracellular Ca2+ into the cytoplasm of the cell, thereby suggesting that the 
response is dependent on the presence of extracellular Ca^+. Incubation of the rat 
tracheal smooth muscle in a Cs?+ free medium containing O.lmM EGTA resulted in an 
attenuation of response to ET-1 (Turner et al., 1989a). Furthermore, following 
readmission of Ca^+ to the medium surrounding the tissue a sustained contraction to 
ET-1 was observed. The failure of a voltage dependent Ca^+ channel blocking agent to 
alter the response to ET-1 further suggests, that influx of Ca^+ occurs via a route other 
than that of the dihydropyridine sensitve Ca^+ channel. The partial inhibition of 
response to ET-1 in a Ca^+ free medium suggests that the contractile action can in part 
be attributed to the mobilization of intracellular Ca^+ stores. Sarria and coworkers 
observed that incubation of guinea-pig tracheal chains in a Ca^+ free medium 
(containing ImM EDTA), resulted in the abolition of the ET-1 induced response to low 
concentrations of ET-1, but only partial inhibition of the response to higher 
concentrations (Sarria et ai, 1990). Therefore, it is suggested that the response to low 
concentrations of ET-1 is totally dependent on extracellular Ca^+, whereas the partial 
dependency observed at higher concentrations, suggests a possible involvement of 
intracellular Ca^+ store mobilization. Unexpectedly, the removal of Ca^+ from the 
extracellular environment was without effect on the ET-1 induced contraction observed 
in human bronchial smooth muscle (McKay et a i, 1991b). This suggests that the 
contractile response to ET-1 in bronchial smooth muscle is elicited via a mechanism
5 8
completely independent of extracellular Ca^+, but does not rule out the involvement of 
intracellular Ca^+. However, it is difficult to compare results from many studies, as 
variations in experimental protocols may give rise to inconsistencies. Indeed, Hay 
(1990), observed that increasing the concentration of the Ca^+ chelating agent EGTA 
from O.lmM to ImM resulted in the abolition of the ET-1 induced response in guinea- 
pig tracheal smooth muscle, which at the lower concentration was unaffected. It is 
possible that such a response is due to high affinity membrane bound Csfl+ being 
removed by the increased concentration of EGTA, but it is equally possible that such a 
response is due to the depletion of intracellular Ca^+ stores. Furthermore, the 
involvement of intracellular Ca2+ in the ET-1 induced contraction of tracheal smooth 
muscle was demonstrated by the use of a naturally occurring alkaloid, ryanodine, 
which affects Ca2 + mobilization specifically from the sarcoplasmic reticulum. 
Incubation of the tissue with ryanodine resulted in an inhibitory effect on the contractile 
response to ET-1 (Hay, 1990). Substitution of the medium with Ca^+ free buffer 
containing ImM EGTA markedly inhibited the contractile response to ET-1 in both 
adult and immature rabbit tracheal smooth muscle (Grunstein et al., 1991b), implying 
an absolute requirement of extracellular Ca^+ in the ET-1 induced response. However, 
the variation in the efficacy of nifedipine in both tissues, suggests that the relative 
contribution of other stores of Ca^+ varies maturadonally.
Further support for ET-1 inducing contraction of respiratory smooth muscle partly by 
the release of intracellular Ca^+ stores, is the finding that ET-1 stimulates PI turnover, 
measured as total inositol phosphate accumulation, in guinea-pig (Hay 1990), rabbit 
(Grunstein et a l, 1991b) and rat (Henry et a l, 1992), tracheal smooth muscle. The ET- 
1 stimulated accumulation of inositol phosphates was determined to be both time and 
dose dependent, and in the case of the rabbit tracheal smooth muscle, IP3 accumulation 
was significantly greater in the tissues from 2 week old rabbits when compared with the 
adult (Grunstein et al., 1991b). Several components of the rat tracheal wall, the smooth 
muscle band, the cartilagenous region and the intercartilagenous region generated
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significant levels of [^Hj-InsP in response to ET-1 (Henry et aL, 1992). On a wet 
weight basis, the airway smooth muscle band was the most responsive to the [^H]- 
InsP generating actions of ET-1 and mechanical removal of the epithelium had no 
significant effect on the levels of [^H]-InsP generated. Previous studies have indicated 
that phosphatidylinositol (4,5)bisphosphate is the major and possibly exclusive 
phosphoinositide hydrolysed by hormone sensitive PLC in airway smooth muscle 
(Chilvers & Nahorski 1990). Therefore, the ET-1 induced accumulation of [^Hj-InsP 
may provide an indirect index of Ins(4,5)P2 hydrolysis, which may in turn 
quantitatively reflect the turnover of Ins(l,4,5)P3, which is linked to mobilization of 
intracellular Ca^+.
The signal transduction pathway associated with ET-1 induced PI turnover, leads to the 
activation of protein kinase C (PKC), which has been shown to contract rabbit airway 
smooth muscle (Schramm et aL, 1989). Therefore, it is possible that the airway 
contractile response to ET-1, like the vascular response, may be coupled to the 
activation of PKC. Indeed, Grunstein et al., (1991a), demonstrated that the PKC 
inhibitors H-7 and staurosporine, did inhibit the ET-1 induced contraction of rabbit 
tracheal smooth muscle. Further studies on rabbit tracheal smooth muscle have 
indicated that H-7 (10nM-100pM), exerts a more potent inhibitory effect on the 
immature smooth muscle (Grunstein et al., 1991b). However, in guinea-pig tracheal 
smooth muscle, both staurosporine and H-7 (3 and 10|iM), failed to affect the ET-1 
induced contractile response, whereas, increasing the dose of H-7 to 30jiM resulted in 
a marked attenuation of response (Hay, 1990), thereby suggesting that the inhibitory 
effect of the higher concentration of the PKC inhibitor may be due to some mechanism 
other than inhibition of PKC. Such equivocal results require further clarification of the 
exact role of PKC in the ET-1 induced contraction of airway smooth muscle, however, 
it must also be borne in mind that such results may also represent a distinct species 
variation.
6 0
1.5.2.3 Involvement o f Eicosanoids
ET-1 has been shown to cause constriction of airway smooth muscle both in vitro and 
in vivo, but the precise mechanism by which this contraction is generated remains 
unclear. Reports of ET-1 promoting the release of both prostaglandins (PGl2 )and 
thromboxanes (TXA2 ) (de Nucci et al., 1988), have led to speculation as to the exact 
involvement of eicosanoids in the ET-1 induced response. ET-1 injected i.v. in an 
anaesthetized guinea-pig results in bronchoconstriction due to an increase in pulmonary 
inflation pressure (PIP), and a decrease in lung conductance and compliance (Payne & 
Whittle 1988; Braquet et a i, 1989; Macquin-Mavier et a i, 1989; Whittle et al., 1989; 
Schumacher et a i, 1990; Touvay et a l, 1990 & Raffestin et a i, 1991), and is 
accompanied by an increase in mean arterial blood pressure (Braquet et a l, 1989 & 
Touvay et al., 1990). However, Touvay and coworkers have indicated that the 
bronchopulmonary effects of ET-1 are in part dissociated from its systemic action 
(Touvay et aL, 1990). Such a view is further strengthened by the fact that aerosol 
administration of ET-1 results in a selective bronchoconstrictor response which is not 
accompanied by a hypertensive reaction (Braquet et al, 1989 & Lagente et a l, 1989). 
Pretreatment with the cyclooxygenase inhibitors indomethacin or sodium 
meclofenamate inhibits the i.v. induced ET-1 increase in PIP (Payne & Whittle 1988 
Braquet et a l, 1989 & Whittle et a l, 1989) and induces a prolonged hypotensive 
reaction (Touvay et al, 1990), thereby suggesting that the action of ET-1 is mediated 
indirectly via the secondary release of the cyclooxygenase metabolites of arachidonic 
acid, rather than by a direct action on the smooth muscle itself. Inhibition of the 
cyclooxygenase enzyme results in the inhibition of formation of both prostaglandins 
and thromboxanes, therefore it is possible that the constrictor actions of ET-1 could be 
mediated via either of the metabolites. Pretreatment of anaesthetized guinea-pigs with a 
thromboxane receptor antagonist BM 13177 (5mg/kg i.v.), (Whittle et a l, 1989) prior 
to ET-1 administration has been shown to substantially attenuate the ET-1 induced
increase in PIP, thereby confirming the involvement of endogenous TXA2 in the 
bronchconstrictor response.
Lagente and coworkers reported that pretreatment of anaesthetized guinea-pigs with 
indomethacin resulted in a 60% inhibition of the bronchopulmonary response induced 
via aerosol administration of ET-1 (Lagente et aL, 1989), suggesting that the 
bronchoconstriction induced by aerosolized ET-1 is only partly mediated via the indirect 
action of the products of cyclooxygenase. In contrast however, aerosolized ET-1 
infused through guinea-pig isolated lungs has been shown to be unaffected by prior 
treatment with indomethacin (Pons et a i, 1991b), furthermore, ET-1 administered in 
this manner did not result in the generation of TXA2 , whereas arachidonic acid was 
shown to induce a marked release of this metabolite in lung effluent. Such 
discrepancies indicate the possibility of other components or cell types being recruited 
during in vivo aerosol challenge with ET-1 and contributing to the indomethacin 
sensitive part of the bronchopulmonary activity of the peptide. However, the route of 
administration of the peptide must also be taken into consideration when determining its 
mechanism of action. De Nucci et aL, (1988), reported that intra arterial (i.a.), 
administration of ET-1 infused through guinea-pig lungs induced the release of PGI2 
and TXA2  and was suject to the inhibitory action of indomethacin, confirmation of 
such an action being provided by Pons et aL, (1991b). Therefore, when administered 
i.a., ET-1 infused through isolated lungs exerts its action via the release of the products 
of cyclooxygenase, but when given via aerosol, another mechanism must come into 
operation.
Studies performed in vitro on airway smooth muscle have reiterated the controversy 
surrounding the involvement of eicosanoids in the ET-1 induced response (Table 4). 
Maggi et aL, (1989c), reported that preincubation of tracheal smooth muscle with 
indomethacin resulted in a slight attenuation of the contractile response to the lower 
concentrations of ET-1, but had no effect on the response to higher concentrations of
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the peptide (>10nM). Furthermore, indomethacin has been demonstrated to attenuate 
the constriction induced by ET-1 in some guinea-pig tracheal and bronchial smooth 
muscle preparations (Sarria et aL, 1990 & Filep et aL, 1991a), whilst having no effect 
in others (Cardell et aL, 1990). The ET-1 induced contraction of the human isolated 
bronchus has been shown to be unaffected by a range of concentrations of 
indomethacin from 3gM (Advenier et aL, 1990) to 25|aM (McKay et aL, 1991), 
indicating that in the human bronchi the products of cyclooxygenase have no 
involvement in the ET-1 induced response. However, it has also been reported that the 
action of ET-1 in guinea-pig tracheal smooth muscle is limited by the formation of 
inhibitory products of cyclooxygenase (Hay, 1989 & 1990 & Henry et aL, 1990). 
Preincubation of the tissues with indomethacin resulted in a potentiated response to ET- 
1, suggesting that a bronchodilator prostanoid attenuates the constrictor action of ET-1. 
It is interesting to note that indomethacin abolished the relaxant responses observed 
upon application of ET-1 in immature rabbit tracheal smooth muscle and attenuated by 
50%, the relaxant responses observed in the adult (Grunstein et aL, 1991b). 
Furthermore, the contractile responses to ET-1 were potentiated in each case, but to a 
relatively greater extent in the adult. Such findings are in direct contrast to the effects of 
cyclooxygenase inhibition in vivo and much of the research reported in vitro.
Thromboxanes have also been implicated in the ET-1 induced response in airway 
smooth muscle in vitro (Battistini et aL, 1990a & Filep et aL, 1991a). The contractile 
response of guinea-pig tracheal smooth muscle to ET-1 was shown to be inhibited by 
50% when in the presence of the thromboxane receptor antagonists BM 13177 or BM 
13505, suggesting that thromboxane receptor activation plays a contractile role in the 
ET-1 induced response. Such results confirm the in vivo findings of Whittle et aL, 
(1989), and Schumacher et aL, (1990). However, the involvement of thromboxanes in 
the ET-1 response is controversial. The thromboxane receptor antagonist SQ 29548 
failed to affect the contractile response to ET-1 in the isolated tracheal smooth muscle of
63
the guinea-pig (Hay, 1990), as did the combined TXA2/PGH2  receptor antagonist SQ 
30741 (Schumacher et ai, 1990).
The role of the products of the lipoxygenase enzyme have also been examined with 
respect to the contractile action of ET-1 (Hay, 1990; Filep et al., 1991a; Pons et aL, 
1991b & Henry et aL, 1992). The combined cyclooxygenase and lipoxygenase inibitor 
BW 755C, inhibited the ET-1 induced increase in PIP, PPP and TXB2 formation 
observed on i.a. administration of the peptide in isolated lungs, an effect not observed 
on aerosol administration (Pons et aL, 1991b). However, the leukotriene receptor 
antagonist FPL 55712, failed to have an effect on both i.a. and aerosol administration 
of ET-1, indicating that the lipoxygenase metabolites are not involved in the 
bronchopulmonary alterations induced by ET-1. Similarly, the lack of effect of SKF 
104353 on the action of ET-1 in guinea-pig (Hay, 1990) and rat (Henry et aL, 1992) 
tracheal smooth muscle promotes the non involvement of leukotrienes in the ET-1 
response. Furthermore, leukotriene C4 and D4  failed to contract rat tracheal smooth 
muscle (Henry et aL, 1992). However, such reports are contradictory to the findings of 
Filep et aL, (1991a), the leukotriene receptor antagonists FPL 55712 and YM 16638, 
attenuating the ET-1 induced contraction in guinea-pig trachea, upper bronchus and 
lung parenchyma, indicating that leukotrienes contribute to the contractile action of ET- 
1. The reasons for such discrepancies in the involvement of the leukotrienes in the ET-1 
induced response are unclear.
1.5.2.4 Involvement o f Platelet Activating Factor
Pretreatment of anaesthetized guinea-pigs with the platelet activating factor (PAF) 
receptor antagonist BN 52021, resulted in a 52% inhibition of the bronchoconstrictor 
response induced by aerosolized ET-1 (Lagente et aL, 1989), indicating that part of the 
response to ET-1 is mediated by the induced release of PAF itself. This hypothesis was
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further supported by the in vitro effectiveness of both BN 52021 and WEB 2086 (two 
structurally unrelated PAF receptor antagonists), in attenuating the constriction evoked 
by ET-1 in isolated guinea-pig tracheal smooth muscle (Battistini et al., 1990b & Filep 
et al., 1991a &1991b). Furthermore, the release of TXA% evoked by lOnM and lOOnM 
ET-1 in lung parenchyma strips was inhibited by more than 30 and 40% respectively, 
by BN 52021 and WEB 2086 (Filep et al., 1991a). Contrary to such observations 
however, WEB 2086 failed to have any significant effect on the ET-1 induced response 
on isolated rat tracheal smooth muscle (Henry et a i, 1992). PAF release however, is 
not the sole mechanism by which ET-1 exerts its action, demonstrated by the 
contractile, although diminished, response to ET-1 observed in tissues precontracted 
with PAF (Battistini et al., 1990b).
■1.5.2.5 The Role o f the Epithelium
The epithelium appears to play a modulatory role in the activity of the neurokinins 
(Devillier et al., 1988). However, the mechanism responsible for this modulatory 
influence remain controversial, although postulates for which there is relatively 
convincing evidence include; (i) the epithelium is a source of prostanoid and 
nonprostanoid inhibitory factors (Tschirhart et a i, 1987 & Braunstein et aL, 1988), 
and (ii) the epithelium is a site of metabolism for some agents including catecholamines 
(Farmer et a i, 1986) and neurokinins (Devillier et a l, 1988). There is preliminary 
evidence to suggest that the epithelium attenuates the ET-1 induced contractile response 
of guinea-pig bronchi as removal of the epithelium resulted in a potentiated response to 
the peptide (Maggi et a i, 1989c). Confirmation of the inhibitory role of the epithelium 
was provided by Hay (1989; 1990), where the mechanical removal of the epithelium 
potentiated the contractile response to ET-1 in guinea-pig tracheal smooth muscle. 
Furthermore, indomethacin potentiated the effects of ET-1 in both intact and denuded 
smooth muscle preparations, thereby suggesting that the epithelium is not the only 
source of inhibitory prostanoids. However, the exact nature of the inhibitory influence
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of the epithelium in the ET-1 induced response, remains to be clearly defined. In a 
study on guinea-pig tracheal smooth muscle, epithelium removal was shown to 
attenuate the ET-1 induced response (Cardell et al., 1990), whereas removal of rat 
tracheal epithelium failed to have any significant effect on the response to ET-1 (Henry 
et a i, 1992), suggesting that in this tissue at least, the epithelium has no involvement in 
the mechanism of action of ET-1. The ET-1 induced relaxation responses observed in 
rabbit tracheal smooth muscle were shown to be ablated upon removal of the epithelium 
and in the presence of indomethacin, suggesting that the epithelium is responsible for 
releasing an epithelium derived relaxing factor as well as bronchodilatory 
prostaglandins (Grunstein et a i, 1991a). However, in immature rabbit tracheal smooth 
muscle, neither the airway relaxant nor contractile response elicited by ET-1, depend 
upon the integrity of the airway epithelium (Grunstein et ai, 1991b).
It is possible that the potentiation of the ET-1 induced response in the absence of a 
functional epithelium may be due to the non-degradation of the peptide. Hay (1989), 
observed the effects of epithelium removal on the ET-1 induced response in the 
presence of leupeptin, bacitracin and captopril, suggesting that the modulatory influence 
of the epithelium on the ET-1 response is not attributed to the influence of epithelium 
derived endopeptidases, aminopeptidases and angiotensin converting enzyme. 
However, a neutral endopeptidase inhibitor phosphoramidon, was shown to inhibit the 
effects of epithelium removal on the response to ET-1. Contrary to such reports 
however, a cocktail of enzyme inhibitors, including thiorphan, bestatin and captopril, 
have been demonstrated to potentiate the response to all three endothelin isoforms in the 
smooth muscle of the guinea-pig bronchus (Maggi et a i, 1990), thereby suggesting 
that in this tissue the contractile activity of ET-1 is limited by the concomitant 
production of an epithelium derived relaxing factor, prostanoid production and possibly 
enzymatic degradation.
7 6
1.5.3 Endothelin Binding Sites on Respiratory Smooth Muscle
Specific binding sites for ET-1 have been identified using radiolabelled [125l]ET-l, on 
rat tracheal smooth muscle (Turner et al, 1989b; Power gf al., 1989 & Henry et al.,
1990), human lung (Hemsen et ai, 1990 & Brink et al., 1991), guinea-pig and mouse 
tracheal smooth muscle (Henry et a i, 1990), guinea-pig lung (Kanse et a i, 1989) and 
rat lung (Koseki et a i, 1989), by both quantitative autoradiography and functional 
binding assays (Table 5). Binding sites for ET-1 have also been localized on the 
smooth muscle of human bronchus, alveoli and airway parasympathetic ganglia 
(McKay et a i, 1991c). The localization of such binding sites coupled with the potent m 
vitro contractile effects observed in human bronchial smooth muscle (McKay et al., 
1991c), suggests that the peptide may be involved in endogenous control of human 
airway smooth muscle tone. In each case, binding was shown to be time dependent and 
saturable and Scatchard analysis of the data revealed a single class of affinity binding 
sites over the respiratory smooth muscle. No specific binding was detected on the 
cartilage or the connective tissues associated with tracheal smooth muscle, however, 
non-specific labelling of respiratory epithelium was observed (Power et al., 1989 & 
Henry et al., 1990). Rat tracheal smooth muscle was shown to display the greatest 
density of ET-1 binding sites (Bolger et a i, 1990b), compared with other tissues 
studied, lung parenchyma, vas deferens, aorta, ventricle and bladder. Furthermore, the 
similar binding properties for [125j]ET-l in rat and guinea-pig lung also suggests 
species similarities for ET-1 binding sites within a single tissue, which is not borne out 
by functional assays, suggesting a possible difference in post receptor mechanisms. 
Non-specific binding in guinea-pig and rat lung parenchyma ranged from 14-19%, but 
generally varied according to the tissue and quantity of membranes present (Bolger et 
al., 1990b).
ET-1 has been shown to constrict airway smooth muscle from a variety of different 
species, however, marked interspecies and intertissue variations exist with respect to
7 7
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the constrictor potency of ET-1 (Uchida et ai, 1988; Maggi et a i, 1989a; Turner et al., 
1989a & Hay, 1990). It is possible that such potency differences may be due to 
different post receptor events or to differences in receptor density. Indeed, Turner et 
al., (1989b), demonstrated that in rat tracheal smooth muscle, the apparent Kd of 
0.134nM, whilst reflecting the potency of ET-1 observed in porcine coronary artery 
strips (Yanagisawa et a i, 1988a), did not correlate with the EC50 value of 5.4jiM, for 
the ET-1 induced contraction. Such a discrepancy may be due to loss of the peptide 
during functional superfusion experiments or suggests that the ET-1 binding sites 
identified in this study may not be associated with the receptors mediating contraction. 
Similarly Bolger et al., (1990a & 1991b), found there to be no correlation between the 
density of ET-1 binding sites and the contractile efficacy of ET-1 in rat and guinea-pig 
tissues. It was suggested that this lack of correlation may arise because ET-1 has the 
ability to gain access to many sources of Ca2+ to support contraction (Bolger et al., 
1990a). Good correlation of binding site density and ET-1 activity in guinea-pig and rat 
tracheal smooth muscle and human bronchus was observed by Henry and colleagues 
(Henry et al., 1990). Guinea-pig tracheal smooth muscle was shown to contain the 
lowest density of ET-1 binding sites and was the least responsive species to the 
constrictor action of ET-1, whereas rat tracheal smooth muscle was the most responsive 
tissue and also contained the highest density of ET-1 binding sites. However, mouse 
tracheal smooth muscle was shown to be an exception, containing a lower number of 
ET-1 binding sites than either rat or human airway smooth muscle, but functionally was 
the most responsive to the constrictor action of ET-1. A possible explanation for the 
high sensitivity of mouse tracheal smooth muscle, which is not indicative of all mouse 
tissues (Henry et a i, 1990), is a more efficient coupling mechanism between ET-1 
binding sites and post receptor mechanisms, processes which are essentially complex 
and require further clarification.
ET-1 binding sites have been demonstrated to be distinct from the dihydropyridine 
voltage dependent Ca^+ channel binding sites evidenced by the lack of effect of
8 0
nicardipine (Power et a i, 1989 & Turner et ai, 1989b) and verapamil (Turner et a i, 
1989b), on the binding of ET-1 to airway structures. Furthermore, the binding of ET-1 
to rat airway smooth muscle has been shown to be unaffected by preincubation with the 
Ca2+ channel agonist Bay K8644 (Davenport et a i, 1989), thereby suggesting that in 
the airway ET-1 is unlikely to be interacting with the dihydropyridine binding site. The 
binding of ET-1 to airway smooth muscle has been shown to be unaffected by various 
peptides e.g VIP, CGRP and BK, toxins and also ion channel blocking agents such as 
the K+ blocking agent tetraethylammonium (Turner et ai, 1989b), thereby indicating 
that specific ET-1 binding is unlikely to be related to an interaction with such channels. 
Whole body autoradiographic studies performed with |^^F|-big-ET-l in rats have 
revealed binding sites for the ET-1 precursor, which form a similar pattern of 
distribution to that of ET-1 itself (Stasch et a i, 1991), binding sites of medium or high 
density observed in the tracheal wall and lungs.
1.5.4 Uptake and Metabolism of Endothelin-1
The radioisotope [125]]et-1 has been shown to disappear rapidly from the circulation 
of anaesthetized rats (Anggard et al., 1989 & Shiba et al., 1989), with 60% of the label 
disappearing within the first five minutes (Anggard et al., 1989). Analysis of tissues 
for accumulated radioactivity has revealed that the lung, kidney and liver displayed the 
highest accumulation of radioactivity (Anggard et al., 1989 & Shiba et al., 1989), and it 
is further suggested that the tissue distribution of radioactivity following i.v. injection 
of radiolabelled ET-1 is a function of distribution of blood flow and the availability of 
binding sites for the peptide, and may implicate these organs as sites of uptake and 
possibly metabolism of ET-1.
ET-1 infused through the isolated lungs of the guinea-pig has been shown to be 
substantially removed by the lungs (De Nucci et ai, 1988 & Anggard et al., 1989). ET-
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1 (InM), infused through the pulmonary circulation of guinea-pig isolated lungs 
resulted in only 40% of the amount infused detected in the effluent (De Nucci et al., 
1988). Similarly, Anggard and coworkers demonstrated that 65% of [^^I]-ET-1 
infused through the isolated lungs of the guinea-pig was lost in a single passage 
(Anggard et al., 1989). Therefore it is suggested that the lung removes two thirds of the 
circulating ET-1, however, it is not precisely known whether the disappearance is due 
to metabolic inactivation or to an uptake system. ET-1 is not a substrate for angiotensin 
converting enzyme evidenced by the lack of effect of captopril on the disappearance of 
the infused peptide. Further analysis of lung tissue however, has indicated that the 
accumulated radioactivity is associated with cell organelles, suggesting a mechanism by 
which circulating ET-1 is bound to the lung with rapid internalization of the peptide into 
cells (Anggard et a l, 1989 & Shiba et al., 1989). However, contrary to such findings 
Pemow et al., (1989), showed that infusion of ET-1 in the pig resulted in no significant 
clearance of the peptide over the lungs, but rather indicated the renal, systemic and 
skeletal muscle vascular beds to be important in the removal and inactivation of 
circulating ET-1 in vivo. Similarly, Lippton et a i, (1989a), suggested that ET-1 does 
not undergo significant first pass pulmonary metabolism in the anaesthetized cat. ET-1 
injected into either the left or right atria resulted in a similar vasodepressor response 
indicating that the systemic vasodilator activity is retained across the lung and 
furthermore indicates that the response is not due to the release of a dilator substance 
from the lung. Such equivocal results may be indicative of a species variance in the 
uptake of ET-1 by the lung or may possibly be a consequence of in vitro versus in vivo 
procedures. However, in the isolated, perfused rat lung ^ ^ ljE T -l (4pM), was rapidly 
removed from the lung perfusate, 90% of the label being removed within five minutes 
(Westcott et al., 1990). Unlabelled ET-1 reduced the uptake of the radiolabel, but did 
not displace the label previously taken up by the lung, furthermore at higher 
concentrations, ET-1 was more slowly removed from the perfusate, suggesting that the 
rat lung has a finite ability to take up ET-1. Neither lung associated nor perfusate ET-1 
was appreciably metabolized by the lung during a 30 minute perfusion, thereby
8 2
suggesting that the slow metabolism of the peptide and its tight binding properties may 
be responsible for the persistance of its constrictor acitvity (Westcott et al., 1990). 
Reports concerning the possible uptake and metabolism of ET-1 by the lung are 
equivocal and therefore remain to be fully elucidated. It must be borne in mind 
however, that the observed differences may be due to differing experimental 
procedures.
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1.6 THE VASCULAR ACTIVITY OF ENDOTHELIN-1
The vascular system, with respect to the action of ET-1, is of prime importance as it 
was within this system that ET-1 was initially discovered, isolated and many of its 
effects and mechanisms of action characterized. However, it is beyond the scope of this 
thesis, which is primarily concerned with the respiratory effects of ET-1, to give more 
than a very brief overview of the activity of the peptide in the vascular system. 
Therefore, key references have been cited and the following reviews concerned with the 
role of ET-1, will be useful in providing a more complete picture of ET-1 activity (Le 
Monnier de Gouville et ai, 1989; Yanagisawa & Masaki, 1989a &1989b; Chabrier & 
Braquet, 1990; Lovenberg & Miller, 1990 & Simonson & Dunn, 1991).
Endothelin-1 is one of the most potent vasoconstrictor agents known, has a threshold 
concentration in the pM range and an EC50 in the nM range (Yanagisawa et al.y 
1988a). ET-1 induces a slow developing, sustained constriction of vascular smooth 
muscle, the response being long lasting and extremely resistant to wash out. ET-1 
induces a dose dependent contraction of isolated vascular preparations from a variety of 
different species including rat (Borges et al., 1990a), rabbit (de Nucci et al., 1988; 
Marsden et al., 1989), cat (Saito et al., 1989), hamster (Ohlen et al., 1989), pig 
(Yanagisawa et a i, 1988a), dog (Shirhase et a i, 1991) and human (Brain et al., 1989 
& Crossman et al.,1991). Furthermore, isolated venous preparations have been 
reported to be more sensitive to the action of ET-1 than arterial preparations (de Nucci 
et al., 1988 & D'Orleans-Juste et al., 1988). Binding studies using the radiolabelled 
ligand [^^fjET-l have revealed specific binding sites for the peptide on a wide variety 
of vascular tissues including blood vessels , for example, the aorta, renal artery and 
vein, the heart, kidney and brain (Koseki et a l, 1989 & Hoyer et a l, 1989), thereby 
indicating the wide diversity of sites of action of ET-1 within the vascular system. 
Therefore, it is evident that ET-1 is a potent vasoconstrictor agonist, active in many 
vascular regions and may have important physiological or pathological roles.
8 4
Within the cardiovascular system, ET-1 exerts its action both on the blood vessels 
supplying the heart and on the heart itself. ET-1 has been demonstrated to be a potent 
constrictor of coronary arteries, the potency of the peptide being greater in the smaller 
diameter vessels of both canine (Larkin et al., 1989) and porcine coronary arteries 
(Tippins et al., 1989), suggesting that ET-1 may cause cardiac ischaemia by 
constriction of resistive vessels rather than by epicardial coronary artery spasm 
(Kurihara et al., 1989). Furthermore, intracoronary doses of ET-1 which result in the 
constriction of resistance coronary vessels, produce a redistribution of blood flow 
within the heart, a reduced flow observed across the myocardium (Larkin et al., 1989), 
and a decrease in myocardial contractility secondary to ischaemia (Domenech et al.,
1991). ET-1 exerts a positive inotropic effect on the electrically driven isolated left atria 
of the guinea-pig (Ishikawa et al., 1988) and rat (Hu et al., 1988), in a dose dependent 
manner, with an EC50 value in the nM range, thereby confirming the original potency 
estimate of Yanagisawa et al., (1988a). It is suggested that ET-1 exerts its action 
directly on the cardiac myocytes as the action of the peptide is unaffected by adrenergic, 
histaminergic, and serotonergic antagonists (Hu et al., 1988; Ishikawa et a i, 1988). 
Moreover, ET-1 has been shown to exert a greater inotropic effect on atrial rather than 
ventricular tissue (Moravec et al., 1989), possibly suggesting a heterogenous 
distribution of ET-1 receptors within the heart. The increased development of force 
observed in response to ET-1 suggests that increased intracellular Ca^+ concentration is 
made available to activate contractile proteins, confimatory evidence provided by 
studies perfomed with vascular smooth muscle cells (see section 1.5.2). However, 
despite the action of ET-1 being thought to be intimately associated with influx of 
extracellular Ca^+ (Baydoun et al., 1989), the site of influx is not necessarily via 
potential operated Ca^+ channels (Chester et a i, 1989 & Reid et al., 1991). 
Autoradiographic localization of ET-1 binding sites in human coronary arteries, have 
revealed binding sites in close proximity with perivascular nerves, suggesting the 
possibility of ET-1 involvement in neural mechanisms (Chester et a i, 1989).
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Studies performed in vivo, have demonstrated that pharmacological concentrations of 
ET-1 result in coronary, renal and systemic vasoconstrictor responses (Goetz et ai., 
1988 & Minkes et al., 1990). Many of the cardiovascular effects evoked by ET-1 
appear to be initiated by its effects on total peripheral resistance (PVR), leading to an 
elevated arterial and left atrial pressure, a decrease in heart rate and cardiac output 
(Goetz et al., 1988). However, i.v. administration of ET-1 has been shown to induce 
biphasic changes in PVR, a decrease observed at low doses of ET-1 accompanied by an 
increased cardiac output and heart rate, which were reversed with an increase in ET-1 
concentration (Minkes et al., 1990). Therefore, ET-1 possesses both vasodilator and 
vasoconstrictor activity, which is not dependent on autonomic reflexes, activation of (3 
receptors or by the release of cyclooxygenase (Minkes et al., 1990).
Cerebral arteries have been shown to be more sensitive to the actions of ET-1 than both 
coronary and renal arteries (Fukuda et al., 1991), suggesting that ET-1 induced 
contractions of large cerebral arteries may play a more significant role in the cerebral 
circulation, than do the ET-1 induced contractions of the large coronary and renal 
arteries in the coronary and renal circulation. The constrictor effects of ET-1 are long 
lasting and resistant to wash out, suggesting that ET-1 may be a candidate for the 
generation of cerebral vasospasm. ET-1 exerts its vasoconstrictor effects, within the 
cerebral circulation, via an extracellular Ca^+ dependent mechanism (Saito et al., 1989 
& 1991; Salom et al., 1991). It is suggested that ET-1 acts directly on the smooth 
muscle rather than an indirect effect via endothelial cells, furthermore, it is hypothesized 
that in cerebral arteries ET-1 does not induce the release of EDRF, evidenced by a lack 
of dilator activities of ET-1 in these preparations (Saito et al., 1991). Binding sites for 
ET-1 have been identified throughout the brain and are partcularly dense in the choroid 
plexus (Kadel et al., 1990). Circulating ET-1 at doses which have no effect on cerebral 
blood vessels, have marked effects on the blood flow to the choroid plexus and may 
therefore contribute to the production of cerebrospinal fluid (Kadel et al., 1990). It is 
possible that the blood brain barrier limits the access of ET-1 to the cerebral vascular
8 6
muscle resulting in the observed effects. Therefore, ET-1 may have a role in the 
maintenance of fluid haemodynamics within the cerebral circulation.
ET-1 also has profound effects on the renal vasculature, causing constriction of isolated 
renal arteries, decreasing the glomerular filtration rate, inhibiting the release of renin 
(Rakugi et al., 1988) and has a number of actions on glomerular mesangial cells 
(Edwards et al., 1990). The afferent and the efferent arterioles are the major sites of 
resistance in the kidney and therefore are important determinants of of renal blood flow 
and glomeruar filtration rate, and ET-1 has been shown to be a potent vasoconstrictor 
of both the pre and post glomerular microvasculature (Badr et al., 1989; Edwards et al., 
1990), but induces a proportionately greater increase of efferent rather than afferent 
arteriolar resistance (King et ai, 1989). Intrarenal infusion of ET-1 induces a transient 
increase in renal blood flow (Banks et al., 1990 & Stacy et al., 1990),followed by a 
progressive vasoconstriction which reduces renal blood flow (Goetz et al.,-1988 & 
Stacy et al., 1990), accompanied by a reduction in the glomerular filtration rate, urine 
volume and urinary sodium and potassium excretion at higher infusion doses. The 
sensitivity of the renal artery to ET-1 has been demonstrated to be greater in 
spontaneously hypertensive rats (SHR) than Wistar Kyoto rats (WKY) (Tomobe et 
a/.,1988). Such an increased sensitivity to ET-1 in the SHR may contribute to the 
hypertensive state in the SHR, or may be involved in the pathogenesis of hypertension. 
Furthermore, it is possible that ET-1 may be involved in acute renal failure (Firth et a i, 
1988).
ET-1 has been shown to have marked systemic vasodilator activity in the cat (Lippton et 
al., 1988, 1989a & 1989b; Minkes et al., 1990), and some researchers have shown 
ET-1 to have pulmonary vasodilator activity in the rat (Hasunuma et a i, 1990 & 
Lippton et al.,1991). The failure of ET-1 to induce pulmonary vasodilation in the cat 
(Lippton et al., 1989a & Minkes et al., 1990), possibly indicates a species variation in 
response to the peptide. The ET-1 induced depressor responses are transient and dose
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related and are followed by a sustained pressor response (Le Monnier de Gouville et 
al., 1990b). Furthermore, when injected i.v. ET-1 produces differential effects 
depending upon the anatomical location of the vascular bed (Wright & Fozard 1988; Le 
Monnier de Gouville et a i, 1990b), which may reflect different local regulatory 
functions. The mediation of the vasodilator response to ET-1 is unclear and 
furthermore, the mechanism by which ET-1 induces vasodilation within the systemic 
and pulmonary circulation may differ (Lippton et al., 1991). ET-1 has been shown to 
induce the release of EDRF and eicosanoids (de Nucci et al., 1988), within the vascular 
system (for review see Botting & Vane 1990). The endothelium, in some vascular 
preparations, modulates the ET-1 constrictor activity in vitro, removal of the 
endothelium enhancing the constrictor response to the peptide (Douglas & Hiley 1990 
& Topouzis et al., 1991). Furthermore, in the presence of methylene blue or Nco-nitro- 
L-arginine methyl ester (NAME), the constrictor effects of ET-1 were shown to be 
potentiated to the same extent as that observed upon endothelium removal (Douglas & 
Hiley, 1990), suggesting that formation of EDRF limits the constrictor activity of ET-1 
in the vasculature. However, the effect of endothelium removal is equivocal, indeed, in 
the isolated canine cerebral arteries, removal of the endothelium failed to affect the 
vasoconstrictive response to ET-1 (Saito et a i, 1991), implying a direct action of ET-1 
on smooth muscle cells independent of the release of EDRF. The systemic vasodilator 
responses to ET-1 however, do not depend upon the formation of cyclooxygenase 
products or EDRF, nor on the activation of dopaminergic, serotonergic, ^-adrenergic, 
muscarinic, histaminergic and PAF receptors (Gardiner et al., 1989; Le Monnier de 
Gouville et al., 1990b). Moreover, the pulmonary vasodilator response to ET-1 may be 
mediated via the activation of glibenclamide sensitive K+ channels (Hasunuma et al., 
1990 & Lippton et al., 1991), and not on the activation of muscarinic and ^-adrenergic
receptors and formation of cyclooxygenase products.
Therefore, the precise mechanism by which ET-1 exerts both its vasoconstrictor and 
vasodilator activity remain to be clearly established, and it is evident that the actions of
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the peptide are complex. Further research is clearly required in order to fully elucidate 
the mechanism of action of ET-1 and to explain why such variability in responses to the 
peptide have been reported. Furthermore, the identification of the multiple mechanisms 
of action of ET-1, may further the knowledge and understanding of certain 
physiological or pathological conditions in which the vascular effects of ET-1 may play 
a contributory role.
1.7 AIMS OF THE THESIS
The aims of the thesis were to investigate the effects of endothelin-1 (ET-1), on isolated 
respiratory smooth muscle, to determine the potency and mechanism of action. The 
mechanisms of action of ET-1 were studied in depth as the peptide was reported to be 
one of the most potent bronchoconstrictor agents known (Uchida et al., 1988). Both 
rats and guinea-pigs were used to study the respiratory effects of ET-1 and to observe 
whether the mechanism of action of the peptide differed between the two species. The 
smooth muscle of the trachea was the tissue preparation of choice, as lung parenchyma 
is highly vascularised and ET-1 a very potent vasoconstrictor (Yanagisawa et al., 
1988), the respiratory effects of the peptide would have been difficult to differentiate 
from its vascular activity.
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CHAPTER 2 
METHODS
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2.1 ANIMALS
The animals used in this study were male Wistar Albino rats (University of Surrey 
strain), weighing 200-250g and male Dunkin Hartley guinea-pigs (obtained from 
Greystones), weighing 250-350g. The rats were housed eight per cage and were 
allowed free access to standard rodent chow and water, the guinea-pigs were housed 
ten to fifteen per cage and were also allowed free access to food and water. 
Furthermore, the animals were housed under controlled conditions of temperature 20- 
22°C and humidity 50-60%. Lighting was controlled on a twelve hour cycle, 07.00- 
19.00h light and 19.00-07.00h dark.
2.2 ISOLATED TISSUE STUDIES
Animals were killed by cervical dislocation, the trachea was exposed and rapidly 
excised by cutting as close to the external bronchi as possible and above the larynx. By 
removing the trachea in this way, it was then possible to identify both the laryngeal and 
bronchial regions of the trachea. The excised trachea was placed in Krebs solution 
aerated with 95% 02 and 5% (X>2. The tissue was washed through with Krebs 
solution to remove any clotted blood and any adherent connective tissue was carefully 
dissected away from the trachea itself. The trachea was cut into two pieces, identified as 
laryngeal and bronchial trachea (referring to the proximity of the larynx and bronchi 
respectively). Each piece of trachea was then cut into rings, each consisting of three 
hoops of cartilage. Tracheal rings were constructed according to the method of Castillo 
& de Beer (1947). Four tracheal rings were connected via the cartilage using 60 gauge 
Silko thread with a minimal amount of thread between each tracheal ring, the rings were 
then cut at a position diametrically opposite the tracheal smooth muscle. In this way, 
tracheal chains consisting of four adjacent plates of smooth muscle were constructed. 
Throughout this procedure, which took 15-20 minutes to complete, the tracheal rings 
were maintained in aerated Krebs buffer. Two tracheal chains were prepared from the
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guinea-pig trachea and designated as upper and lower, referring to the laryngeal and 
bronchial portions of the trachea respectively. One tracheal chain was prepared from 
each rat trachea.
The tissue preparations were mounted in siliconized organ baths, of internal diameter 
10mm and depth of 52mm which were then filled to 3ml with Krebs buffer (mM 
composition; NaCl 118, KH2PO4 1.2, KC1 4.8, NaHCOg 25, MgS0 4  1.2, CaCl2 2.5 
and glucose 11), maintained at 37°C and aerated continuously with 95% O2 and 5% 
CO2 . The tissues were then set under an initial resting tension and allowed to 
equilibrate. The rat tracheal chains were set under an initial resting tension of 0.5g and 
allowed to equilibrate for 45 minutes, whilst the guinea-pig tracheal chains were set 
under Ig tension and allowed to equilibrate for 60 minutes. During the period of 
equilibration the tissues were washed at regular intervals with Krebs buffer. Responses 
were recorded isometrically via a FT03 force displacement transducer and displayed on 
a Grass polygraph model 79D (Stag Instruments Ltd.).
2.2.1 Response of the Tracheal Smooth Muscle to ET-1
Following the period of equilibration, a reference cumulative concentration response 
curve to carbachol (CCh), (O.l-lOOpM) using a non linear arithmetic dosing regime of 
1,5, 10, was constructed, each agonist concentration was maintained in contact with 
the tissue until a plateau in the response was achieved, prior to addition of a subsequent 
concentration. The cumulative concentration response to CCh took between 18-20 
minutes to complete using the rat trachea and 25-30 minutes for the guinea-pig trachea, 
each concentration of CCh maintained in contact with the tissue for 2-3 minutes for the 
rat and 4-5 minutes for the guinea-pig. The tissues were then washed thoroughly with 
Krebs buffer and allowed to recover for at least 30 minutes. Following the return to 
baseline, the tissues were dosed in a cumulative fashion with ET-1 (0.01-1 or lOftM),
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guinea-pig trachea and designated as upper and lower, referring to the laryngeal and 
bronchial portions of the trachea respectively. One tracheal chain was prepared from 
each rat trachea.
The tissue preparations were mounted in siliconized organ baths, of internal diameter 
10mm and depth of 52mm which were then filled to 3ml with Krebs buffer (mM 
composition; NaCl 118, KH2PO4 1.2, KC14.8, NaHCOg 25, MgS0 4  1.2, CaCl2  2.5 
and glucose 11), maintained at 37°C and aerated continuously with 95% O2  and 5% 
CO2 . The tissues were then set under an initial resting tension and allowed to 
equilibrate. The rat tracheal chains were set under an initial resting tension of 0.5g and 
allowed to equilibrate for 45 minutes, whilst the guinea-pig tracheal chains were set 
under Ig tension and allowed to equilibrate for 60 minutes. During the period of 
equilibration the tissues were washed at regular intervals with Krebs buffer. Responses 
were recorded isometrically via a FT03 force displacement transducer and displayed on 
a Grass polygraph model 79D (Stag Instruments Ltd.).
2.2.1 Response of the Tracheal Smooth Muscle to ET-1
Following the period of equilibration, a reference cumulative concentration response 
curve to carbachol (CCh), (0.1-100jiM) using a non linear arithmetic dosing regime of 
1, 5,10, was constructed, each agonist concentration was maintained in contact with 
the tissue until a plateau in the response was achieved, prior to addition of a subsequent 
concentration. The cumulative concentration response to CCh took between 18-20 
minutes to complete using the rat trachea and 25-30 minutes for the guinea-pig trachea, 
each concentration of CCh maintained in contact with the tissue for 2-3 minutes for the 
rat and 4-5 minutes for the guinea-pig. The tissues were then washed thoroughly with 
Krebs buffer and allowed to recover for at least 30 minutes. Following the return to 
baseline, the tissues were dosed in a cumulative fashion with ET-1 (0.01-1 or 10|iM),
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* EC50 values for CCh were defined as the concentration of agonist which induced 50% of 
the maximum contractile response. ET-1 responses were expressed as a % of the maximum 
contractile response induced by CCh, EC50 values generated for ET-1 therefore represent 
the concentration of ET-1 which induced 50% of the maximum response to CCh. With 
regard to the ET-1 induced concentration response curves, the term ’maximum response' 
did not reflect a true maximum response as this point was not achieved, but rather 
represented the contractile response induced by l\iM ET-1.
using a non linear arithmetic dosing regime of 1, 5,10. Each agonist concentration was 
maintained in contact with the tissue preparation until the response reached a plateau 
which took 10 minutes using rat trachea and 15-20 minutes in the guinea-pig trachea, 
prior to addition of the subsequent concentration. The cumulative concentration 
response to ET-1 took between 50-60 minutes to complete using rat trachea, whereas 
using guinea-pig trachea the cumulative concentration response curve took 70-110 
minutes to complete. Only one concentration response curve to ET-1 was obtained per 
tissue. Due to the limited availability of the peptide the full dose response curve to the 
peptide could not be constructed, therefore responses to ET-1 were expressed as a 
percentage of the maximum contractile tension induced by the reference concentration 
response curve to the contractile agonist CCh. Measurements of contractile responses to 
CCh were made from the plateau of each response to the reference baseline and 
expressed in terms of gram tension. The magnitude of the contractile responses to ET-1 
was determined by measuring from the plateau of response to the reference baseline, 
converted to gram tension and subsequently expressed as a % of the maximum 
contracile response to CCh. The magnitude of the relaxant response was determined by 
measuring from the plateau of the contractile response to the base of the relaxant 
response, converted to gram tension and subsequently expressed as a % of the 
maximum contractile response to CCh. *
2.2.2 Inhibition of the Peptidase Enzymes
To determine whether the ET-1 induced response, in both the rat and guinea-pig was 
susceptible to degradation by peptidase enzymes, a variety of enzyme inhibitors, 
bestatin, captopril, phosphoramidon and thiorphan were utilised. Following the 
reference cumulative concentration response curve to CCh (O.l-lOOjiM), see section 
2.2.1, the tissues were dosed with an enzyme inhibitor, at a concentration of 10|iM, 
and incubated with the tissue for 30 minutes. The concentration of enzyme inhibitor
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used was determined by dosing the tissues, in a cumulative fashion, with the peptide 
Neurokinin A (NKA) (0.01-l|iM), in the absence and presence of the enzyme 
inhibitor. Following the period of incubation with the enzyme inhibitor, the tissues 
were dosed in a cumulative fashion with ET-1 (0.01-l|iM). Experiments were 
performed on unpaired tissues and only one enzyme inhibitor was used per tissue. 
Responses to ET-1 in the presesnce of the enzyme inhibitor was expressed as a % of 
the maximum contractile response to the reference cumulative concentration response to 
CCh and compared with the control response to ET-1 in the absence of the enzyme 
inhibitor.
2.2.3 Extracellular Calcium Dependence
To determine whether the ET-1 induced response observed in the tracheal smooth 
muscle of both the rat and the guinea-pig was affected by the extracellular Ca^+ 
concentration, the Ca^+ content of the Krebs buffer was modified accordingly. The 
Ca2+ concentration of the buffer was reduced from 2.5mM to 0.8mM. Following the 
reference cumulative concentration response to CCh (O.l-lOOmM), see section 2.2.1, 
the tissues were washed, allowed to recover for 30 minutes and following the return to 
baseline were subsequently dosed in a cumulative fashion with ET-1 (0.01-ljiM). 
Responses to ET-1 were expressed as a % of the maximum contractile response 
obtained to CCh and compared with the responses to ET-1 achieved with normal Krebs 
buffer (Ca2+ concentration of 2.5mM).
2.2.4 Calcium Channel Inhibition
The possible involvement of the calcium channel in the ET-1 induced response was 
investigated using the dihydropyridine Ca^+ channel antagonist nicardipine. Following
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the reference contraction obtained to CCh (O.l-lOOjxM) see section 2.2.1, nicardipine 
(IOjiM) was incubated with the tissue for 30 minutes and was maintained in contact 
with the tissue for the remainder of the experiment. Following the 30 minute incubation 
period the tissues were cumulatively dosed with ET-1 (O.Ol-lpM). Only one 
concentration response curve to ET-1 was determined on each tissue and experiments 
were performed as unpaired experiments, the responses to ET-1 in the presence of 
IOjiM nicardipine compared with control responses to ET-1 in the absence of the Ca^+ 
antagonist. Responses were expressed as a % of the maximum contractile response to 
CCh (O.l-lOOgM).
2.2.5 Inhibition of the Cyclooxygenase Enzyme
The possible involvement of the products of the cyclooxygenase enzyme in the ET-1 
induced response was investigated using a cyclooxygenase enzyme synthesis inhibitor 
indomethacin. Following the reference cumulative concentration response curve 
obtained with CCh (0.1-100|iM) see section 2.2.1, indomethacin (25gM) was 
incubated with the tissue for 30 minutes and maintained in contact with the tissue for 
the remainder of the experiment. Following the period of incubation, the tissues were 
dosed in a cumulative manner with ET-1 (0.01-lp.M). The effects of indomethacin 
(25jiM), were also determined on the response of the tracheal smooth muscle to CCh. 
The effects of 10pM indomethacin were also investigated on the tracheal smooth 
muscle, the tissues incubated with IOjiM indomethacin for 30 minutes prior to 
cumulatively dosing with ET-1 (0.01-lpM). Only one concentration response curve to 
ET-1 was determined on each tissue and experiments were performed as unpaired 
experiments, the response to ET-1 in the presence of indomethacin (25|iM), compared 
with control responses to ET-1 determined in the absence of indomethacin. Responses 
to ET-1 were expressed as a % of the maximum contractile response of the reference 
cumulative concentration response curve to CCh (0.1-100jiM). Inhibition of the
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cyclooxygenase enzyme was confirmed by the ability of indomethacin (25fiM) to 
inhibit the relaxation response of the tracheal smooth muscle to arachidonic acid 
(O.lmM). Vehicle control experiments were also performed to ensure no specific 
effects of the vehicle, ethanol/phosphate buffer 1:19 v/v, affected the ET-1 induced 
response.
2.2.6 Inhibition of the Lipoxygenase Enzyme
The effects of a lipoxygenase enzyme inhibitor nordihydroguaiaretic acid (NDGA), 
were investigated on the response of the tracheal smooth muscle to ET-1. Following the 
reference concentration response curve to CCh (O.l-lOOjiM) see section 2.2.1, the 
tissues were dosed with IOjiM NDGA and allowed to incubate with the tissue for 30 
minutes, following which the tissues were dosed in a cumulative manner with ET-1 
(0.01-ljiM). Throughout the cumulative concentration response curve to ET-1, NDGA 
(10p.M), was maintained in contact with the tissue. Only one cumulative concentration 
response curve to ET-1 was determined for each tissue preparation. The response to 
ET-1 in the presence of NDGA was compared to the control response to ET-1 in the 
absence of the lipoxygenase inhibitor. Responses to ET-1 in the presence of NDGA 
were expressed as a % of the maximum contractile response of the reference cumulative 
concentration response curve to CCh (0.1-100jiM).
2.2.7 Inhibition of Platelet Activating Factor
The viability of the PAF antagonist [l-0-Hexadecyl-2-acetyl-sn-glycero- 
3phospho(N,N,N-trimethyl)hexanolamine] (1-lOOnM) to inhibit the action of PAF on 
the tracheal smooth muscle was determined by the use of PAF C i6 (0.01-l|iM). 
Following a reference cumulative concentration response curve to CCh (0.1-100fiM)
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see section 2.2.1, the tissues were dosed in a cumulative manner with PAF (0.01- 
using a non linear dosing regime of 1, 5, 10, only one concentration response 
curve to PAF was determined on each tissue preparation. The effects of the PAF 
antagonist on the PAF induced response were evaluated by incubating the tissue 
preparations with a single concentration of the PAF antagonist InM, lOnM or lOOnM 
following completion of the reference cumulative concentration response curve to CCh 
(O.l-lOOpM). The tissues were incubated with the PAF antagonist for 30 minutes and 
was maintained in contact with the tissue for the remainder of the experiment. 
Following the period of incubation the tissues were cumulatively dosed with PAF 
(0.01-lgM). Responses to PAF both in the absence and presence of the PAF 
antagonist were expressed as a % of the maximum contractile response to the reference 
cumulative concentration response curve to CCh (O.l-lOOpM), and the responses to 
PAF in the presence of the various concentrations of the PAF antagonist compared. The 
concentration of the antagonist which maximally inhibited the response to PAF was 
subsequently utilized in experiments with ET-1 to examine the possible involvement of 
PAF in the ET-1 induced response. Following a reference cumulative concentration 
response curve to CCh (0.1-100fiM), the tissues were incubated for 30 minutes with 
the previously determined concentration of PAF antagonist. The antagonist was 
maintained in contact with the tissue for the remainder of the experiment. Following the 
period of incubation, the tissues were dosed in a cumulative manner with ET-1 (0.01- 
IgM). Experiments were performed as unpaired, only one cumulative concentration 
response curve to ET-1 determined per tissue. Responses to ET-1 were expressed as a 
% of the maximum contractile response to the reference cumulative concentration 
response curve to CCh (0.1-100jiM). The responses to ET-1 in the presence of the 
PAF antagonist were compared with the control responses determined in the absence of 
the PAF antagonist.
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2.2.8 Removal of the Tracheal Epithelium
The effect of removal of the epithelium from both rat and guinea-pig tracheal smooth 
muscle was investigated. The epithelium was removed by drawing through the lumen 
of the intact trachea, a piece of Krebs buffer soaked cotton wool attached to a thread (60 
gauge Silko), which gently rubbed against the luminal surface of the smooth muscle, 
the cotton wool was passed through the tracheal lumen twice. Care was taken not to 
cause undue disruption to the tracheal smooth muscle. Tracheal rings were then 
prepared as outlined in section 2.2. Following a period of equlibration (45 minutes rat; 
60 minutes guinea-pig), a reference cumulative concentration response curve to CCh 
(O.l-lOOpM) see section 2.2.1, was determined. The tissues were allowed to return to 
the reference baseline and were subsequently dosed in a cumulative manner with ET-1 
(O.Ol-lpM). In the case of the guinea-pig trachea, the epithelium was removed from 
the upper or lower portion of the trachea, the remaining portion used as a paired control 
and in the rat trachea, unpaired experiments were performed. Only one concentration 
response curve to ET-1 was determined in each tissue preparation. Responses to ET-1 
were expressed as a % of the maximum contractile response obtained with the reference 
cumulative concentration response curve to CCh (O.l-lOOpM). Responses to ET-1 in 
the epithelium denuded trachea were compared with those obtained from experiments 
using epithelium intact tracheal tissue preparations. Epithelium removal was verified 
both histologically and by the absence of a relaxation response to O.lmM arachidonic 
acid.
2.2.8.1 Histological Verification o f Tracheal Epithelium Removal
On completion of experiments to determine the action of ET-1 on epithelium denuded 
tracheal smooth muscle of both the rat and guinea-pig (see section 2 .2 .8), tracheal 
chains were removed from the organ baths, the thread carefully removed and the
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sections of trachea placed in vials containing 10% neutral buffered formalin and 
allowed to fix for at least one week. Following the period of fixation, the tissues were 
embedded in paraffin wax by the processes of dehydration with 70-100% alcohol, 
clearing using toluene and finally impregnating with wax (Fibrowax BDH Ltd.). The 
tissues were then blocked out by placing the samples on a plastic mould filled with 
molten wax, the tissue samples being orientated so the surface to be cut rested on the 
base of the mould. Sections were cut from the blocks at a thickness of 5 microns using 
a LKB Historange. The sections were floated on distilled water at a temperature of 
50°C until the creases disappeared. The tissue sections were mounted on slides which 
were then allowed to dry overnight in an incubator at a temperature of 37°C. Tissue 
sections were stained with Ehrlich's acid haematoxylin (BDH Ltd.) and eosin (BDH 
Ltd.), and were mounted in DPX (BDH Ltd.). The slides were then examined using a 
Vickers M15 c microscope and the process of epithelium removal evaluated.
2.2.9 Endothelin-1 Induced Tachyphylaxis
To investigate the effects of repeated dosing with ET-1 (O.Ol-lpM), on the responses 
of the tracheal smooth muscle to the peptide, a second cumulative concentration 
response curve to ET-1 (0.01-ljiM) was constructed. Following a reference cumulative 
concentration response curve to CCh (O.l-lOOpM) see section 2.2.1, the tissues were 
dosed in a cumulative manner with ET-1 (0.01-l|iM). On completion of the cumulative 
response curve to ET-1 the tissues were washed through with Krebs buffer and 
allowed to recover and return to the reference baseline. Following recovery (1-2 hours) 
from the initial exposure to the peptide the tissues were once again dosed in a 
cumulative manner with ET-1 (0.01-lpM). Responses to ET-1 were expressed as a % 
of the maximum contractile response to the reference cumulative concentration response 
curve to CCh (O.l-lOOjiM). Responses to the initial cumulative concentration response 
curve to ET-1 were compared with the subsequent concentration response curve.
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The effect of repeated dosing with a single concentration of the peptide was also 
investigated. Following the reference cumulative concentration response curve to CCh 
(O.l-lOOpM) see section 2.2.1, the tissues were dosed with single concentrations 
O.OlpM, O.SjjM  or I jiM  of ET-1. Each dose was repeated 5 times with a 35 minute 
recovery interval maintained between each application of ET-1. Only one concentration 
of the peptide was used per tissue. Responses to each concentration of ET-1 were 
expressed as a % of the maximum contracile response to the reference cumulative 
concentration response curve to CCh (O.l-lOOjiM). The effects of repeat dosing with 
single concentrations of ET-1 O.OljiM, 0.5p,M or IjiM in the presence of indomethacin 
(25|iM), was studied in the guinea-pig tracheal smooth muscle. Following the reference 
cumulative concentration response to CCh (O.l-lOjiM), the tissues were incubated for 
30 minutes with indomethacin (25JJ.M). Following the period of incubation the tissues 
were dosed with a single concentration of the peptide O.OlpM, 0.5jiM or I jiM  in the 
presence of indomethacin. When the response to the single concentration of ET-1 had 
plateaued, the tissues were washed through with Krebs buffer and allowed to return to 
the reference baseline. The dosing interval of ET-1 was maintained at 35 minutes 
including an incubation period with indomethacin (25|iM), added 10 minutes prior to 
the application of subsequent doses of the peptide. Each tissue preparation was exposed 
to five applications of a single concentration of ET-1. This procedure was repeated for 
the three concentrations of ET-1. Responses to ET-1 were expressed as a % of the 
maximum contractile response to the reference cumulative concentration response curve 
to CCh (O.l-lOOgM), and the five responses to each single concentration of ET-1 
O.OlpM, 0.5pM or I jiM  compared.
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2.3 BINDING STUDIES
Binding studies were performed on the tracheal smooth muscle of the rat and the 
guinea-pig. Homogenate preparations of both the tracheal smooth muscle and cartilage 
were prepared and binding assays using the radioligand [125l]ET-l Were performed.
2.3.1 Homogenate Preparation
The tracheal smooth muscle homogenate of the rat and guinea-pig was prepared 
according to the method for lung homogenate preparation outlined by Kanse et al., 
(1989), with slight modifications. Trachea from the rat and guinea-pig were rapidly 
excised and placed in icecold Tris buffer (50mM), containing 0.32M sucrose and 
buffered with 1M HC1 to maintain a pH of 7.4. The tissues were cleaned of any 
adherent connective tissue and the larynx removed. The trachea was then cut along its 
length at a position diametrically opposite the smooth muscle band. The trachea was 
then opened out to expose the luminal surface of the smooth muscle taking care to 
preserve the integrity of the smooth muscle. The cartilage was then dissected away 
from the band of smooth muscle resulting in two strips of cartilage and a single strip of 
smooth muscle. This procedure was repeated for each trachea used. For each 
homogenate preparation between 16 and 25 animals were used. Homogenate 
preparations of both the cartilage and smooth muscle were made. The smooth muscle 
was blotted dry, to remove any excess buffer and then weighed. Buffer (TrisHCl 
50mM; 0.32M sucrose), was added to the muscle in a ratio of 1:10 w:v. The smooth 
muscle was then roughly scissor chopped and then homogenized using a Kinematica 
Polytron homogenizer (Northern Media, Philip Harris Scientific), set at a mid speed 
setting of 4, the tissue being exposed to three 10 second bursts of homogenization. The 
homogenate was centrifuged at 1000g for 20 minutes using a desk top centrifuge IEC 
CENTRA-3R temperature controlled at 0°C. The pellet was discarded and the 
supernatant recentrifuged at 50,000g for 20 minutes using the Beckman L5-65
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Ultracentrifuge. The supernatant was discarded and the pellet resuspended in 1ml of 
ice-cold Tris HC1 buffer containing 0.32M sucrose, separated into 0.5ml aliquots and 
snap frozen in liquid nitrogen. The membrane preparations were stored at -80oC until 
ready for use. In this way the membrane preparations could be stored for upto three 
months, however, in these studies the membrane preparations were stored for a 
maximum of six weeks before use. The procedure was repeated for the strips of 
cartilage, with the exception that the final pellet was resuspended in 1.5ml of buffer.
2.3.2 Pre-exposure of the Trachea to Endothelin-1
To investigate the effects of preincubation with ET-1 on the binding of the radiolabelled 
ligand [125r|ET-l to the tracheal smooth muscle, the trachea were exposed to ET-1 
prior to homogenization. The trachea were excised and placed in Krebs buffer as 
outlined in the isolated tissue studies (section 2.2). Following removal of any 
connective tissue, the trachea was cut along the length of the cartilage, at a position 
diametrically opposite the smooth muscle band, and placed in plastic vials containing 
3ml of Krebs buffer, aerated with 95% O2 and 5% CO2 and maintained at 37°C. The
tissues were then allowed to equilibrate for one hour, the buffer being changed at 30 
minute intervals. Following equilibration the tissues were transferred to clean vials 
containing 3ml of Krebs buffer and were exposed to a single concentration of ET-1 
(0.5jjM) and allowed to incubate for 20 minutes, the time taken for the response to ET- 
1 to plateau, observed in isolated tissue studies. Following the period of incubation the 
tissues were placed in clean vials containing 3ml of Krebs buffer, which was changed 
every 10 minutes over a period of 30 minutes thereby simulating a wash out in isolated 
tissue studies. For the final wash the tissues were placed in ice cold 50mM Tris buffer 
containing 0.32M sucrose buffered to pH 7.4 using. 1M HC1 for 5 minutes, after which 
the tissues were prepared for homogenization as outlined in section 2.3.1.
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2.3.3 Determination of Protein Content of the Membrane Preparations
The protein content of the membrane preparations was assayed using the method of 
Lowry et al., (1951). The protein content of the test samples was determined by the 
construction of a protein assay standard curve, against which the protein content of the 
membrane samples was calculated.
To tubes in triplicate, bovine serum albumin (BSA), reverse osmosis (RO) water and 
sodium hydroxide (NaOH) were added to give a final concentration of BSA ranging 
from lOgg/ml to 250|J.g/ml. The contents were mixed well and incubated at 37°C for at 
least 15 minutes until a clear solution was observed. To this was then added 5ml of 
copper tartrate reagent and the tube allowed to stand for 10 minutes at room 
temperature. Following this, 0.5ml of IN Folin-Ciocalteu reagent was added to each 
tube, the contents mixed immediately and left for 30 minutes at room temperature. The 
membrane homogenate samples were also carried out in triplicate at the stock 
concentration and following a 1:1 dilution of the stock sample with buffer. To lOOpl of 
the membrane preparation was added 500pl of 1M NaOH and R.O. H2 O to make the 
final volume 1ml; the 1:1 dilution contained 50{il of membrane preparation and 50gl of 
buffer (50mM Tris/HCl containing 0.32M sucrose). The same procedure for the 
membrane homogenates was followed as that for the construction of the standard 
curve.
The absorbance of the samples was read on a Gilford spectrophotometer at a 
wavelength of 700nm. The spectrophotometer was zeroed using R.O. H2 O and the 
standard samples were read against a standard blank of 0.5ml R.O. H2O and 0.5ml of 
1M NaOH and the absorbance of the standard corrected accordingly. The membrane 
homogenates were read against a test blank of lOOjil of buffer as well as R.O. H2 O and 
NaOH and once again the absorbance was corrected accordingly. The protein assay
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standard curve was constructed plotting the corrected mean absorbance against jig 
protein/ml and from this the protein content of the homogenate preparations was 
determined. The protein content of both the tracheal smooth muscle and cartilage with 
and without prior exposure to ET-1 was determined.
2.3.4 Saturation Assays
An [125i]ET-l binding assay was performed in polypropylene tubes in duplicate using 
a total assay volume of 200|il. The amount of protein used per tube was determined 
from the protein dilution profile constructed for both the rat and the guinea-pig see 
section 2.3.5. For the rat tracheal smooth muscle assay 4jig of protein was used and 
for the guinea-pig 2|Xg of protein. The concentrations of [^^I]ET-1 used were 
staggered around the putative Kd value derived from the literature, for both the rat and 
the guinea-pig, and ranged from 0.1-0.8nM for the rat and 0.05-0.5nM for the guinea- 
pig, eight concentrations of [125j]et-1 used in each case. Stock concentrations of the 
radioligand were prepared and variable volumes added to the tubes to achieve the 
required concentration. The assay was performed in the presence of 50|iM 
phosphoramidon, the putative inhibitor of the conversion of big ET-1 to ET-1, lp.M 
phenylmethylsulfonylfluoride (PMSF), an inhibitor of serine proteases, and 5U/ml 
bacitracin. Non-specific binding was determined in the presence of an excess (lOOnM), 
of unlabelled ET-1 and the final assay volume of 200|il achieved by the addition of an 
appropriate quantity of 50mM Tris buffer. The reaction was initiated by the addition of 
the homogenate preparation to the tubes which were then incubated at 25°C for 50 
minutes in a temperature controlled Julabo shaking water bath (Jencons Scientific Ltd.). 
Binding was terminated by the addition of ice-cold 50mM Tris buffer (pH 6.8 adjusted 
for temperature) followed by vacuum filtration of the membrane suspension through 
Whatman GF/B glass fibre filters which were soaked prior to filtration in a 0.1% v/v 
solution of polyethyleneimine/distilled water for 15 minutes and subsequently in a 1%
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w/v solution of albumin/distilled water, followed by three 3ml washes with ice-cold 
50mM Tris buffer using a Brandel Cell Harvester (Semat Technical U.K. Ltd.). 
Following filtration the filters were removed placed in LP4 tubes and counted on a 
1260 Multigamma II Gamma counter (LKB Wallac), each tube counted for 100 
seconds at an efficiency rating of 80%.
2.3.5 Protein Dilution Profile
The amount of tissue/protein utilised in a binding assay can critically affect the resultant 
binding profile. Specific binding is usually linear with increasing tissue concentrations 
up to approximately 2-3mg protein, therefore for more precise and reproducible data it 
is essential to conduct the binding assay at a tissue concentration known to be on the 
linear portion of the tissue binding curve. Therefore a protein dilution profile was 
constructed. The concentration of protein of both rat and guinea-pig tracheal smooth 
muscle homogenate preparations ranged from O-lOpg. To tubes in duplicate was added 
the membrane preparation, the putative ET-1 converting enzyme inhibitor, 
phosphoramidon (50pM), an inhibitor of serine proteases, phenylmethylsulfonyl 
fluoride (PMSF) (ImM) and bacitracin (5U/ml). Non-specific binding was determined 
in the presence of an excess (lOOnM) of unlabelled ET-1. The concentration of ligand 
used was maintained at a constant value throughout the experiment and was used at the 
Kd concentration, for the rat a concentration of 0.4nM and the guinea-pig O.lnM, 
values obtained from the literature. The final assay volume was 200fXl, the total volume 
being achieved by the addition of an appropriate quantity of buffer (50mM Tris, 
pH7.4).
The reaction was initiated by the addition of the radioligand [125]]e t -1, the tubes 
incubated for 50 minutes at 25°C, in a Julabo shaking water bath (Jencons Scientific 
Ltd.). The reaction was terminated by vacuum filtration of the membrane suspension
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through Whatman GF/B glass-fibre filters followed by three 3ml washes with ice-cold 
50mM Tris buffer using a Brandel Cell Harvester (Semat Technical U.K. Ltd.). Prior 
to filtration the filters were soaked in a 0 .1% v/v solution of polyethyleneimine/distilled 
water for 15 minutes and subsequently in a 1% w/v solution of albumin/distilled water. 
Following filtration the filters were removed and placed in tubes and counted 
immediately on a 1260 Multigamma II Gamma counter (LKB Wallac), each filter being 
counted for 100 seconds at an efficiency rating of 80%.
2.4 STATISTICAL ANALYSIS
Statistical analysis was performed using one way analysis of variance (ANOVA) and 
Duncans Multiple Range Test. Values were considered to be significant at the p< 0.01 
and p< 0.05 level, non-significant values are represented as p> 0.05.
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2.5 DRUGS
DRUG Mr
Arachidonic Acid 346.6
Bacitracin 50,200U/g
Bestatin 308.4
Bombesin 1619.9
Bovine Serum Albumin
Calcitonin gene related peptide 3789.33 
(human)
Calcitonin gene related peptide 3806.9
(rat)
Captopril 217.3
Carbachol 182.6
Endothelin-1 2492
[125i]„Endothelin-l 50|iCi
Indomethacin 357.8
Nicardipine 516
Neurokinin A 1133.5
Nordihydroguaiaretic acid 302.4
Phenylmethylsulfonylfluoride 174.2
Phosphoramidon 543.5
Platelet Activating Factor C l6 523.7
P.A.F. Antagonist 579.8
Polyethyleneimine 50% soln.
Substance P 1347.6
Sucrose 342.3
Thioiphan 253.3
Tris buffer 121.1
SUPPLIER
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.) 
Cambridge Research Biochemicals 
Sigma Chemical Co. (U.K.) 
Cambridge Research Biochemicals
Cambridge Research Biochemicals
Squibb & Sons
Sigma Chemical Co. (U.K.)
Calbiochem-Novabiochem UK Ltd. 
Cambridge Research Biochemicals
NEN Research Products
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
Cambridge Research Biochemicals
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
Calbiochem- Novabiochem UK Ltd
Calbiochem-Novabiochem UK Ltd.
Sigma Chemical Co. (U.K.)
Cambridge Research Biochemicals
BDH Ltd. Poole
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
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Arachidonic Acid was dissolved in 0.1M NaHC03, fresh solutions were prepared daily 
prior to use.
Indomethacin was dissolved in ethanol/phosphate buffer 1:19 vol/vol, the pH was 
approximately 7.4 in this way the drug remains fresh for up to 24 hours (Curry & 
Brown, 1982), fresh solutions were prepared daily prior to use.
Phenylmethylsulfonylfluoride (PMSF), was dissolved in 0.1M ethanol to a 
concentration of 0.01M and then diluted with buffer prior to use.
Nordihydroguaiaretic acid was dissolved in 20% ethanol and then diluted with Krebs 
buffer prior to use.
All other drugs were dissolved in reverse osmosis water.
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CHAPTER 3 
RESULTS
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3.1 PILOT STUDIES
Pilot studies were performed to evaluate the effectiveness of Carbachol as the reference 
contractile response on both rat and guinea-pig tracheal smooth muscle. The response 
of the tracheal smooth muscle to various peptides other than ET-1 was also determined 
and the viability of the tracheal chain tissue preparation evaluated.
3.1.1 Control Reference Contractile Response of Tracheal Smooth 
Muscle
To decide upon the control reference contractile response to be utilized throughout the 
experimental procedures the upper and lower portions of guinea-pig tracheal smooth 
muscle were dosed with Carbachol (O.l-lOOpM), Acetylcholine (ljj,M-6mM) and 
Histamine (0.1p.M-lmM). It was shown that the tracheal smooth muscle responded the 
most consistently to CCh (Table 6), there being no significant difference between the 
EC50 values generated in both the upper and lower portions of the tract and only a 
small degree of variation was observed compared with the response to both 
Acetylcholine and Histamine. Furthermore, on repeat cumulative dosing with CCh 
(O.l-lOOjiM), there was no significant attenuation of response, the EC50  values 
remained consistent compared with the response of the tracheal smooth muscle to the 
other agonists. A similar response to CCh was demonstrated on rat tracheal smooth 
muscle an EC50 value of 0.46 ± 0 .0 8 2 jiM  upper and 0.50 ± 0.085}iM lower, achieved 
on the initial cumulative concentration response curve and 0.57 ±  0 .0 7 2 jiM  upper and 
0.60 db 0.076|iM lower, on the repeat response curve. Dosing both rat and guinea-pig 
tracheal smooth muscle with CCh (0.1-100|iM) resulted in the generation of a 
maximum contractile tension of 1.15g for the guinea-pig and Ig for the rat (Figure 3). 
The viability of the tracheal chain tissue preparation was determined by comparing the 
responsiveness of the zig-zag tracheal smooth muscle preparation. The zig-zag tracheal
1 10
Table 6:
Control reference responses to Acetylcholine. Carbachol and Histamine 
on guinea-pig tracheal smooth muscle.
Region of trachea Response curve mean EC50 ± sem
number (pM)
upper 1 9.08 ± 3.45
upper 2 31.8 ±7.05
lower 1 12.0 ±6.09
lower 2 45.3 ±16.77
Carbachol fCCh) O.l-lOOuM.
Region of trachea Response curve mean EC50 — sem
number (M-M)
upper 1 0.51 ±0.066
upper 2 0.71 ± 0.091
lower 1 0.54 ±0.076
lower 2 0.49 ± 0.063
Histamine O.lpM-lmM.
Region of trachea Response curve mean EC50 ± sem
number (pM)
upper 1 18.4 ±4.99
upper 2 13.7 ±1.18
lower 1 6.95 ±1.13
lower 2 13.8 ± 2.08
Response curve number denotes the initial (response curve number 1) and the repeat 
(response curve number 2) cumulative concentration response curve to the agonist. 
Each experiment is the mean of 5 observations.
I l l
Figure 3 : Effect of Carbachol on the tracheal smooth muscle of the 
guinea-pig and the rat.
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Effect of cumulative dosing with CCh (O.l-lOOpM) on guinea-pig (□ ) and rat (■ ) 
tracheal chains. Responses are expressed in terms of the contractile tension 
generated (g) by CCh. Each point is the mean of 10 observations and the vertical 
bars show s.e. mean.
112
strip produced very poor responses to both CCh and ET-1 (data not shown) and 
therefore the tracheal chain tissue preparation was used for all future experiments.
3.1.2 Response of the Tracheal Smooth Muscle to Other Peptides
The response of the tracheal smooth muscle of the rat and guinea-pig to various 
peptides Bombesin, Calcitonin Gene Related Peptide (human and rat), Neurokinin A 
and Substance P is summarised in Table 7. The tracheal smooth muscle of the rat was 
shown to be relatively insensitive to the actions of these peptides. The guinea-pig 
tracheal smooth muscle responded to all of the peptides but only moderately when 
compared with the actions of ET-1 (see section 3.2). Neurokinin A and Substance P 
induced the better contractile response on guinea-pig tracheal smooth muscle however, 
their actions were limited by the breakdown of the peptides by various peptidase 
enzymes. In the presence of lOpM bestatin, captopril, phosphoramidon or thiorphan 
the contractile actions of Neurokinin A were potentiated (maximum contractile tension 
generated by 1|0.M NKA increased from 0.42g to 0.58 d: 0.074g, 0.55 d: 0.03g, 0.76 d: 
0.09g and 0.6 d: 0.09g in the presence of bestatin, captopril, phosphoramidon and 
thiorphan respectively), indicating that inhibition of these enzymes prevents the 
breakdown of the peptide.
3.2 ISOLATED TISSUE STUDIES USING ET-1
3.2.1 Response of Tracheal Smooth Muscle to ET-1
The response observed upon cumulative dosing with the peptide ET-1, differed 
considerably between guinea-pig and rat tracheal smooth muscle. Preliminary studies 
were also undertaken on the tracheal smooth muscle of the rabbit, however responses 
to ET-1 were very poor and subject to great variability, therefore further experiments 
with this tissue preparation were not pursued. The tracheal smooth muscle of the rat 
exhibited a consistent contractile response to ET-1 (Figure 4) with equivalent activity
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Table 7:
Summary of pilot studies performed on the tracheal smooth muscle of 
the guinea-pig and rat.
Peptide Effect on tracheal smooth muscle
Guinea-pig Rat
Bombesin Response up to 20% of No response up to 0.1 pM
the maximum tension 
induced by CCh (0.1-100jiM)
CGRP (h) Minimal contractile response No response up to 0.1 pM
10|iM
CGRP (r) Minimal contractile response No response up to 0.1 pM
lOpM
Neurokinin A Contraction at lOnM No response up to IOjiM
Substance P Contraction at O.lpM No response up to IpM
CGRP (h) Calcitonin Gene Related Peptide (human) 
CGRP (r) Calcitonin Gene Related Peptide (rat)
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observed in the upper and lower portions of the tract (EC50  upper 0.27 ±  0.067 vs 
lower 0.32 ± 0.069 (J.M). Therefore, in further experiments only one tissue preparation 
was constructed from each trachea. ET-1 was a potent constrictor of rat tracheal smooth 
muscle (EC50 0.22 ± 0.085}iM) and generated a tension of 76 ± 7% of the maximum 
contractile tension induced by CCh (0.1-100pM) (0.87 ±  0.05g) (Figure 5). The effect 
of intermittent dosing with ET-1 (0.01-lpM) was also observed on rat tracheal smooth 
muscle (Figure 6). In this case the maximum response to the peptide achieved only 62 
d: 6% of the maximum tension induced by CCh.
The response observed to ET-1 on guinea-pig tracheal smooth muscle differed both 
qualitatively and quantitatively from that observed on rat tracheal smooth muscle. The 
tracheal smooth muscle of the guinea-pig displayed equivalent activity in the upper and 
lower portions of the tract generating contractile tensions of 58 d: 8% upper and 44 d: 
6% lower of the maximum contractile tension induced by CCh (0.98 d: 0.13g upper, 
0.88 d: 0.1 g lower). However, guinea-pig tracheal smooth muscle displayed variability 
in the response to cumulative dosing with ET-1. Consistent contractile responses to ET- 
1 were not observed on guinea-pig tracheal smooth muscle, rather transient relaxation 
responses which preceeded the contractile responses, were observed on dosing with 
ET-1. These relaxation responses limited the constrictor activity of the peptide and the 
presence of two qualitatively distinct responses were observed; (i) concentration
response curves achieving >50% of the maximum contractile tension induced by CCh, 
and (ii) flat concentration response curves, plateauing at IpM ET-1 and generating 
tensions only 25-30% of that induced by CCh (Figure 8). Concentration response 
curves constructed for these two populations of responses are shown in Figure 8. 
Where the response to ET-1 was > 50% of the maximum contractile tension induced by 
CCh, a maximum contractile tension of 76 d: 6% of that induced by CCh (0.88 d: 
0.13g) was observed and an EC50 value of 1.59 d: 0.37|iM (Figure 8$. Figure 8 a 
shows the concentration response curve constructed when the response to ET-1 was < 
50% of the maximum contractile tension induced by CCh (0.91 d: 0.086g), in this case
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Figure 5 :Effect o f ET-1 on rat tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-l(iM) on rat tracheal chains. 
Responses are expressed as a % of the maximum contractile tension induced 
by CCh (0.1-100jiM). Each point is the mean of 5 observations and the vertical 
bars show s.e. mean.
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Figure 6 : Effect o f intermittent dosing with ET-1 (P.l-I^IVD on rat
tracheal smooth muscle
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Effect of intermittent dosing with ET-1 (O.l-ljxM) on rat tracheal chains. 
Responses are expressed as a % of the maximum contractile tension induced 
by CCh (0.1-100jiM). Each point is the mean of 6 observations and the 
vertical bars show s.e. mean.
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Figure 7 : Effect o f ET-1 (0.01-10 |liND on the upper and lower
portions of the guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-10|iM) on the upper (□ ), 
and lower (■ ) portions of guinea-pig tracheal chains. Responses are 
expressed as a % of the maximum contractile tension induced by CCh 
(O.l-lOOpM). Each point is the mean of 12 observations and the vertical 
bars show the s.e. mean. (p> 0.05 ANOVA).
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Figure 8 : Effect o f ET-1 on guinea-pig tracheal smooth muscle.
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Effect of ET-1 (0.01-IOjiM) on guinea-pig tracheal chains where the maximal 
response is (a) < 50% and (b) > 50% of the maximum contractile tension 
induced by CCh (0.1-100jiM). Responses are expressed as a % of the maximum 
contractile tension induced by CCh (0.1-100(iM). Each point is the mean of 10-12 
observations and the vertical bars show s.e. mean.
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an EC50 value was unable to be determined. Furthermore, it was observed that the ET-
I induced relaxation responses observed on dosing guinea-pig tracheal smooth muscle 
with the peptide were more prevalent when the contractile response to ET-1 was poor 
(i.e. maximum tension generated by ET-1 < 50% of the contractile tension induced by 
CCh).
3.2.2 Effect of Peptidase Inhibition on the ET-1 Induced Response on 
Tracheal Smooth Muscle
Incubation of rat tracheal smooth muscle with IOjiM of each of the peptidase inhibitors 
Bestatin, Captopril, Phosphoramidon or Thiorphan prior to dosing with ET-1 failed to 
potentiate the contractile response to ET-1. The peptidase inhibitors had no significant 
effect on the concentration response curve to ET-1 (Figures 9 and 10). There was no 
significant difference observed in the EC50 values generated by the action of ET-1 on 
rat tracheal smooth muscle in the absence or presence of the enzyme inhibitors (Table 
8), and the tension generated ranged from 69-85% of the maximum contractile tension 
induced by CCh. In terms of absolute tension generated by ET-1 in the absence and 
presence of the enzyme inhibitors however, the tension ranged from 0.44-0.72g (Table 
8), demonstrating that although the potency of ET-1 in the presence of the inhibitors is 
not significantly different from that observed in the absence of the inhibitors, the 
maximum tension generated by ET-1 (0.01-1 pM) is variable.
Determinations of the effect of peptidase inhibition on the ET-1 induced response on 
guinea-pig tracheal smooth muscle were performed as unpaired experiments, one 
portion of the trachea used as a control (ET-1 alone), the other incubated with the 
enzyme inhibitor. Incubation of guinea-pig tracheal smooth muscle with the peptidase 
inhibitors had no positive effect on the response of the smooth muscle to ET-1 (Figures
II & 12). The transient relaxation responses observed on dosing with ET-1 alone were 
unaffected in the presence of the peptidase inhibitors. Maximum responses to ET-1 in
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Figure 9 : Effect o f ET-1 in the absence and presence of
Bestatin and Captopril on rat tracheal smooth muscle.
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Effect of ET-1 (0.01-lgM) in the absence (open symbols) and presence (closed 
symbols) of (a) Bestatin 10|iM and (b) Captopril 10|iM on rat tracheal chains. 
Responses are expressed as a % of the maximum contractile tension induced by 
CCh (0.1-100jxM). Each point is the mean of 4-5 observations and the vertical 
bars show s.e. mean. (p> 0.05 ANOVA).
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Figure 10 : Effect of ET-1 in the absence and presence of
Phosphoramidon and Thiorphan on rat tracheal smooth muscle.
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Effect of ET-1 (O.Ol-lpM) in the absence (open symbols) and presence (closed 
symbols) of (a) Phosphoramidon lOpM and (b) Thiorphan lOpM on rat tracheal 
chains. Responses are expressed as a % of the maximum contractile tension 
induced by CCh (O.l-lOOpM). Each point is the mean of 5 observations and the 
vertical bars show s.e. mean. (p> 0.05 ANOVA).
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Table 8:
Comparative EC50 values and maximum tension generated bv ET-1 in 
the absence and presence of various inhibitors on rat tracheal smooth 
muscle.
ET-1 in the presence of EC 50 value Maximum tension (g)
(pM) generated by IpM
ET-1
- 0.22 ±0.085 0.67 ±  0.090
Bestatin lOpM 0.34 ±  0.061 0.72 ±  0.049
Captopril lOjiM 0.22 ± 0.069 0.54 ± 0.096
Ca2+0.8mM 0.32 ±0.099 0.48 ±  0.073
Epithelium denuded 0.59 ±  0.24 0.45 ±  0.055
Indomethacin 25gM 0.31 + 0.077 0.61 ±  0.059
Nicardipine lOgM 0.62 ±  0.049 f 0.55 ±  0.042
NDGA lOpM 0.51 ±0.14 0.69 ±  0.061
Phosphoramidon 10|rM 0.35 ± 0.063 0.44 ±  0.036
Thiorphan 10|xM 0.37 ±0.11 0.54 ±  0.069
t  p< 0.01 significantly different from control, Duncans Multiple Range Test.
NDGA Nordiyhdroguaiaretic acid
EC50 values were determined by linear regression analysis of individual concentration 
response curves
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Figure 11 : Effect o f ET-1 in the absence and presence o f Bestatin
and Captopril on guinea-pig tracheal smooth muscle.
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Effect of ET-1 (0.01-ljiM) in the absence (open symbols) and presence (closed 
symbols) of (a) Bestatin lOpM and (b) Captopril lOjiM on guinea-pig tracheal 
chains. Responses are expressed as a % of the maximum contractile tension 
induced by CCh (O.l-lOOpM). Each point is the mean of 8-9 observations and 
the vertical bars show s.e. mean. (p> 0.05 ANOVA).
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Figure 12 : Effect o f ET-1 in the absence and presence of
Phosphoramidon and Thiorphan on guinea-pig tracheal
smooth muscle.
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Effect of ET-1 (O.Ol-lpM) in the absence (open symbols) and presence (closed 
symbols) of (a) Phosphoramidon lOpM and (b) Thiorphan lOpM on guinea-pig 
tracheal chains. Responses are expressed as a % of the maximum contractile 
tension induced by CCh (0.1-100pM). Each point is the mean of 8-9 observations 
and the vertical bars show s.e. mean. (p> 0.05 ANOVA).
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both the absence and presence of the inhibitors ranged from 15-23% of the maximum 
contractile tension generated by CCh (0.1-100jiM) (Table 9) and were not significantly 
different from each other (p> 0.05). In view of the poor responses observed on dosing 
with ET-1 in the presence of the enzyme inhibitors EC50  values were unable to be 
calculated.
3.2.3 Extracellular Calcium Dependence of the ET-1 Induced Response
Reducing the Ca2+ content of the Krebs buffer from 2.5mM to 0.8mM resulted in a 
slight, but not significant (p> 0.05) attenuation of the ET-1 induced response, at low 
concentrations of the peptide, observed on rat tracheal smooth muscle (Figure 13). The 
maximum contractile tension generated by ET-1 in Ca^+ reduced Krebs achieved 78 ± 
7% of the maximum contractile tension generated by CCh (0.61 ± 0.049g) and the 
EC50  values so generated were not significantly different (p> 0.05) (Table 8). ET-1 
induced responses were also examined in a Ca^+ free buffer, on rat tracheal smooth 
muscle the ET-1 response was virtually abolished, however, the magnitude of the CCh 
response was also significantly reduced and therefore the effects were not comparable.
Reduced Ca^+ Krebs buffer had no effect on the response induced by CCh (EC50 0.45 
±  0.055pM; maximum tension 1.31 ±  0.08g) on guinea-pig tracheal smooth muscle. 
The contractile response to ET-1 generated in reduced Ca%+ Krebs buffer on guinea-pig 
tracheal smooth muscle was not significantly different from the response to ET-1 
observed in normal Krebs (Figure 14), although the maximum tension generated was 
attenuated (Table 9). The response to ET-1 in both normal and Ca2+ reduced Krebs 
failed to attain 50% of the maximum contractile tension generated by CCh and therefore 
EC50 values could not be generated. Reduced Ca^+ Krebs buffer produced a variable 
effect on the ET-1 induced relaxation responses. At lower concentrations (O.OljiM) 
there was a small but significant attenuation of the ET-1 induced response whereas at
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Table 9:
Maximum tension generated bv l|nM ET-1 in the absence and presence 
of various inhibitors on guinea-pig tracheal smooth muscle.
Inhibitor Maximum tension (g) generated by IjjM ET-1
absence of inhibitor presence of inhibitor
(i) 0.67 ± 0.1 
(n) 0.29 ±0.09
Bestatin lOpM 0.13 ±0.029 0.12 ±0.024
Captopril lOjiM 0.14 ±0.018 0.11 ±0.038
Ca2+0.8mM 0.47 ±0.13 0.41 ±0.087
Epithelium denuded 0.48 ±  0.12 0.49 ±0.14
Epithelium denuded 
+ Indomethacin 25|tM
0.49 ±0.14 0.86 ±0.11
Indomethacin 25pM 0.26 ± 0.053 0.86 ±0.16
Nicardipine 10|lM 0.47 ±0.13 0.19 ±0.09
NDGAlOpM 0.47 ±0.13 0.00
Phosphoramidon lOpM 0.19 ±0.058 0.14 ±0.04
PAF antagonist InM 0.44 ±0.11 0.26 ±  0.044
Thiorphan lOgM 0.13 ± 0.021 0.11 ±0.026
NDGA Nordiyhdroguaiaretic acid
PAF antagonist [l-0-H exadecyl-2-acetyl-sn-glycero-3phospho(N ,N,N- 
trimethyl)hexanolamine]
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Figure 13 : Response to ET-1 in normal and Ca^+ reduced Krebs
buffer on rat tracheal smooth muscle.
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Effect of cumulative dosing on rat tracheal chains with ET-1 (0.01-lpM) in normal 
Krebs buffer (Ca2+ 2.5mM) (□), and in Ca2+ reduced buffer (Ca2+ 0.8mM) (■ ). 
Responses are expressed as a % of the maximum contractile tension induced by CCh 
(O.l-lOOjiM). Each point is the mean of 5 observations and the vertical bars show 
s.e. mean. (p> 0.05 ANOVA).
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Figure 14: Response to ET-1 in normal and Ca^+ reduced Krebs
buffer on guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing on guinea-pig tracheal chains with ET-1 (0.01-ljiM) 
in normal Krebs buffer (Ca2+ 2.5mM) ( □), and in Ca2+ reduced buffer 
(Ca2+ 0.8mM)( ■  ). Responses are expressed as a % of the maximum contractile 
tension induced by CCh (0.1-100gM). Each point is the mean of 5 observations 
and the vertical bars show s.e. mean. (p> 0.05 ANOVA).
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Figure 15 : Effect o f reduced Ca^+ buffer on the relaxation responses
induced bv ET-1 on guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-l(iM) on the relaxation responses 
induced in normal Krebs buffer (Ca2+ 2.5mM) and Ca2+ reduced buffer 
(Ca2+ 0.8mM) on guinea-pig tracheal chains.The closed histograms indicate 
the relaxation responses to ET-1 in normal Krebs and the striped histograms 
the relaxation responses observed in reduced Ca2+buffer. Each point is the 
mean of 5 observations and the vertical bars show s.e. mean.
( t  P< 0.05, f t  p< 0.01 significantly different from control values Duncans 
Multiple Range Test).
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higher concentrations (0.05, 0.5, IjiM) a more marked significant potentiation of the 
relaxation response was observed (Figure 15).
3.2.4 Response to ET-1 in the Presence of Nicardipine
Incubating rat tracheal smooth muscle with lOjiM Nicardipine had a significant effect 
(p< 0.05) on the ET-1 induced concentration response curve. At all concentrations of 
ET-1 (0.01-l|iM) incubation with Nicardipine resulted in a significant inhibitory effect 
on the ET-1 induced contractile response (Figure 16). The maximum tension generated 
in response to ET-1 (IpM) was reduced from 76 ± 9% of the maximum contractile 
tension generated by CCh (0.87 ±  0.052g) to 58 ± 1% of the maximum contractile 
tension generated by CCh (0.95 ± 0.069g) in the presence of Nicardipine (see Table 8 
for absolute tension values). The EC50 value of ET-1 in the presence of Nicardipine 
was 4 fold higher than that observed in the absence of the Ca^+ channel entry blocker 
(Table 8).
Incubating guinea-pig tracheal smooth muscle with 10|iM Nicardipine had no 
significant effect (p> 0.05) on the ET-1 induced contractile response (Figure 17). In 
both the absence and presence of lOjiM Nicardipine the response to ET-1 failed to 
achieve 50% of the maximum contractile tension induced by CCh and therefore EC50 
values were unable to be calculated. The maximum contractile tension induced by ET-1 
was reduced, but not to a significant level in the presence of the Ca^+ channel blocker 
(Table 9). On dosing with O.OljiM ET-1 in the presence of Nicardipine, the guinea-pig 
tracheal smooth muscle responded by relaxing, resulting in a loss of tension (0.022 db 
0.0Ig), the response failing to contract above the reference baseline. The relaxation 
responses observed on dosing guinea-pig tracheal smooth muscle with ET-1 alone were 
unaffected by the presence of 10|iM Nicardipine, no significant difference in the 
magnitude of response to each concentration of ET-1 being observed (Figure 18).
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Figure 16 : Effect o f ET-1 in the absence and presence o f 10\iM
Nicardipine on rat tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-l|iM) on rat tracheal chains in the 
absence ( □) and presence (■ ) of lOpM Nicardipine. Responses are expressed 
as a % of the maximum contractile tension induced by CCh (0.1-100gM). Each 
point is the mean of 6 observations and the vertical bars show s.e. mean.
(f p< 0.05, t t  P< 0.01 significantly different from control values Duncans Multiple 
Range Test).
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Figure 17 : Effect o f ET-1 in the absence and presence o f lOjiM
Nicardipine on guinea-pig tracheal smooth muscle.
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Effect of dosing with ET-1 (O.Ol-lpM) on guinea-pig tracheal chains in the 
absence ( □) and presence ( ■ ) of lOpM Nicardipine. Responses are expressed 
as a % of the maximum contractile tension induced by CCh (0.1-100jiM). Each 
point is the mean of 5 observations and the vertical bars show s.e. mean.
(p> 0.05 ANOVA)
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Figure 18 : Effect o f 10|nM Nicardipine on the relaxation responses
induced by ET-1 on guinea-pig tracheal smooth muscle.
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Effect of incubating with 10(iM Nicardipine on the relaxation responses induced by 
ET-1 (O.Ol-lpM) on guinea-pig tracheal chains. The closed histograms indicate the 
relaxation responses to ET-1 in the absence of Nicardipine and the hatched histograms 
the relaxation responses observed in the presence of IOjiM Nicardipine. Responses are 
expressed as a % of the maximum contractile tension induced by CCh (O.l-lOOpM). 
Each point is the mean of 5 observations and the vertical bars show s.e. mean.
(p> 0.05 ANOVA).
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3.2.5 Inhibition of the Cyclooxygenase Enzyme in the ET-1 Induced 
Response
Inhibition of the cyclooxygenase enzyme by Indomethacin was confirmed by the ability 
of 25pM Indomethacin to abolish the relaxation response induced by 0.1 mM 
arachidonic acid. A lower concentration of Indomethacin (lOpM) failed to consistently 
abolish the arachidonic acid induced relaxation responses, therefore 25p.M 
Indomethacin was used throughout.
Incubating rat tracheal smooth muscle with 25pM Indomethacin prior to dosing with 
ET-1 (O.Ol-lpM) had no significant effect on the ET-1 induced response (Figure 19). 
The EC50  value for ET-1 in the presence of Indomethacin was not significantly 
different from that induced by ET-1 in the absence of Indomethacin. The maximum 
tension induced by ET-1 in the presence of Indomethacin was directiy comparable with 
that generated in the absence of Indomethacin.
The guinea-pig trachea was divided into upper and lower portions, one part was used 
as a control to ET-1 whilst the other portion was dosed with ET-1 in the presence of 
25|iM Indomethacin. The smooth muscle of the guinea-pig trachea incubated with 
25pM Indomethacin responded very differently to ET-1 (0.01-1 pM) (Figure 20). In the 
absence of Indomethacin the response to ET-1 achieved only 25 ± 3% of the maximum 
contractile tension induced by CCh (1.01 ± 0.12g). In the presence of Indomethacin the 
concentration response curve to ET-1 was significantly different (p< 0.05) from that 
observed in the absence of Indomethacin. In the presence of Indomethacin the 
contractile response to ET-1 was potentiated, the action of the peptide achieving a 
response in excess of 50% of the maximum contractile tension induced by CCh (0.1- 
lOOpM), generating an EC50 value of 0.57 ± 0.15pM compared with an EC50  value 
of 1.59 ± 0.37pM generated by ET-1 alone (see section 3.2, figure 8a). In the absence 
of Indomethacin the relaxation responses induced by ET-1 were evident (Figure 20)
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Figure 19 : Effect o f ET-1 in the absence and presence of
Indomethacin on rat tracheal smooth muscle.
j 100-
Ir
U
B
1
g
se
60 -
4 0 -
20 -
o-J
0.1 10.01
[ENDOTHELIN-1] jiM
Effect of cumulative dosing with ET-1 (0.01-l|iM) in the absence (□ ) and 
presence ( ■) of 25jiM Indomethacin on rat tracheal chains. Responses are 
expressed as a % of the maximum contractile tension induced by CCh 
(0.1-100gM). Each point is the mean of 5 observations and the vertical bars 
show s.e. mean. (p> 0.05 ANOVA).
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Figure 21 : Effect o f ET-1 in the absence and presence o f
Indomethacin on guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-ljiM) in the absence (□ ) and 
presence (■ ) of 25|iM Indomethacin on guinea-pig tracheal chains. Responses 
are expressed as a % of the maximum contractile tension induced by CCh 
(0.1-100jiM). Each point is the mean of 10 observations and the vertical 
bars show the s.e. mean.
(t p< 0.05, t t  p<0.01 significantly different from control values Duncans 
Multiple Range Test).
139
however, in the presence of Indomethacin the relaxation responses to ET-1 were 
abolished and the contractile response potentiated. In the presence of Indomethacin the 
maximum contractile tension induced by IjiM ET-1 was potentiated (Table 9 & Figure 
21). The time taken to complete a cumulative concentration response curve to ET-1 
(0.01-lp.M) on guinea-pig tracheal smooth muscle was also reduced from 70-110 
minutes to 50-60 minutes.
3.2.6 Role of the Lipoxygenase Enzyme in the ET-1 Induced Response
Inhibition of the lipoxygenase enzyme by incubation of rat tracheal smooth muscle with 
lOpM Nordihydroguaiaretic acid (NDGA) had no significant effect (p> 0.05) on the 
ET-1 induced concentration response curve (Figure 22; Table 8)). The maximum 
tension generated by ET-1 in the presence of NDGA was not signifcantly different (p> 
0.05) from that generated by ET-1 in the absence of NDGA.
Guinea-pig tracheal smooth muscle incubated with 10|J.M NDGA demonstrated a 
significantly (p< 0.01) inhibited response to ET-1 (O.Ol-lpM) (Figure 23). In the 
presence of NDGA, ET-1 failed to elicit a contractile response on guinea-pig tracheal 
smooth muscle. In the presence of NDGA the relaxation responses induced by ET-1 
were significantly (p< 0.01) potentiated at the higher concentrations of ET-1 (0.1-ljiM) 
compared with those induced by ET-1 alone (Figure 24). An equivalent loss in tension 
was observed at 0.01, 0.1 and IpM ET-1 (0.098 ±  0.025g; 0.11 ±  0.034g; 0.10 ±  
0.010g), with a maximum loss of tension 0.28 ± 0.034g observed at 0.5pM ET-1. The 
responses to ET-1 in the presence of NDGA displayed two qualitatively different 
responses (i) flat concentration response curves where the tracheal smooth muscle did 
not contract above the reference baseline when dosed with ET-1, and (ii) those tissue 
preparations which displayed a slight contractile response to ET-1, generating a 
maximum contractile tension of 19 ± 3% of the maximum contractile tension generated
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Figure 22 : Effect of NDGA on the ET-1 induced response on rat
tracheal smooth muscle.
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Effect of the lipoxygenase inhibitor Nordihydroguaiaretic acid 10|iM on 
the ET-1 (O.Ol-lpM) induced response on rat tracheal chains, (□ ) ET-1 
in the absence and (■ ) presence of NDGA. Responses are expressed as 
a % of the maximum contractile tension induced by CCh (0.1-100jiM). 
Each point is the mean of 4 observations and the vertical bars show s.e. 
mean.
(p> 0.05 ANOVA).
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Figure 23 : Effect o f NDGA on the ET-1 induced response on guinea-pig
tracheal smooth muscle.
Effect of the lipoxygenase inhibitor Nordihydroguaiaretic acid 10|J.M on the 
cumulative ET-1 (0.01-ljiM) induced response on guinea-pig tracheal chains, 
(□ ) ET-1 in the absence and (■ ) presence of NDGA. Responses are expressed 
as a % of the maximum contractile tension induced by CCh (O.I-IOOjjM). Each 
point is the mean of 8 observations and the vertical bars show s.e. mean.
(f p< 0.05, f t  p< 0.01 significantly different from control values Duncans 
Multiple Range Test).
- 10-1
0.01 0.1
[ENDOTHELIN-1] jaM
1
142
Figure 24 : Effect o f NDGA on the ET-1 induced relaxation responses
on guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-ljiM) on the relaxation responses 
induced in guinea-pig tracheal chains in the absence (closed histograms) and 
presence (hatched histograms) of lOjiM Nordihydroguaiaretic acid. Responses are 
expressed as a % of the maximum contractile tension induced by CCh 
(O.l-lOOjiM). Each point is the mean of 8 observations and the vertical bars 
show s.e. mean.
( t t  p< 0.01 significantly different from control values Duncans Multiple 
Range Test).
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Figure 25 : Effect of NDGA on the ET-1 induced contractile and 
relaxant responses on guinea-pig tracheal smooth 
muscle.
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The ET-1 (0.01-ljiM) induced effect on (a) the contractile responses and (b) the 
relaxant responses observed on guinea-pig tracheal chains. The open symbols 
indicate those tissue preparations which contracted in the presence of IOjiM  
NDGA and the closed symbols those preparations which failed to contract. 
Responses are expressed as a % of the maximum contractile tension induced by 
CCh (0.1-100pM). Each point is the mean of 4 observations and the vertical bars 
show s.e. mean, (f p< 0.05, f t  p< 0.01 significantly different from corresponding 
responses at same dose, Duncans Multiple Range Test).
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by CCh (1.17 ± 0.099g) at 0.1 (iM ET-1 (Figure 25a). In contrast, the ET-1 induced 
relaxant responses did not differ significantly between the two groups at 0.1-lpM ET- 
1, however, at O.OljiM and 0.05|iM ET-1 a significant difference (p< 0.05) in 
response was observed between the two groups (Figure 25b).
3.2.7 Involvement of Platelet Activating Factor in the ET-1 Induced 
Response
The rat tracheal smooth muscle was shown to be completely insensitive to the action of 
Platelet Activating Factor (PAF Ci6) (data not shown), and therefore the effects of the 
PAF antagonist [l-0-Hexadecyl-2-acetyl-sn-glycero-3phospho(N ,N,N- 
trimethyl)hexanolamine] were not evaluated.
Guinea-pig tracheal smooth muscle exhibited relaxant responses only when dosed with 
PAF (O.Ol-lpM) (Figure 26). When incubated with the PAF antagonist at 
concentrations of InM, lOnM or lOOnM, the response to PAF was abolished. For 
further experiments involving the PAF antagonist a concentration of InM was utilized. 
In the presence of the PAF antagonist the concentration response curve to ET-1 was not 
shown to be significantly different (p> 0.05) from that of ET-1 alone on guinea-pig 
tracheal smooth muscle (Figure 27a). The presence of the PAF antagonist had no 
inhibitory effect on the ET-1 induced relaxation responses but rather had a significant 
potentiating effect (p< 0.05) on the relaxation responses induced by 0.05-1 pM ET-1.
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Figure 26 : Effect of Platelet Activating Factor on guinea-pig tracheal 
smooth muscle.
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Effect of cumulative dosing with PAF (0.01-l|iM) on guinea-pig tracheal chains. 
Responses are expressed as a % of the maximum tension induced by CCh (0.1-100pM). 
Each point is the mean of 8 observations and the vertical bars show s.e. mean.
Figure 27 : Effect of the PAF antagonist (InMD on the ET-1 induced
response on guinea-pig tracheal smooth muscle.
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Effect of incubating with InM PAF antagonist on guinea-pig tracheal chains, (a) 
the contractile responses induced by ET-1 (0.01-lpM) in the absence ( □  ) and the 
presence (■ ) of the antagonist, (b) the relaxation responses induced by ET-1 
(0.01-lpM) in the absence (open histograms) and the presence (closed histograms) 
of the antagonist. Responses are expressed as a % of the maximum contractile tension 
induced by CCh (0.1-100jiM). Each point is the mean of 4 observations and the 
vertical bars show s.e. mean, (f p< 0.05, f t  p< 0.01 significantly different from control 
values, Duncans Multiple Range Test).
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3.2.8 Effect of Tracheal Epithelium Removal on the ET-1 Induced 
Response
Removal of the tracheal epithelium was verified by the absence of a relaxation response 
to O.lmM arachidonic acid and by the preparation of tracheal slices for histological 
studies. Epithelium removal from the tracheal smooth muscle of the rat had no 
significant effect on the CCh (O.l-lOOpM) induced response, the maximum contractile 
tension generated by CCh in the absence of epithelium 0.87 i  0.064g was not 
significantly different from that generated in epithelium intact tissues 0.74 ± 0.067g.
Removal of the epithelium from rat tracheal smooth muscle failed to significantly affect 
the ET-1 induced response (Figure 28). The EC50 value calculated in the absence of a 
functional epithelium was not significantly different from that generated in epithelium 
intact tissues, and the maximum tension generated by ET-1 in the absence of the 
epithelium, was not significantly different from that generated in epithelium intact 
tissues.
Removal of the tracheal epithelium from guinea-pig tracheal smooth muscle failed to 
affect the contractile response induced by CCh (0.1-100jiM). A maximum contractile 
tension generated by CCh in the absence of a functional epithelium 1.25 ± O.llg was 
not found to be significantly different from that generated in epithelium intact tissues 
1.15 ±  0.13g. ET-1 displayed a pattern of response on epithelium denuded guinea-pig 
tracheal smooth muscle which was not significantly different from that generated in 
epithelium intact tissues. Removal of the epithelium had no effect on the contractile 
responses (Table 9 & Figure 29a) nor the relaxant responses (Figure 29b) induced by 
ET-1.
Incubation of epithelium denuded guinea-pig tracheal smooth muscle with 25p.M 
Indomethacin had a significant (p< 0.01) effect on the ET-1 induced concentration
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Figure 28 : Effect o f epithelium removal on the ET-1 induced
response on rat tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-IpM) in the presence (□ ) and 
absence (■ ) of a function^ epithelium on rat tracheal chains. Responses are 
expressed as a % of the maximum tension induced by CCh (0.1-100jiM). 
Each point is the mean of 5 observations and the vertical bars show s.e. mean. 
(p> 0.05 ANOVA).
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Figure 29 : Effect o f epithelium removal on the ET-1 induced response
on guinea-pig tracheal smooth muscle.
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Effect of cumulative dosing with ET-1 (0.01-IjiM) (a) on epithelium intact (□ ) 
and denuded (■ ) guinea-pig tracheal chains and (b) on the ET-1 induced relaxation 
responses, the open histograms indicate epithelium intact tissues and the closed 
histograms epithelium denuded preparations. Responses are expressed as a % of 
the maximum contractile tension induced by CCh (0.1-100jiM). Each point is the 
mean of 7 observations and the vertical bars show s.e. mean. (p> 0.05 ANOVA).
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Figure 30 : Response to ET-1 on epithelium intact and denuded 
guinea-pig tracheal smooth muscle in the presence 
of 25 pM Indomethacin.
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Effect of cumulatively dosing guinea-pig tracheal chains with ET-1 (0.01-lpM) in 
the presence of 25pM Indomethacin on epithelium intact (□  ) and epithelium 
denuded (■ ) tissue preparations. Responses are expressed as a % of the maximum 
contractile tension induced by CCh (O.l-lOOpM). Each point is the mean of 5 
observations and the vertical bars show s.e. mean.
(f p< 0.05, t t  P< 0.01 significantly different from control values, Duncans Multiple 
Range Test).
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response curve (Figure 30). Although the maximum contractile tension generated by 
ET-1 (1|J.M) in epithelium intact tissues 0.86 ± 0.17g was not significantly different 
from that observed in epithelium denuded preparations 0.86 d: 0.1 Ig, at 0.01-0.l|iM 
ET-1 the response to ET-1 in the absence of a functional epithelium was significantly 
(p< 0.05) potentiated (Table 9). The EC50 values generated in response to ET-1 in the 
presence of 25pM Indomethacin in epithelium intact 0.57 ± 0.15pM and denuded 0.16 
d: 0.065j-iM tissues were shown to be significantly different at the 5% level.
3.2.9 ET-1 Induced Tachyphylaxis on Tracheal Smooth Muscle
Repeat cumulative dosing with ET-1 (0.01-lp.M) on rat tracheal smooth muscle 
resulted in a marked attenuation of the contractile response (p< 0.05) (Figure 31). The 
contractile response to the repeated administration of the peptide failed to achieve a 
response greater than 50% of the maximum contractile tension induced by CCh (0.1- 
100 |J.M), therefore an EC50  value was unable to be calculated. The maximum 
contractile tension generated by ET-1 (IpM) was significantly (p< 0.01) reduced from 
0.67 d: 0.09g to 0.32 ± 0.057g on repeated cumulative dosing.
Tachyphylaxis was also observed on repeat cumulative dosing with ET-1 on guinea-pig 
tracheal smooth muscle (Figure 32). The response to the repeat administration of the 
peptide was significantly different (p< 0 .01) from the initial response to the peptide. 
The response to ET-1 failed to reach 50% of the maximum contractile tension induced 
by CCh on both the initial exposure and on repeat administration. The maximum 
response to ET-1 was significantly reduced (p< 0.05) from 0.47 d: 0.13g to 0.16 d: 
0.027g on repeat dosing with the peptide. Furthermore, the ET-1 induced relaxation 
responses did not exhibit tachyphylaxis on repeat cumulative dosing with ET-1 (Figure 
33).
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Figure 31 : Effect of repeat cumulative dosing with ET-1 on
rat tracheal smooth muscle.
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Effect of repeat cumulative dosing with ET-1 (0.01-lgM) on rat tracheal 
chains, (Q) initial concentration response curve to ET-1, ( ®  repeat 
concentration response curve following recovery from the initial exposure 
to the peptide. Responses are expressed as a % of the maximum contractile 
tension induced by CCh (0.1-lOOjiM). Each point is the mean of 6 
observations and the vertical bars show s.e. mean.
(f p< 0.05, f f  p< 0.01 significantly different from control values, Duncans 
Multiple Range Test).
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Figure 32 : Effect o f repeat cumulative dosing with ET-1 on
guinea-pig tracheal smooth muscle.
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Effect of repeat cumulative dosing with ET-1 (O.Ol-lpM) on guinea-pig 
tracheal chains, (□ ) initial concentration response curve to ET-1, (■ ) 
repeat concentration response curve to ET-1 following recovery from the 
initial exposure to the peptide. Responses are expressed as a % of the 
maximum contractile tension induced by CCh (O.l-lOOpM). Each point is 
the mean of 8 observations and the vertical bars show s.e. mean.
(t p< 0.05, t t  P< 0.01 significantly different from control values, Duncans 
Multiple Range Test).
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Figure 33 : Effect o f repeat cumulative dosing with ET-1 on the ET-1
induced relaxation responses on guinea-pig tracheal smooth
muscle.
[ENDOTHELIN-1] pM
Effect of repeat cumulative dosing with ET-1 (0.01-lp.M) on the ET-1 induced 
relaxation responses observed in guinea-pig tracheal chains. The closed 
histograms indicate the relaxation responses observed on the initial response to 
ET-1, the hatched histograms the relaxation responses observed on the repeat 
concentration response. Responses are expressed as a % of the maximum 
contractile tension induced by CCh (O.l-lOOpM). Each point is the mean of 9 
observations and the vertical bars show s.e. mean. (p> 0.05 ANOVA).
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Figure 34 : Effect of repeat cumulative dosing with ET-1 on guinea-pig 
tracheal smooth muscle when the initial response is < and > 
50% of the maximum contractile response to CCh.
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Effect of repeat cumulative dosing with ET-1 (0.01-lpM) on guinea-pig tracheal 
chains where (a) the initial concentration response curve to ET-1 was < 50% and 
(b) > 50% of the maximum contractile tension induced by CCh (0.1-100|iM).
The open symbols indicate the initial concentration response curve to ET-1 and the 
closed symbols the repeat concentration response curve. Responses are expressed 
as a % of the maximum contractile tension induced by CCh (O.l-lOOpM). Each 
point is the mean of 5 observations and the vertical bars show s.e. mean.
(f p< 0.05, f f  p< 0.01 significantly different from control values, Duncans Multiple 
Range Test).
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Figure 35 : Effect of repeat cumulative dosing with ET-1 on the 
relaxation responses induced in guinea-pig tracheal 
smooth muscle when the initial response is < and > 
50% of the maximum contractile tension induced by CCh.
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Effect of repeat cumulative dosing with ET-1 (O.Ol-lpM) on the relaxation 
responses observed in guinea-pig tracheal chains where the initial concentration 
response curve to ET-1 was (a) < 50% and (b) > 50% of the maximum contractile 
tension induced by CCh (O.l-lOOpM). The closed bars indicate the relaxation 
responses observed on the initial response to ET-1; the hatched bars the relaxation 
responses observed on the repeat concentration response. Values show the mean 
and s.e. mean of 6 observations. (p> 0.05 ANOVA).
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The degree of tachyphylaxis induced by ET-1 on guinea-pig tracheal smooth muscle 
was dependent on the initial response to the peptide. Those tissues where the initial 
response to ET-1 (0.01-lgM) was less than 50% of the maximum contractile tension 
induced by CCh, displayed no significant difference in response to repeat dosing with 
the peptide (maximum tension ET-1 IpM 0.24 + 0.045g vs 0.14 + 0.03g) (Figure 
34a), whereas those tissues which exhibited good contractile responses to the initial 
exposure to the peptide, displayed marked tachyphylaxis (p< 0.01) on repeat dosing 
(maximum tension ET-1 l|iM 0.93 + 0.18g vs 0.20 + 0.056g) (Figure 34b). The ET-1 
induced relaxation responses observed in both groups however, exhibited the same 
pattern of response on repeat dosing as was observed on the initial exposure to the 
peptide (Figure 35).
Repeat single dosing with ET-1 (0.05pM) on rat tracheal smooth muscle showed 
significant tachyphylaxis (p< 0.05) after the fifth repeat dose only (Figure 36), whereas 
at higher concentrations of ET-1 ( 0.5|iM and l|iM) a tachyphylactic response was 
evident after the second repeat dose (p< 0.01) and a further attenuation of response was 
observed after the third repeat dose (p< 0.01 vs second repeat dose) (Figures 37 and 
38). The ET-1 induced contractile responses at 0.05gM and 0.5pM ET-1 on guinea-pig 
tracheal smooth muscle showed no tachyphylaxis on repeated dosing (Figures 40a and 
41a), whereas at IgM ET-1 the contractile responses to the peptide showed a 
significant attenuation of response (p< 0.01) after the second repeat dose, the response 
then remaining constant through to the fifth repeat dose (Figure 42a). In contrast, at 
O.SjiM ET-1 the ET-1 induced relaxtion responses exhibited tachyphylaxis (Figure 41a) 
whereas at 0.05gM and IjiM ET-1 no significant attenuation of the relaxation response 
was observed (Figure 40a and 42a).
In the presence of 25gM Indomethacin, the ET-1 induced relaxation responses at all 
concentrations of ET-1 (0.05, 0.5 andlpM) were abolished (Figure 39). Furthermore, 
tachyphylaxis to repeat single dosing with ET-1 was observed at all concentrations of
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Figure 36 : Effect o f repeat dosing with ET-1 (0.05juM) on rat
tracheal smooth muscle.
30-1
I '
<PQ
PP 20 -
d
! ■
§  • » -
I .
3 421 5
DOSE NUMBER
Effect of dosing rat tracheal chains with a single concentration of ET-1 
(0.05|iM) each dose repeated 5 times. The dotted histograms indicate the 
contractile responses to ET-1. Responses are expressed as a % of the 
maximum contractile response induced by CCh (O.l-lOOpM). Values 
show the mean and s.e. mean of 8 observations.
( t  P< 0.05 significantly different from dose number 1,
* p< 0.05 significantly different from dose number 2, Duncans Multiple 
Range Test).
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Figure 37 : Effect of repeat dosing with ET-1 (0.5[nlVD on rat
tracheal smooth muscle
100-,
90 -
20 -
3 41 2 5
DOSE NUMBER
Effect of dosing rat tracheal chains with a single concentration of ET-1 
(0.5|iM) each dose repeated 5 times. The dotted histograms indicate the 
contractile responses to ET-1. Responses are expressed as a a % of the 
maximum contractile response induced by CCh (0.1-100gM). Values 
show the mean and s.e. mean of 6 observations.
( f t  p< 0.01 significantly different from dose number 1 
** p< 0.01 significantly different from dose number 2, Duncans Multiple 
Range Test).
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Figure 38 : Effect o f repeat dosing with ET-1 fl[iiIVD on rat
tracheal smooth muscle.
100-,
90 - 
y  80 —
S  7 0 - 
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z  6 0  ■
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I 4 0 -
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2 0 - ■ **
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3 42 51
DOSE NUMBER
Effect of dosing rat tracheal chains with a single concentration of ET-1 
(IjiM), each dose repeated 5 times. The dotted histograms indicate the 
contractile responses to ET-1. Responses are expressed as a % of the 
maximum contractile response induced by CCh (O.l-lOOpM). Values 
show the mean and s.e. mean of 6 observations.
( t t  P< 0.01 significantly different from dose number 1 
** p< 0.01 significantly different from dose number 2, Duncans Multiple 
Range Test).
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Figure 40 : Effect of repeat dosing with ET-1 (O.OSiuM) on guinea-pig
tracheal smooth muscle in the absence and presence of 25\iM  
Indomethacin.
(a)
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DOSE NUMBER
(b)
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DOSE NUMBER
Effect of dosing guinea-pig tracheal chains with a single concentration of ET-1 
(0.05|xM) each dose repeated 5 times, (a) in the absence and (b) in the presence 
of 25jiM Indomethacin. The closed histograms indicate the relaxation responses 
and the dotted histograms the contractile responses to ET-1. Responses are 
expressed as a % of the maximum contractile response induced by CCh 
(0.1-100jiM). Values show the mean and s.e. mean of 6 observations.(ff p< 0.01 
significantly different from dose number 1, Duncans Multiple Range Test ).
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Figure 41 : Effect o f repeat dosing with ET-1 (0.5|nlVD on guinea-pig
tracheal smooth muscle in the absence and presence of 25|nM
Indomethacin.
(a)
30-i
H b)
2 3 4
DOSE NUMBER
120-,
60 -
4 0 -
20 -
DOSE NUMBER
Effect of dosing guinea-pig tracheal chains with a single concentration of ET-1 
(0.5jiM) each dose repeated 5 times, (a) in the absence and (b) in the presence 
of 25|iM Indomethacin. The closed histograms indicate the relaxation responses 
and the dotted histograms the contractile responses to ET-1.Responses are 
expressed as a % of the maximum contractile response induced by CCh 
(0. 1-100jiM). Values show the mean and s.e. mean of 6 observations.
( t t  p< 0.01 significantly different from dose number 1, ** p< 0.01 significantly 
different from dose number 2, Duncans Multiple Range Test).
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Figure 42 : Effect o f repeat dosing with ET-1 fljLtM) on guinea-pig
tracheal smooth muscle.in the absence and presence of
25|liM  Indomethacin ,
(a)
50-1
4 0 -
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4 0 -
20 -
1 2 3 4 5
DOSE NUMBER
Effect of dosing guinea-pig tracheal chains with a single concentration of ET-1 
(IfiM) each dose repeated 5 times, (a) in the absence and (b) in the presence of 
25p.M Indomethacin. The closed histograms indicate the relaxation responses and 
the dotted histograms the contractile responses to ET-1. Responses are expressed 
as a % of the maximum contractile tension induced by CCh (0.1-100jiM).
Values show the mean and s.e. mean of 6-8 responses.
(ff  p< 0.01 significantly different from dose number 1, **p< 0.01 significantly 
different from dose number 2, Duncans Multiple Range Test).
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the peptide. With O.OSjjM ET-1 a significant attenuation of response (p< 0.01) was 
observed after the second repeat dose, the response then remaining constant through to 
the fifth dose (Figure 40b). At higher concentrations of ET-1 (0.5|iM and IjiM) 
tachyphylaxis was observed after the second repeat dose (p< 0.01). A further 
attenuation of response occurred at the fourth repeat dose (p< 0.01 vs the second repeat 
dose) with 0.5p,M ET-1 (Figure 41b) and after the third repeat dose (p< 0.01 vs the 
second repeat dose) with IpM ET-1 (Figure 42b), which was then maintained in each 
case through to the fifth repeat dose.
3.3 LIGAND BINDING STUDIES USING [125I] ET-1
3.3.1 Protein Content of Rat and Guinea-pig Tracheal Smooth Muscle
The protein content of the tracheal smooth muscle homogenate of the rat was shown to 
be 60-70% of the protein content of the cartilage, whereas, the protein content of the 
guinea-pig tracheal smooth muscle homogenate was approximately 50% of the protein 
content of the cartilage (Table 10). Prior exposure of the trachea to 0.5jiM ET-1 for 20 
minutes resulted in a significant reduction (p<0.05) of the available protein of both rat 
and guinea-pig tracheal smooth muscle (Table 10).
3.3.2 Protein Dilution Profile
Protein dilution profiles for rat and guinea-pig tracheal smooth muscle homogenate 
were constructed using [125j]e t -1 concentrations at the Kd value derived from the 
literature, 0.4nM for the rat and O.lnM for the guinea-pig. However, the protein 
dilution profiles so constructed were subject to great variability and consequently little 
information was gained from such studies. Therefore, due to the limited availability of 
protein and the number of concentrations of ligand required, it was decided to use 4jig 
of protein for the rat and 2(ig for the guinea-pig in further studies.
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3.3.3 Saturation Assays Performed on Tracheal Smooth Muscle Using
[1 2 5 i]E T - l
Saturation assays performed with [l^IJET -l and 4pg of rat tracheal smooth muscle 
homogenate and 2gg of guinea-pig tracheal smooth muscle homogenate were variable 
(Figure 43 and 45). Total binding increased with an increase in [125l]ET-l 
concentration, however, this was closely paralleled by the non-specific binding which 
ranged from 50-90% of the total binding. Saturablebinding was low, ranging from 
0.01-0.9fmol/|ig protein and 0.37-1.42fmol/gg protein for the rat and the guinea-pig 
respectively. Using rat tracheal homogenate (smooth muscle and cartilage) (Figure 44), 
a similar profile was obtained, saturabfe binding remaining very low. The ranges of 
concentrations of used were varied however, the saturation assays so
obtained remained variable and inconsistent
Increasing the amount of protein to a maximum, 15.6gg for the rat and using the 
maximum concentration of [1^I]ET-1, 0.4nM, reduced the non-specific binding and 
potentiated the saturablebinding of the ligand to rat tracheal smooth muscle (Table 11). 
Similarly, increasing the amount of protein to lOjig for the guinea-pig and using 0.3nM 
[125i]ET-l slightly decreased the non-specific binding but not to the level observed 
with the rat (Table 11). Unfortunately, the lack of radioligand prevented further 
experiments being undertaken with guinea-pig tracheal smooth muscle homogenate and 
furthermore, prevented experimentation with tracheal smooth muscle pre-exposed to 
ET-1.
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Figure 43 : The binding characteristics o f T^ Il Endothelin-1 on rat
tracheal smooth muscle.
(a)
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Saturation assays performed on rat tracheal smooth muscle homogenate, (□ ) total 
binding, (■ ) non-specific binding and (O) specific binding determined as the amount 
of [12^ I] Endothelin-1 bound fmolAig protein. Each saturation assay was performed in 
duplicate with concentrations of t1^ 5!] Endothelin-1 ranging from (a) 0.11-0.84 nM 
and (b) 0.02-0.4nM. Non-specific binding was determined in the presence of an excess 
of unlabelled Endothelin-1.
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Figure 44 : The binding characteristics of f^^Il Endothelin-1 on rat 
tracheal homogenate.
3.5 -
3 -
2.5 -
£  2 " 
1.5 -
I£  0.5 -  
1 J
0.3
[125I-ENDOTHELDN-l] nM
I1
3.5
3
2.5
2
1.5
1
0.5
0
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35
[125I-ENDOTHELIN-l] nM
0.4
Saturation assay performed on rat tracheal homogenate (tracheal smooth muscle 
and cartilage), (□ ) total binding, (■ ) non-specific binding and (O) specific 
binding determined as [125I] Endothelin-1 bound fmol/|J.g protein. Each saturation 
assay was performed in duplicate with concentrations of [^ 25I] Endothelin-1 
ranging from 0.02-0.4 nM. Non-specific binding was determined in the presence of 
excess unlabelled Endothelin-1.
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Figure 45 : The binding characteristics o f r- ^ II Endothelin-1 on
guinea-pig tracheal smooth muscle homogenate.
(a)
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0J
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i
0.1 0.30.250.15
[125I-ENDOTHELIN-1] nM
Saturation assay performed on guinea-pig tracheal smooth muscle homogenate,
(□ ) total binding, (■ ) non-specific binding and (O) specific binding determined 
as the amount of [125I] Endothelin-1 bound fmol/pg protein. Each saturation assay 
was performed in duplicate with concentrations of [125I] Endothelin-1 ranging from 
(a) 0.05-0.5 nM and (b) 0.01-0.3 nM. Non-specific binding was determined in the 
presence of an excess of unlabelled Endothelin-1.
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CHAPTER 4 
DISCUSSION
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* Observed differences in the apparent EC50 values generated for ET-1 may therefore be a 
consequence of the method used for the generation of potency estimates for the peptide. 
Variations in the maximum contractile response induced by ET-1 may result in differences 
in the apparent EC50 value though the true EC50 would remain unchanged. Therefore, 
differences in the EC50 values indicated in this thesis may reflect either a change in the 
potency of the peptide, or a change in the maximum response induced by ET-1.
4.1 CHARACTERISTICS OF THE ET-1 INDUCED RESPONSE ON 
ISOLATED TRACHEAL SMOOTH MUSCLE
Since its initial discovery, the pharmacological action of endothelin-1 (ET-1), has been 
intensely investigated, particularly with respect to its role in modulating vascular 
smooth muscle tone. However, many researchers have also focussed their attention on 
the pharmacological activity of the peptide on non-vascular smooth muscle with 
particular reference to the smooth muscle of the respiratory system. Uchida and 
colleagues, originally reported ET-1 to be one of the most potent known 
bronchoconstrictor agents with a potency of more than two log units greater than either 
Neurokinin A or Leukotriene D4 (Uchida et al., 1988), and an EC50 value of 0.53nM 
observed on guinea-pig tracheal smooth muscle, a value found to be in accord with that 
originally demonstrated by Yanagisawa and coworkers on isolated porcine coronary 
artery strips (Yanagisawa et al., 1988a). However, since the initial report of the activity 
of the peptide within the respiratory system, the potency of ET-1 on respiratory smooth 
muscle has become a topic of great controversy.
4.1.1 Rat Tracheal Smooth Muscle
The tracheal smooth muscle of the rat was shown to exhibit a consistent contractile 
response to ET-1 which was slow in onset and taking 60 minutes to complete a 
cumulative concentration response curve to the peptide (0.01-ljiM). Limited availability
of the peptide prevented concentrations of ET-1 greater than IjiM being studied,
! *
thereby preventing completion of a full concentration response curve. Rat tracheal 
smooth muscle did not display any relaxation responses on administration of ET-1, 
suggesting that in this tissue preparation ET-1 does not induce the release of a relaxant 
factor or that the potent contractile activity of the peptide masks any effect of the release 
of such a factor. The EC50  value calculated for the action of ET-1 on rat tracheal
smooth muscle was shown to be seven fold less than that generated by guinea-pig
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* Therefore, the same reservations apply to the EC50 values generated for the action of 
ET-1 on guinea-pig tracheal tissue as those mentioned previously for the rat.
tracheal smooth muscle. The potency of ET-1 on rat tracheal smooth muscle is 
equivocal (see Table 12); several laboratories have failed to achieve potency estimates 
equivalent to that observed by Uchida et aL, (1988) on guinea-pig tracheal smooth 
muscle, which may possibly be indicative of a species variation in the response of 
tracheal smooth muscle to ET-1. However, Turner et al., (1989a) demonstrated ET-1 to 
have an EC50  value of 5pM on rat tracheal smooth muscle, a 23 fold lower potency
estimate compared with that calculated for this study. In general however, with the 
exception of the work described in this thesis, ET-1 was shown to be more potent on 
the tracheal smooth muscle of the guinea-pig than the rat.
4.1.2 Guinea-pig Tracheal Smooth Muscle
ET-1 was shown to elicit a contractile effect on guinea-pig tracheal smooth muscle in
vitro, with concentrations of ET-1 ranging from 0.01-lpM. Limited availability of the
*
peptide prevented the actions of higher concentrations of the peptide being studied. 
Others have shown ET-1 to have a threshold concentration ranging from IpM-lOnM 
(Uchida e ta l, 1988; Hay, 1989; Turner ef a/., 1989a & Henry e ta l, 1990) on guinea- 
pig tracheal smooth muscle, indicating the variability of the action of ET-1 observed 
throughout the literature. Furthermore, de Nucci et al., (1988) showed the isolated 
tracheal smooth muscle of the guinea-pig to be insensitive to the actions of the peptide 
(l-30pM), whereas Eglen et a i, (1989) observed only a small response to ET-1 at the 
concentration range studied (lpM-32nM) in the same tissue preparation.
The potency of ET-1 on the tracheal smooth muscle of the guinea-pig reported in this 
thesis has indicated the peptide to be markedly less potent than that postulated by 
Uchida et a l, (1988). Guinea-pig tracheal smooth muscle exhibited a variability in 
response to the peptide which resulted in the generation of two qualitatively different 
responses;
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(i) concentration response curves achieving > 50% of the maximum contractile 
tension induced by CCh (0.1-1 OOjjM),
(ii) flat concentration response curves plateauing at I jiM  ET-1 and generating tensions 
of only 25-30% of the maximum contractile tension induced by CCh.
In those tissue preparations where calculation of EC50 values was possible, ET-1 was 
shown to be 3000 fold less potent on guinea-pig tracheal smooth muscle than that 
originally proposed by Uchida et al., (1988). Many factors may contribute to such an 
observed variability in potency estimates, different strains of animal used, different 
methods of tissue preparation, different experimental buffers, and may also indicate 
diversity in tissue factors such as receptor density and receptor/effector coupling 
mechanisms. Others have also failed to confirm the original potency estimate of ET-1 in 
isolated respiratory tissue (Table 12). Hay (1989) whilst confirming the the contractile 
activity of ET-1 on guinea-pig tracheal smooth muscle, demonstrated a 45 fold lower 
potency estimate and Batüstini et ai, (1991) a 65 fold lower potency estimate than that 
demonstrated in this thesis. Turner et a i, (1989a) whilst providing confirmatory 
evidence for the low potency estimate of the action of ET-1 observed in this study, 
indicated a 5000 fold decrease in potency compared with the EC50 value of 0.53nM 
generated by the action of ET-1 on guinea-pig tracheal smooth muscle observed by 
Uchida et al., (1988). Differences in potency estimates have also been observed 
between different regions of the respiratory system (Table 12). It is therefore possible 
that the distribution of ET-1 receptors within the respiratory system is heterogenous, 
with EC50  values varying between the isolated bronchus, lung and trachea of the 
guinea-pig (Table 12). The lack of difference in the potency of the peptide between 
different regions of the trachea (upper and lower) observed in this thesis however, 
suggests that within trachea the distribution of ET-1 receptors is homogenous.
The ET-1 induced variability in the response of the isolated tracheal smooth muscle of 
the guinea-pig was further emphasised by the presence of transient relaxation responses 
observed on immediate dosing with the peptide, thus the response to ET-1 was shown
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Table 12:
Comparative EC50 values showing the effects of ET-1 on isolated
respiratory smooth muscle.
Tissue Species
ii
Reference
Bronchus cow 3 a Kamm gf <2/., (1989)
dog 24.3*: a McKay ef aL, (1992)
guinea-pig 7 t ; a Maggi ef û/., (1989a)
32.6 a Batüstini et aL, (1991)
human 4.5* ij a McKay et aL, (1992)
17.9 ! a McKay et aL, (1991c)
18 ! a McKay et aL, (1991b)
28.2 a McKay et aL, (1991a)
35.2* a Henry et aL, (1990)
rabbit 33.1 | a McKay et aL, (1991a)
42.2*1 a McKay et aL, (1992)
Lung parenchyma guinea-pig 14 j a Bolger et aL, (1990)
Trachea guinea-pig 0.53 b Nomura etaL, (1991)
0.53 b Uchida etaL, (1988)
6.8 !; b Schumacher et aL, (1990)
11.7 a Cardell et aL, (1991)
12.3 i
a Cardell et aL, (1990)
15.5 a 1 Cardell et al,, (1992)
23.4 a ; Hay, (1989)
24.4 a : Filep et aL, (1991)
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Tissue Species EC50 Reference
(nM)
guinea-pig 34.4 :a Battistini et aL, (1991)
30.9ft a Hay, (1990)
241* a Henry er <2/., (1990)
1590 : : this study
3000 ■ a Turner et aL, (1989a)
mouse 3.4* ! a i Henry era/., (1990)
rabbit (adult) 15.1 a : Grunstein et aL, (1991b)
(2 wk old) 2.6 a Grunstein et aL, (1991a)
rat 74 a Bolger ef tf/., (1990)
18.2* ! a Henry etaL, (1990)
38 j a Henry etaL, (1992)
220 this study
5000 a Turner et aL, (1989a)
5400 a Turner et aL, (1989b)
* EC30 values
f  buffer contains Indomethacin, Thiorphan, Captopril & Restatin 
t t  in the presence of 5|iM Indomethacin
a responses calculated as a % of the maximum response to a reference contractile agonist 
! b absolute values
178
to be biphasic. The transient relaxation responses were shown to be more prevalent in 
those tissue preparations exhibiting maximal responses to ET-1 of 25-30% of the 
maximum contractile tension induced by CCh, but were also observed in those tissues 
which demonstrated good contractile responses to ET-1. It was clear that the constrictor 
properties of the peptide were limited by the transient relaxation responses, which did 
not appear to be dose related. It is possible that ET-1 induces the release of some 
relaxant agents from either the tracheal smooth muscle itself or the tracheal epithelium, 
which results in the relaxant response observed to ET-1. In those tissues which 
demonstrated few ET-1 induced relaxation responses it is possible that the release of 
such relaxant factors is masked by the more potent constrictor actions of the peptide. 
Reports of ET-1 induced relaxant responses in airway smooth muscle have been very 
limited. Turner et aL, (1989a) reported observing transient relaxation responses which 
preceeded the contractile responses to ET-1 on isolated guinea-pig tracheal smooth 
muscle, but failed to further investigate such a phenomenon. It is interesting to note 
however, that the observed EC50 value of 3pM for the action of ET-1 on guinea-pig 
tracheal smooth muscle (Turner et aL, 1989a), is comparable with that value of 1.59|iM 
generated in this study, and therefore further supports the theory that ET-1 induces the 
release of a relaxant product which ultimately limits the constrictor activity of this 
peptide. Further, Uchida et aL, (1991) demonstrated that in the post-anaphylactic 
guinea-pig trachea (guinea-pigs sensitized and challenged with ovalbumin) in vitro, ET- 
1 induces a transient relaxation response followed by constriction. Such transient 
relaxation responses were shown to be more prominent in dose ranges of 10pM-10nM 
ET-1, whereas higher concentrations of the peptide immediately contracted the trachea, 
thereby suggesting once again that ET-1 induces the release of a relaxant factor. The 
animals used in this study were not subjected to any undue stressors prior to being used 
in experiments and could not be considered to be highly sensitized as would be 
expected post-anaphylaxis. Both the rat and the guinea-pig were killed by cervical 
dislocation and the absence of ET-1 induced relaxation responses on isolated rat 
tracheal smooth muscle suggests that the responses observed on guinea-pig tracheal
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smooth muscle are due to a functional difference in response rather than a consequence 
of prior induced stress. Indeed, ET-1 (lOnmol/kg) has been shown to induce a biphasic 
response in the tracheal active tension of the guinea-pig in vivo (White et aL, 1991), a 
short initial relaxation response maximal in 30 seconds, followed by a sustained 
smooth muscle contractile response, maximal within three minutes. ET-1 induced 
airway transient relaxation responses are not limited to the guinea-pig, indeed Grunstein 
et aL, (1991sl & b) demonstrated ET-1 to have a duality of action on rabbit tracheal 
smooth muscle (adult and two week old animals), wherein at lower concentrations of 
ET-1 (< InM) a relaxation response is elicited due to the release of a relaxant factor, 
whereas at higher concentrations ET-1 induces primarily airway constriction. Similar 
biphasic responses to ET-1 have been observed on vascular smooth muscle both in 
vitro and in vivo, with ET-1 initiating a transient vasodilator response which preceeds 
the constrictor response (De Nucci et aL, 1988; Inoue et aL, 1989; Withrington et aL, 
1989; Minkes et aL, 1990 & Otsuka et aL, 1990). The mechanism by which ET-1 
induces relaxation responses in airway smooth muscle is both complex and equivocal 
and will therefore be discussed in greater detail in subsequent sections (section 4.4).
4.2 THE ROLE OF THE PEPTIDASE ENZYMES IN THE ET-1 
INDUCED RESPONSE
The epithelium has long been regarded as possessing a regulatory role in the control of 
airway smooth muscle function. The airway epithelium may regulate smooth muscle 
tone in a variety of different ways; it has been proposed as a source of prostanoid and 
non-prostanoid inhibitory factors (Hay, 1986), it has also been proposed that epithelial 
cells may act as a diffusion barrier (Holroyde, 1986). Advenier et aL, (1988) showed 
that the epithelium possesses a metabolic role evidenced by an increased responsiveness 
of airway smooth muscle to adenosine following epithelium removal. Support for such 
a role of airway epithelium was provided by Devillier and colleagues, who
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demonstrated that removal of the tracheal epithelium of the guinea-pig or treatment with 
thiorphan increased to a similar extent the sensitivity of the smooth muscle to the 
neurokinins with no additive effects, thereby suggesting that the epithelium has a 
metabolic role in promoting the degradation of neurokinins (Devillier et al., 1988). In 
view of the tracheal epithelium possessing a metabolic role in the regulation of the 
effects of both neurokinins (Devillier etal., 1988) and tachykinins (Frossard et aL, 
1989) it was considered possible that ET-1 too, was subject to degradation by 
peptidases located within the tracheal epithelial cells (Xu et aL, 1986) and conditions 
associated with diminished peptidase activity may result in enhanced responses.
The enzyme inhibitors bestatin, captopril, thiorphan and phosphoramidon were chosen 
as they had previously been shown to potentiate the actions of Substance P in the 
airways (Shore et aL, 1988; Thompson et aL, 1988 & Subissi et aL, 1990). Peptidases 
are generally classified as either exopeptidases, removing one or two residues from 
either the N or the C terminus, or endopeptidases, hydrolysing at internal sites in the 
peptide chain (Turner et aL, 1985). Phosphoramidon and thiorphan, known as 
enkephalinase, endopeptidase or neutral metalloendopeptidase inhibitors, inhibit the 
action of the endopeptidase-24-11 enzyme (Turner et aL, 1985). Angiotensin 
converting enzyme or peptidyldipeptide hydrolase is widely distributed in mammalian 
tissues, although its major location is considered to be the lung (Turner et aL, 1985). 
Inhibitors of this enzyme, such as captopril, may therefore play an important role in 
enhancing the response of various peptides within the respiratory system. Bestatin is an 
aminopeptidase enzyme inhibitor, however, it is not as selective nor as potent as the 
inhibitors of endopeptidase (Turner et aL, 1985). The aforementioned peptidase 
inhibitors at concentrations of 10|iM were shown to potentiate the contractile action of 
Neurokinin A (NKA) (0.01-lp.M) on guinea-pig tracheal smooth muscle, thereby 
indicating that NKA is indeed subject to degradation by those enzymes 
(aminopeptidase, angiotensin converting enzyme and neutral endopeptidase) and that
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inhibition of the enzymes is apparent at inhibitor concentrations of lOpM. Furthermore, 
such results demonstrate the existence of these enzymes within the tracheal tissue.
Incubation of rat tracheal smooth muscle with the peptidase inhibitors failed to have any 
effect on the subsequent ET-1 induced response. The response to ET-1 was not 
enhanced in the presence of either bestatin, captopril, phosphoramidon or thiorphan 
suggesting that ET-1 is not a substrate for these enzymes and the action of the peptide is 
not limited by its degradation within the tracheal tissue. Furthermore, it is apparent that 
on rat tracheal smooth muscle, the peptide mediates its action directly on the smooth 
muscle and that relatively poor response to ET-1 observed in this study is not due to the 
metabolism of ET-1 by peptidase enzymes.
Incubation of guinea-pig tracheal smooth muscle with the enzyme inhibitors prior to 
administration of ET-1 (0.01-lqM) also failed to have any significant effect on the 
responsiveness of the tracheal smooth muscle to ET-1. The ET-1 induced relaxation 
responses observed immediately on dosing with the peptide were unaffected, indicating 
that metabolism or degradation of the peptide or resultant metabolic products are not 
responsible for the relaxant response of the guinea-pig tracheal smooth muscle. The 
contractile response of the guinea-pig tracheal smooth muscle was slightly attenuated in 
the presence of bestatin, however, the degree of attenuation was not significant. 
Therefore, the lack of effect of these enzyme inhibitors on the ET-1 induced response 
observed on guinea-pig tracheal smooth muscle indicate that the peptide is not a 
substrate for the aminopeptidase, angiotensin converting nor endopeptidase enzymes. It 
is evident that the ET-1 induced relaxation responses are not due to the degradation 
products from the action of the above enzymes, however the possibility of ET-1 being 
broken down by some other enzyme located within the tracheal epithelium cannot be 
excluded.
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Reports concerning the metabolism of ET-1 by various peptidase enzymes are 
equivocal. Confirmatory evidence for the lack of effect of phosphoramidon on the ET-1 
induced airway response was provided by McKay et aL, (1992), who demonstrated 
that the response to ET-1 on human and rabbit bronchus was unaffected by 
preincubation of the tissue with 10|iM phosphoramidon, whereas ET-3 was shown to 
be a substrate for the neutral endopeptidase enzyme. Furthermore, the ET-1 induced 
response on rat tracheal smooth muscle has been shown to be unaffected by the 
presence of lOpM phosphoramidon (Henry et al., 1992), thereby confirming the 
findings presented here. In vivo, phosphoramidon blocked the action of big ET-1, 
which is consistent with the role of phosphoramidon as the endothelin converting 
enzyme inhibitor (see section 1.3), but failed to affect the pressor and airway contractile 
effects induced by ET-1 (Fukuroda et ai, 1990).
In contrast, Uchida and colleagues have demonstrated that in the presence of 
phosphoramidon (lOpM), ET-1 induces a relaxation response on guinea-pig tracheal 
smooth muscle which was not observed in the absence of the peptidase inhibitor 
(Uchida et aL, 1991). Although relaxation responses to ET-1 were observed in the 
presence of phosphoramidon on guinea-pig tracheal smooth muscle in this study, they 
were not a consequence of phosphoramidon administration, therefore it is possible that 
the response observed by Uchida and colleagues was due to the metabolism of an ET-1 
released substance rather than ET-1 itself. Maggi ef a/., (1989a & 1990) have 
demonstrated that the response to ET-1 on guinea-pig bronchus is enhanced in the 
presence of the neutral endopeptidase inhibitor thiorphan, suggesting that in the 
bronchi, ET-1 is a substrate for this enzyme. However, it is not possible to determine 
absolutely whether the observed enhancement of the ET-1 induced response is due to 
inhibition of the neutral endopeptidase enzyme alone, as experiments were performed in 
the presence of bestatin, captopril and indomethacin as well as thiorphan, it is therefore 
possible that one or all of the enzyme inhibitors were responsible for the increased 
response of the guinea-pig bronchi to ET-1. It is possible to conclude however, that the
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action of ET-1 is not mediated via a direct mechanism and in this respect confirms the 
findings of this study. Hay, (1989) suggested that ET-1 is not a substrate for the 
angiotensin converting enzyme, endopeptidase or aminopeptidase, however 
phosphoramidon (10|iM) inhibited the effect of epithelium removal on the ET-1 
induced response thereby suggesting that ET-1 is normally metabolized by a neutral 
endopeptidase enzyme located within the tracheal epithelium. Confirmatory evidence 
for ET-1 acting as a substrate for the neutral endopeptidase enzyme was provided by 
Tschirhart et aL, (1990) an enhanced response to ET-1 observed on guinea-pig tracheal 
smooth muscle in the presence of phosphoramidon. In vivo, the bronchopulmonary 
response to aerosolized ET-1 in guinea-pigs has been demonstrated to be markedly 
enhanced following pretreatment with aerosolized phosphoramidon (Boichot et aL, 
1991 & Ohse et aL, 1991), and in vitro pretreatment of isolated guinea-pig lungs with 
phosphoramidon has been shown to potentiate the ET-1 induced increase in pulmonary 
inflation pressure (Boichot et aL, 1991).
The reasons for such discrepancies in the effect of ET-1 in the presence of peptidase 
inhibitors on airway smooth muscle is unclear, but may possibly be multifactorial. All 
three isoforms of endothelin have been shown to be good substrates for the activities of 
neutral endopeptidase 24-11 (Sokolovsky et aL, 1990 & Vijayaraghavan et aL, 1990), 
indeed within the ET-1 structure there exist seven potential sites for cleavage of the 
peptide (Vijayaraghavan et al., 1990). It is further suggested that the hydrolysis of the 
endothelins differs according to the amino acid sequence and conformation of the 
peptide. However, no explanation is offered for the differential activity of ET-1 
observed in the presence of the neutral endopeptidase inhibitors on airway smooth 
muscle. It is possible however, that the failure of phosphoramidon and thiorphan to 
affect the ET-1 induced response is indicative of a regulatory dysfunction which may 
possibly contribute to the pathological effects of asthma.
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4.3 THE ROLE OF CALCIUM IN THE ET-1 INDUCED RESPONSE
The involvement of Ca^+ in the ET-1 induced response has been a matter of intense 
investigation since Yanagisawa et aL, (1988a) proposed ET-1 to be an endogenous 
agonist of the dihydropyridine Ca^+ channel, blockade of the Ca^+ channel by 
nicardipine attenuating the ET-1 induced contraction of porcine coronary artery strips. 
Furthermore, complete inhibition of the ET-1 induced response was observed in Ca^+ 
free Krebs buffer containing ImM EGTA, thereby suggesting the actions of ET-1 to be 
ultimately dependent on the presence of extracellular Ca%+.
4.3.1 Extracellular Calcium Dependence of the Tracheal Smooth Muscle 
Response to ET-1
Uchida et aL, (1991) demonstrated that in the presence of a buffer containing 0.8mM 
Ca2+, guinea-pigs sensitized and challenged with ovalbumin, produced relaxation 
responses. It was considered that ET-1 induced the release of some relaxant factor 
which resulted in the observed relaxation responses. It was questioned whether 
modification of the Krebs buffer used in the studies presented here would alter the 
responsiveness of the tracheal smooth muscle to ET-1, therefore experiments were 
conducted in the presence of a reduced Ca^+ containing buffer.
Construction of a cumulative concentration response curve to ET-1 on rat tracheal 
smooth muscle in the presence of a reduced Ca^+ containing buffer (0.8mM) had no 
significant effect on the maximum contractile tension induced by IpM ET-1. A slight, 
although not significant, attenuation of response was observed at low concentrations of 
ET-1 (0.05-0. IpM). A reduction in the Ca^+ content of the buffer had no significant 
effect on the EC50 value calculated for ET-1 and therefore it would appear that the 
Ca2+ content of the buffer may vary (from 0.8-2.5mM) without significant alteration in
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the ET-1 induced response. The slight attenuation in contractile response at the lower 
concentrations of ET-1 may possibly be indicative of an increased 
requirement/dependence on extracellular Ca^+ and may suggest that the ET-1 induced 
response is biphasic in nature with regard to extracellular Ca2+ dependence. However, 
the lack of a significant difference in response prevents firm analysis and therefore such 
suggestions can only be considered to be tentative. To fully examine the contribution of 
extracellular Ca2+ to the ET-1 induced response on rat tracheal smooth muscle, 
experiments are required to be performed in the absence of extracellular Ca^4*. 
However, in the absence of extracellular Ca^+, although the ET-1 induced response 
was virtually abolished, the reference contractile response to CCh was significantly 
inhibited thereby preventing direct comparisons between the ET-1 induced response 
observed both in the absence and presence of extracellular Csfi+. Turner et aL, 
(1989b), demonstrated that rat tracheal smooth muscle in a Ca^4" free medium 
containing O.lmM EGTA, exhibited a significant attenuation of response to ET-1 
compared with that observed in normal Cd?+ containing buffer, thereby suggesting that 
the ET-1 induced response is partly dependent on the presence of extracellular Ca^4-, 
but that mobilization of intracellular stores may also contribute to the observed 
response.
The contractile response of guinea-pig tracheal smooth muscle to ET-1 in the presence 
of a reduced Ca^4" buffer exhibited a slight, but not significant, attenuation. As was 
observed on rat tracheal smooth muscle, the contractile response of the guinea-pig 
tracheal smooth muscle in reduced Ca^4- buffer is not significantly different from that 
observed in normal Ca^4" containing buffer, thereby suggesting that the ET-1 response 
is not influenced by the higher concentration of Ca^4" utilized in normal Krebs buffer. 
Calcium ions are essential for contraction of smooth muscle, the Csfi+ in the 
extracellular medium gaining access to the cell following opening of ion channels, 
however mobilization of intracellular Ca^4- stores also contributes to the contractile 
action. Hay, (1990) observed that incubation of guinea-pig tracheal smooth muscle in
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Ca2+ free buffer containing O.lmM EGTA had no significant effect on the ET-1 
induced response suggesting that the ET-1 induced contractile action is not dependent 
on the presence of extracellular Ca^+.
Interestingly, the ET-1 induced relaxation responses observed on guinea-pig tracheal 
smooth muscle were potentiated at 0.05jjM, 0.5pM and IjiM ET-1 in the presence of a 
reduced Ca?+ containing buffer. It is not suggested that the reduction in extracellular 
Ca2+ is responsible for the potentiated relaxation responses, but may possibly be due 
to an attenuation in the contractile response which usually masks the relaxant effects of 
ET-1 at the higher concentrations. The response of the guinea-pig tracheal smooth 
muscle has been shown to be biphasic in nature and the mechanism of response can be 
considered to be a balance between the ET-1 induced release of relaxant factors and the 
mechanism of the contractile response; when one of these factors is effectively altered, 
the balance between the two responses is disrupted. It is possible that the slight 
attenuation of contractile response to ET-1 results in a potentiation of the relaxation 
response, as the contractile activity of the peptide is insufficient to overcome or mask 
the relaxation response. Alternatively however, it is possible that the reduced Ca2+ 
buffer results in a potentiation of the ET-1 induced release of relaxant factors thereby 
accounting for the observed potentiation of response. Grunstein etal., (1991a & b) 
observed that dosing rabbit tracheal smooth muscle with ET-1 in a Ca^+ free medium 
virtually ablated the contractile response to the peptide. Experiments using the tracheal 
smooth muscle of the rabbit (Grunstein etal., 1991a & b) were however, performed in 
the presence of IOjiM  indomethacin, which inhibited the ET-1 induced relaxation 
responses in this tissue and therefore the effect of extracellular Ca2+ depletion on the 
ET-1 induced relaxation response could not be evaluated. The effects of Ca2+ depletion 
on the ET-1 induced response appear to be species dependent. McKay et a i, (1991b) 
demonstrated that removal of extracellular Ca?+ had no significant effect on the ET-1 
induced response observed on human lung preparations indicating that in this species 
mobilization of intracellular Cs?+ stores occurs. To further understand the involvement
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of Ca2+ in the ET-1 induced response on guinea-pig tracheal smooth muscle, the 
precise nature of the contribution of intracellular Ca2+ to the contractile response must 
be determined.
4.3.2 Effect of Calcium Channel Inhibition on the ET-1 Induced 
Response
Nicardipine is a type 1 dihydropyridine Ca^+ channel antagonist (Ohtsuka et aL,
1989). The inhibitory action of nicardipine on the ET-1 induced response observed on 
porcine coronary artery strips by Yanagisawa et a l (1988), suggests that L-type Ca^+ 
channels are involved in the ET-1 induced response on vascular smooth muscle. In the 
respiratory system, L-type Ca^+ channels have been implicated in the ET-1 induced 
response. The lack of effect of NiCl2 and co conotoxin on the ET-1 induced response 
on guinea-pig tracheal and bronchial smooth muscle excludes the involvement of both T 
and N type Ca^+ channels, whereas, the inhibitory effect of nifedipine on the ET-1 
response suggests the involvement of the L-type channel (Maggi et aL, 1989c).
Incubation of rat tracheal smooth muscle with IOjiM nicardipine prior to dosing with 
ET-1 had a significant inhibitory effect on the ET-1 induced response. Only one 
concentration response curve was constructed on each tissue preparation and therefore 
the inhibitory effects of the Ca2+ channel antagonist on the ET-1 induced response 
could not be attributed to tachyphylaxis. A greater inhibiory effect on the ET-1 induced 
response was observed at the lower concentrations of ET-1 (0.01-0.IpM). The 
inhbitory action of nicardipine on the ET-1 induced response indicates that Ca^+ influx 
occurs via the dihydropyridine sensitive Ca^+ channel and that influx of Ca^+ via this 
channel is essential for the full expression of constrictor activity to ET-1 on rat tracheal 
smooth muscle. However, the role of the dihydropyridine Ca^+ channel on the ET-1 
induced response on airway smooth muscle is controversial. Turner et aL, (1989b) 
demonstrated that the response to ET-1 on rat tracheal smooth muscle was unaffected in
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the presence of 0.1 p.M nicardipine, furthermore the binding of [^^I]ET-1 to rat trachea 
was unaffected by nicardipine, thereby it is suggested that in the rat airway, ET-1 is 
unlikely to be interacting at the dihydropyridine site and therefore Ca^+ influx must 
occur by some route other than that of the dihydropyridine channel. The inhibitory 
effect of nicardipine observed in this study however does not rule out the possibile 
involvement of other routes of Ca^+ influx contributing to the ET-1 induced response. 
Furthermore, the contribution of intracellular Ca^+ stores to the ET-1 induced response 
cannot be fully evaluated, however, the apparently greater inhibitory effect of 
nicardipine at lower doses of ET-1, may possibly suggest that the ET-1 action on rat 
tracheal smooth muscle involves two components of response; one of which is more 
sensitive to the action of the dihydropyridine Ca^+ channel antagonist and occurs at 
lower concentrations of ET-1 < 0.1 pM.
In contrast, in the presence of nicardipine, the response of the guinea-pig tracheal 
smooth muscle to ET-1 was shown to be unaffected, although a slight attenuation of the 
contractile response occurred, it did not achieve a significant level. Furthermore, the 
ET-1 induced relaxation responses were neither attenuated nor potentiated in the 
presence of the Ca2+ channel antagonist Such results suggest that influx of Ca^+ does 
not occur via the dihydropyridine Ca%+ channel, although influx via other routes cannot 
be excluded. However, Chilvers and Nahorski (1990) have proposed that contraction 
of airway smooth muscle results from an increase in cytoplasmic free Ca^+ and appears 
to be independent of changes in membrane potential or the presence of extracellular 
Ca2 +, therefore, it is possible that influx of extracellular Ca^+ via any route is not 
neccessary for the contractile response to ET-1 to be observed. Confirmatory evidence 
for the lack of effect of Ca2+ channel antagonists on the ET-1 induced response on 
guinea-pig tracheal smooth muscle has been provided by Hay, (1990) and Sarria et aL,
(1990), where nicardipine, verapamil and diltiazem were without effect on the tissue 
response to the peptide. However, in contrast, others have indicated the guinea-pig 
tracheal smooth muscle to exhibit an attenuated response to ET-1 in the presence of the
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Ca2+ channel antagonists. The variation in the concentration of the antagonists used 
however, may contribute to the variety of responses observed. Uchida et a/., (1988) 
showed lOnM nicardipine to have an inhibitory effect on the response of guinea-pig 
trachea to ET-1, whereas Hay, (1990) showed the same concentration of nicardipine to 
have no effect. It is also interesting to note that those studies where IOjiM nicardipine 
was utilized, the same concentration as was used in this study, an attenuated response 
to the lower concentrations of ET-1 on guinea-pig tracheal smooth muscle was 
observed (Sarria et aL, 1990), whereas in this study, nicardipine was without effect. It 
is not known why such differences in response occur, but may possibly be a function 
of experimental protocol. Grunstein et aL, (1991b) showed that IOjiM nifedipine 
attenuated the contractile responser to ET-1 on rabbit tracheal smooth muscle, however 
experiments were conducted in the presence of indomethacin and therefore, the effects 
of Ca2+ channel inhibition on the ET-1 induced relaxation responses were unable to be 
evaluated. Furthermore, the effects of Ca2+ channel inhibition were shown to be 
relatively more pronounced on immature tissues. Such observations may go further to 
explain the equivocal reports concerning the effects of Ca^+ channel inhibition! J t is 
possible that the mechanism of action of ET-1 does vary maturationally in the guinea- 
pig resulting, in what seems on initial observation to be a set of discordant results, but 
in fact represents the development of the ET-1 induced response. Such a theory is 
speculative and therefore requires further investigation into the ontogeny of the ET-1 
induced response on guinea-pig respiratory smooth muscle.
4.4 INVOLVEMENT OF SECONDARY MEDIATORS IN THE ET-1 
INDUCED RESPONSE
Cyclooxygenase like endopeptidase has been localised to the tracheal epithelial cells 
(Xu et aL, 1986). The relaxant products generated by the cyclooxygenase enzyme from 
arachidonic acid, have been shown to be released by the epithelial layer in guinea-pig
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isolated trachea by the application of exogenous arachidonic acid itself (Tschirhart et 
aL, 1987). Indeed, Braunstein et aL, (1988) showed that arachidonic acid stimulated 
the release of prostaglandin E% from isolated tracheal preparations, as determined by 
radioimmunoassay, and that this release was attenuated in those preparations where the 
epithelium had been removed. Furthermore, Frossard et aL, (1989) demonstrated that 
the tachykinins, such as neurokinins and Substance P, may induce the release of 
relaxant prostaglandins in airways, evidence for which was provided by the observed 
potentiating effect of the cyclooxygenase synthesis inhibitor, indomethacin on the 
response induced by the peptides. The contribution of the cyclooxygenase enzyme and 
the epithelium with respect to the ET-1 induced response was examined on rat and 
guinea-pig tracheal smooth muscle.
4.4.1 The Role of the Cyclooxygenase Enzyme in the ET-1 Induced 
Response
The functional activity of the cyclooxygenase synthesis inhibitor indomethacin (25jiM) 
was determined by its inhibitory effect on the relaxation response induced by O.lmM 
arachidonic acid on epithelium intact guinea-pig tracheal smooth muscle. Such a 
response indicates that exogenously applied arachidonic acid induces the release of a 
relaxant factor which can be inhibited by indomethacin. Indomethacin, by virtue of 
cyclooxygenase inhibition, inhibits the formation of both prostaglandins and 
thromboxanes which possess both relaxant and contractile properties on the isolated 
respiratory system. In addition, De Nucci et a l ., (1988) have shown that ET-1 induces 
the release of both prostacyclin (PGI2) and thromboxane A2 from the isolated lungs of
both rats and guinea-pigs, furthermore, ET-1 has recently been shown to induce the 
release of PGI2  from rat isolated lungs via the activation of ETA (ET-1) preferring
receptors (D'Orleans-Juste et al., 1992). Therefore, it is clear that both the
prostaglandins and the thromboxanes play a role in the response induced by ET-1 on
airway smooth muscle.
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Indomethacin (25|iM) incubated with the tracheal smooth muscle of the rat for 30 
minutes prior to dosing with ET-1 had no significant effect on the subsequent response 
to the peptide. Rat tracheal smooth muscle did not display any anomalies in response 
upon administration of ET-1 in the absence of indomethacin, such a response however 
does not exclude the possible involvement of the products of cyclooxygenase. 
However, when in the presence of the cyclooxygenase inhibitor the pattern of response 
to ET-1 was unchanged, indicating that in this tissue preparation the response to ET-1 
is not mediated via the ET-1 induced release of products of the cyclooxygenase 
pathway of arachidonic acid metabolism, but rather appears to act directly on the 
smooth muscle itself. Chand et aL, (1990) however, have shown that the ET-1 induced 
contractile response on rat tracheal smooth muscle was potentiated in the presence of 
5pM indomethacin, suggesting that secondary mediators play a role in the response of 
tracheal smooth muscle to ET-1. Confirmatory evidence for the findings presented in 
this study however, has been provided by Henry et aL, (1990 & 1992) where 
indomethacin was shown to be without effect on the tracheal smooth muscle of the rat. 
In view of such findings it is worthy of note that rat isolated lungs exposed to ET-1 
induce a much stronger release of PGI2 than guinea-pig lungs (De Nucci et aL, 1988) 
and yet indomethacin has no effect on the ET-1 induced response on rat tracheal smooth 
muscle. It is possible that the ET-1 induced release of the products of cyclooxygenase 
is heterogenous within the respiratory system of the rat and that secondary mediator 
involvement is ultimately dependent on the anatomical region of the respiratory system 
studied; in the tracheal smooth muscle however, it would appear that the contribution of 
the products of cyclooxygenase is negligible.
Indomethacin, incubated with guinea-pig tracheal smooth muscle for 30 minutes prior 
to dosing with ET-1, abolished the ET-1 induced transient relaxation responses. The 
abolition of the relaxation responses suggests that ET-1 induces the release of a relaxant 
product of cyclooxygenase which limits the constrictor activity of the peptide. 
Furthermore, in the presence of indomethacin, the contractile responses to ET-1 were
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potentiated, indicated by an increase in the maximum contractile tension generated by 
ET-1 (1|J.M) on isolated guinea-pig tracheal smooth muscle and by a three fold shift in 
the calculated EC50 value. Therefore, indomethacin blocks the release of the relaxant 
product induced by ET-1 and in doing so potentiates the contractile action of the 
peptide, thereby indicating that ET-1 does not act directly on the smooth muscle of 
guinea-pig trachea, but rather induces the release of secondary mediators which 
contribute to the ET-1 induced response. The release of such relaxant factors however, 
masks the contractile action of the peptide and increases the time taken to complete a 
cumulative concentration response curve to the peptide. Despite the potency of ET-1 
being increased on guinea-pig tracheal smooth muscle in the presence of indomethacin, 
the EC50 value (0.57 ± 0.15p.M) so generated remains significantly higher (1000  fold) 
than that originally postulated by Uchida et ai, (1988).
The role of cyclooxygenase in the ET-1 induced response remains controversial. 
Grunstein et aL, (1991a & b) demonstrated a biphasic response induced by ET-1 on 
rabbit tracheal smooth muscle (adult and two week old rabbits), the relaxation 
responses of which were sensitive to the actions of indomethacin. In the adult 50% 
inhibition of the ET-1 induced relaxation responses was observed in the presence of 
IOjiM  indomethacin, whereas in the immature airway smooth muscle abolition of the 
relaxation responses occurred, suggesting that ET-1 induces the release of a relaxant 
product of cyclooxygenase. Indeed, the ET-1 induced relaxation responses were found 
to be associated with an increase in prostaglandin E2 and I2 production. Such results 
support the findings of this thesis in proposing ET-1 to induce the release of a relaxant 
product of cyclooxygenase on guinea-pig tracheal smooth muscle, and further suggest 
the involvement of PGI2 and PGE2 in such a response. Other researchers have 
indicated that, despite the absence of ET-1 induced relaxation responses, indomethacin 
has a potentiating effect on the contractile activity of the peptide on guinea-pig tracheal 
smooth muscle (Hay, 1990 & Henry et aL, 1990). The observation of such a 
potentiated response further supports the findings of this thesis by indicating that the
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ET-1 induced contractile response is limited by the release of substances sensitive to the 
actions of a cyclooxygenase inhibitor. However, indomethacin (25|iM) has been 
demonstrated to have no effect on the ET-1 induced contractile response on isolated 
bovine tracheal smooth muscle (Kamm et aL, 1989), nor on human isolated bronchus 
(McKay etal., 1991b) thereby suggesting a direct action of ET-1 on the smooth muscle 
and further suggests a species variation in the mechanism of action of ET-1, supporting 
the lack of effect of indomethacin on the ET-1 induced response on rat tracheal smooth 
muscle observed in this study. The action of ET-1 on isolated guinea-pig tracheal 
smooth muscle has also been shown to be attenuated, both in vivo and in vitro, in the 
presence of cyclooxygenase inhibitors, indicating that the peptide induces the release of 
a contractile product of cyclooxygenase which contributes to the overall constrictor 
activity of ET-1 (Maggi et aL, 1989c; Sarria et aL, 1990; Filep et aL, 1991a; Pons et 
aL, 1991b & White etal., 1991). Such observations however, although suggesting an 
indirect action of ET-1, are contradictory to the findings presented in this thesis. Some 
researchers have indicated that the attenuated response to ET-1 observed in the presence 
of indomethacin, is due to the inhibition of thromboxanes which mediate a contractile 
response on the airway smooth muscle (Whittle et aL, 1989; Battistini et aL, 1990b & 
Filep et aL, 1991a). Thromboxane receptor antagonists BM 13177 (Whittle et aL, 1989 
& Battistini et aL, 1990b) and BM 13505 (Battistini et aL, 1990b & Filep et aL, 1991) 
inhibited ET-1 induced contractions of guinea-pig respiratory smooth muscle 
suggesting that the contractile response to ET-1 is mediated indirectly via the release of 
thromboxanes. Thromboxanes are not implicated in the ET-1 induced response on 
guinea-pig tracheal smooth muscle observed in this study. Indomethacin inhibits the 
formation of both prostaglandins and thromboxanes, and in this study inhibits the ET-1 
induced relaxation responses on guinea-pig tracheal smooth muscle and potentiates the 
contractile action. If thromboxanes were involved in the ET-1 induced contractile action 
then an attenuation of the ET-1 response would be expected in the presence of 
indomethacin, the absence of such an effect and the abolition of the ET-1 induced
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relaxation responses suggests that prostaglandins rather than thromboxanes are 
involved in the mediation of the ET-1 induced effects observed here.
It has been suggested that at high concentrations indomethacin acts as a calcium channel 
antagonist and the responses to ET-1 observed in this study are a consequence of 
calcium channel inhibition rather than cyclooxygenase inhibition. However, the profile 
of ET-1 induced responses in the presence of a calcium channel inhibitor (see section 
4.3 & Figures 16-18) is completely different to that observed in the presence of 
indomethacin, in both rat and guinea-pig tracheal smooth muscle, thereby excluding the 
possibility that indomethacin is blocking Ca^+ channels.
4.4.2 The Effect of Tracheal Epithelium Removal on the ET-1 Induced 
Response
The epithelium is considered to possess a regulatory role in the control of airway 
smooth muscle function, therefore, removal of the epithelium and thus the regulatory 
role, alters the responsiveness of a variety of both bronchoconstrictor and 
bronchorelaxant agents. The airway epithelium has been proposed as a source of both 
prostanoid and non-prostanoid inhibitory factors (Hay et al., 1986), or alternatively 
may be considered as a site of metabolism of some bronchoactive agents (Devillier et 
al., 1988). The response of the airway smooth muscle to the tachykinins has been 
shown to be potentiated by the removal of the epithelium (Tschirhart et al., 1987; 
Devillier et al., 1988 & Frossard et al., 1989), thereby suggesting that within the 
airway epithelial cells are substances which breakdown the tachykinins and inhibition 
of these substances prevents the degradation of the peptide resulting in an enhanced 
response.
Experiments performed with the cyclooxygenase inhibitor indomethacin on the ET-1 
induced response on guinea-pig tracheal smooth muscle have indicated that the
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response to the peptide is limited by the release of relaxant products of cyclooxygenase. 
Furthermore, cyclooxygenase has been localized to the tracheal epithelium (Xu et al., 
1986), therefore, removal of the epithelium should mimic the action of cyclooxygenase 
inhibition on the ET-1 induced response on guinea-pig tracheal smooth muscle. 
Verification of tracheal epithelium removal was provided by the absence of a relaxation 
response to O.lmM arachidonic acid and by histological techniques. Dosing the tissue 
with arachidonic acid tended to affect subsequent responses to other drugs, therefore 
verification of the method of tracheal epithelium removal using arachidonic acid was 
undertaken on separate tissues and the procedure of removal repeated on those 
experimental tissues.
Epithelium removal failed to have any effect on the contractile response of both rat and 
guinea-pig tracheal smooth muscle to CCh (0.1-100jiM). In each case the maximum 
contractile tension generated in response to CCh was not significantly different in 
epithelium intact and denuded tissues, thereby suggesting that CCh acts directly on the 
smooth muscle and the response is neither mediated nor modulated by substances 
released from the tracheal epithelium.
Removal of the epithelium from rat tracheal smooth muscle did not modify the 
contractile response to ET-1 (O.Ol-lpM). No significant difference was observed in 
both the calculated EC50 value and the maximum tension generated in response to the 
peptide. Such results indicate that the response to ET-1 on rat tracheal smooth muscle is 
not influenced by epithelium derived inhibitory factors and rather suggests that in such 
tissue preparations the peptide exerts its action directly on the smooth muscle. Such 
findings confirm the results of experiments performed with ET-1 on rat tracheal smooth 
muscle in the presence of indomethacin (section 4.4.1) and peptidase inhibitors (section 
4.2), where inhibition of both cyclooxygenase and peptidase enzymes, both known to 
be located within tracheal epithelium, failed to influence the response of the smooth 
muscle to the peptide. Confirmation of the lack of effect of epithelium removal on the
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ET-1 induced response on rat tracheal smooth muscle has been provided by Henry et 
ai, (1992), who demonstrated that the tracheal epithelium has no significant influence 
on the responsiveness of the smooth muscle to the peptide, thus supporting the direct 
mode of action of ET-1 indicated in this study.
The response of epithelium denuded tracheal smooth muscle of the guinea-pig to ET-1 
was not significantly different from that observed in epithelium intact tissues. The ET-1 
induced relaxation responses were very much in evidence and were of a similar 
magnitude and pattern of response to that observed in epithelium intact tissues. 
Similarly the contractile response of the smooth muscle to ET-1 was not significantly 
different to that observed in epithelium intact tissues, the response achieving 40-50% of 
the maximum contractile tension generated in response to CCh in both cases. Such 
results suggest that the response of the tracheal smooth muscle of the guinea-pig to ET- 
1 is not affected by the absence of a functional epithelium and furthermore suggests that 
the ET-1 induced relaxation responses are mediated via an inhibitory substance possibly 
released from the smooth muscle itself rather than the epithelium. Confirmation of the 
lack of effect of epithelium removal on the ET-1 induced response on guinea-pig 
tracheal smooth muscle has been provided by Cardell et a i, (1990) however, the role 
of the epithelium in the ET-1 induced response is equivocal. Hay, (1989) observed an 
increased responsiveness of the guinea-pig tracheal smooth muscle to ET-1 in the 
absence of a functional epithelium, thereby suggesting that the tracheal epithelium has a 
modulatory influence on the contractile activity of the peptide. In contrast however. 
White et a i, (1991), observed that removal of the tracheal epithelium from guinea-pigs 
in vivo, resulted in an attenuated contractile response to ET-1, furthermore, the ET-1 
induced relaxation responses were not affected by epithelium removal, thereby 
suggesting that the epithelium has a role in the contractile activity only and that the 
initial relaxation responses to ET-1 are not a function of the epithelium.
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To further investigate the response of epithelium denuded guinea-pig tracheal smooth 
muscle to ET-1, the tissues were incubated with 25|iM indomethacin for 30 minutes 
prior to cumulative dosing with ET-1. The ET-1 induced relaxation responses observed 
in epithelium denuded tissues were abolished in the presence of indomethacin. The 
maximum tension generated by epithelium denuded tissues to ET-1 was not 
significantly different from that generated by epithelium intact tissues, both in the 
presence of indomethacin, but was however, significantly potentiated when compared 
with the maximum tension generated by epithelium denuded tissues in the absence of 
indomethacin. The shape of the concentration response curve to ET-1 in the presence of 
indomethacin in epithelium denuded tissues depicted a much steeper relationship in 
response than that of epithelium intact tissues under the same experimental conditions. 
The contractile response to the lower concentrations of ET-1 (0.01-0.1|J.M) was 
significantly potentiated and furthermore, ET-1 was 3.5 fold more potent on epithelium 
denuded tissues in the presence of indomethacin than epithelium intact tissues in the 
presence of the cyclooxygenase inhibitor. Such a potentiation of response to ET-1 
observed in epithelium denuded tissues in the presence of indomethacin compared with 
epithelium denuded tissues in the absence of indomethacin suggests that the ET-1 
induced relaxant products which limit the contractile response of the peptide, are located 
within the smooth muscle itself rather than the tracheal epithelium. However, when 
comparing the response of epithelium denuded and intact tissue preparations, both in 
the presence of indomethacin, the potentiated response to ET-1 at lower concentrations 
in epithelium denuded tissues suggests that the epithelium does contribute some 
relaxant factors which limit the constrictor activity of the peptide. It is therefore 
interesting to note that in the absence of a functional epithelium the tracheal smooth 
muscle elicited a response to ET-1 which was not significantly different from that 
observed in epithelium intact tissue preparations. If the cyclooxygenase enzyme is 
located within the tracheal epithelium, then a profile of response similar to that observed 
on intact tracheal smooth muscle would be expected, however, it is possible that the 
contribution of epithelial derived relaxant factors is negligible when compared with that
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released from the smooth muscle itself. Reports have varied with respect to the role of 
the guinea-pig tracheal epithelium in the response to ET-1. Hay, (1990), reported that 
removal of the tracheal epithelium from guinea-pigs markedly potentiated the contractile 
response to ET-1, evidenced by a 4.7 fold increase in the EC50 value and an increase in 
the tension generated by 0.3|iM ET-1. However, it must be borne in mind that in this 
case all experiments were performed in the presence of 5|iM indomethacin, which was 
also shown to potentiate the contractile effects of ET-1 on intact tissue, therefore, the 
increase in potency observed by Hay (1990), confirms the findings of this study.
Grunstein et a i, (1991a) observed that removal of the epithelium from rabbit tracheal 
smooth muscle attenuated, rather than abolished the ET-1 induced relaxation responses. 
In the presence of indomethacin however, the relaxation responses were abolished. 
These findings suggest that the ET-1 induced relaxation responses of tracheal smooth 
muscle is dependent in part on both the integrity of the airway epithelium and on the 
release of a relaxant factor from the underlying smooth muscle. Confirmatory evidence 
for the ET-1 induced release of bronchoactive prostaglandins from airway smooth 
muscle was provided by the finding that dosing epithelium denuded tissues with ET-1, 
resulted in a significantly enhanced release of PGI2  and PGE2 compared with 
epithelium intact tissues, indicating that the source of the eicosanoids was not solely the 
airway epithelium and that the underlying smooth muscle plays a significant role in the 
ET-1 induced relaxation responses.
4.4.3 The Role of the Lipoxygenase Enzyme in the ET-1 Induced 
Response
The presence of the lipoxygenase inhibitor Nordihydroguaiaretic acid (NDGA) (lOpM) 
was shown to have no significant effect on the ET-1 induced contractile activity 
observed on rat tracheal smooth muscle, thereby indicating that the lipoxygenase
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metabolites of arachidonic acid play no part in the mediation of the ET-1 response on 
this tissue preparation. At the concentration of 10|iM the enzyme inhibitor NDGA, had 
previously been shown to attenuate the contractile activity of ET-1 on rat tracheal tissue 
preparations (Chand et a i, 1990) and it was for this reason that IOjiM NDGA was 
utilized in this study. The involvement of leukotrienes in the ET-1 induced response on 
rat tracheal smooth muscle was also observed by Henry et a i, (1992). NDGA (IOjiM) 
significantly inhibited the ET-1 induced response observed on rat tracheal smooth 
muscle, thereby indicating that the metabolites of the lipoxygenase enzyme released in 
response to ET-1, mediate in part, the contractile activity of the peptide. However, 
incubation of the tissue preparation with the leukotriene antagonist SKF 104353, failed 
to affect the ET-1 induced response and leukotrienes C4 and D4 were without effect on 
rat tracheal smooth muscle thereby suggesting that the effect of the lipoxygenase 
inhibitor on the ET-1 induced response is not due to the inhibition of leukotriene 
synthesis (Henry et a i, 1992). Such observations are in direct contrast to the findings 
of this study and once again illustrate the variability of tissue responses to ET-1. The 
lack of effect of NDGA on the ET-1 induced response on rat tracheal smooth muscle 
further supports the direct action of the peptide on this tissue preparation and confirms 
the original findings of Yanagisawa et al., (1988a), where NDGA (IOOjiM) failed to 
have any significant effect on the ET-1 induced response on porcine coronary artery 
strips, suggesting that ET-1 does not induce the release of the products of the 
lipoxygenase enzyme.
The lipoxygenase inhibitor failed to have any effect on the relaxation response induced 
by O.lmM arachidonic acid on guinea-pig tracheal smooth muscle, thereby indicating 
that the metabolites of the lipoxygenase enzyme are not involved in the relaxation 
responses induced by arachidonic acid. Incubation of guinea-pig tracheal smooth 
muscle with NDGA prior to exposure to ET-1 had a significant inhibitory effect on the 
ET-1 induced contractile response. The contractile response to ET-1 was abolished in 
the presence of NDGA indicating that the metabolites of the lipoxygenase enzyme are
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involved in the ET-1 induced contractions. However, closer examination revealed the 
presence of two types of response to ET-1 in the presence of NDGA; (i) no contractile 
response observed to ET-1 and (ii) slight contractile response at 0.05 and 0.1 pM ET-1 
which subsequently returns to the initial level of response. In contrast, NDGA had no 
effect on the relaxation responses to O.l-ljiM ET-1. It has previously been shown that 
the relaxation responses induced by ET-1 on this tissue preparation are due to the ET-1 
induced release of the products of the cyclooxygenase enzyme. Inhibition of the 
lipoxygenase enzyme leads to the selective formation of the products of the 
cyclooxygenase enzyme, therefore resulting, on the guinea-pig tracheal smooth muscle, 
in the potentiation of relaxation responses. Therefore, the biphasic response to ET-1 
observed on guinea-pig tracheal smooth muscle involves the products of both the 
cyclooxygenase and lipoxygenase enzyme, mediating relaxant and contractile responses 
respectively.
In contrast, Saotome et ai, (1991), showed that the ET-1 induced relaxation response 
observed on sensitized guinea-pig tracheal strips were sensitive to the actions of the 
lipoxygenase inhibitors NDGA (lOpM) and AA-861 (30|iM), whereas inhibition of the 
cyclooxygenase enzyme had no effect, thereby indicating that the metabolites of the 
lipoxygenase enzyme contribute to the ET-1 induced relaxation responses. Such 
observations however, are in direct contrast to those observed in this study. Others 
have shown that NDGA and FPL 55712 (a leukotriene receptor antagonist), have no 
effect on the intra-arterial (i.a.) ET-1 induced bronchopulmonary response thereby 
suggesting that the lipoxygenase metabolites of arachidonic acid are not involved in the 
mediation of response on guinea-pig isolated lungs (Pons et a i, 1991b). Such studies 
confirmed the lack of effect of leukotriene receptor antagonist SKF 104353, on the ET- 
1 induced response observed on guinea-pig tracheal smooth muscle (Hay, 1990), 
suggesting a direct mode of action of the peptide on this tissue preparation. However, 
since then the antagonists of the sulphidopeptide leukotrienes FPL 55712 and YM 
16638, have been shown to attenuate the contractile activity of ET-1 on guinea-pig
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isolated airways (trachea, bronchus and lung parenchyma), thereby indicating the 
involvement of the metabolites of the lipoxygenase enzyme in the mediation of the 
contractile response to ET-1 (Filep et a i, 1991a). Such results confirm the findings of 
this study with respect to the involvement of the metabolites of the lipoxygenase 
enzyme in the ET-1 induced response and further confirm the indirect action of ET-1 on 
airway smooth muscle, however, the precise involvement of lipoxygenase may only be 
fully established by the use of specific leukotirene receptor antagonists in this study. 
Furthermore, such discordant results are once again indicative of the variability in the 
ET-1 induced effects on airway smooth muscle and the ability of ET-1 to induce release 
of the products of the lipoxygenase enzyme varies from tissue preparation to 
preparation.
4.4.4 Involvement of Platelet Activating Factor in the ET-1 Induced 
Response
Platelet activating factor (PAF), is a potent mediator of lung mechanical changes 
indicative of bronchoconstriction in vivo (for review see Barnes et al., 1988). 
Furthermore, the binding of radiolabelled PAF receptor antagonist [3h]WEB 2086 to 
specific sites on membrane fractions from homogenized guinea-pig and human lungs 
and the competitive displacement of such binding by PAF suggests that the sites are 
PAF receptors (Dent et al., 1989). The finding that the specific receptor antagonist of 
PAF, BN 52021, diminished the bronchoconstrictor actions of ET-1 in the guinea-pig 
in vivo (Lagente et al., 1989) suggested that the action of ET-1 may be mediated in part 
by PAF.
Rat tracheal smooth muscle was shown (this study) to be insensitive to the actions of 
PAF, thereby indicating the absence of specific PAF receptors. Due to the insensitivity 
of this tissue preparation to PAF, the effects of the PAF antagonist [l-O-Hexadecyl-2-
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acetyl-sn-glycero-3 phospho(N,N,N-trimethyl)hexanolamine] were not evaluated and 
the contractile action of ET-1 was not considered to be an indirect action of PAF. In 
support of the lack of involvement of PAF in the ET-1 induced response on rat tracheal 
smooth muscle, Henry et al., (1992) showed that the PAF antagonist WEB 2086 was 
without effect on the ET-1 induced contractile activity.
In contrast, guinea-pig tracheal smooth muscle exhibited relaxation responses upon 
cumulative dosing with PAF. Incubation with the PAF antagonist prior to exposure of 
the tissue to PAF resulted in the abolition of the PAF induced relaxation responses. The 
contractile responses to ET-1 however, observed on guinea-pig tracheal smooth muscle 
in the presence of the PAF antagonist, exhibited a slight but not significant attenuation 
in response. The absence of effect of the PAF antagonist on the ET-1 induced 
contractile response indicates the non-involvement of PAF in the observed response. 
Confirmatory evidence for the lack of involvement of PAF in the ET-1 induced 
response on guinea-pig tracheal smooth muscle was provided by Hay & Undem,
(1991) where WEB 2086 was shown to have no effect on the ET-1 induced response. 
Other researchers however, have indicated that the ET-1 induced contractile response 
on guinea-pig airways is attenuated both in vitro (Battistini et ai, 1990b & Filep et a l, 
1991a) and in vivo (Braquet et a l, 1989), thereby suggesting that PAF induces a 
contractile response on these tissues and is released in response to ET-1. Furthermore, 
cross desensitization experiments with ET-1 and PAF lend further support to the 
involvement of PAF in the ET-1 induced response (Battistini et a l, 1990b). The effects 
of PAF are conflicting, in this study PAF induces relaxation responses on guinea-pig 
tracheal smooth muscle, whereas in others the PAF induced response is that of 
contraction. However, studies examining the effects of PAF on guinea-pig isolated 
large airways and parenchymal strips have reported both contractile and relaxant 
responses (reviewed by Halonen et a l, 1990). It is possible that PAF applied to 
different preparations of isolated airways may be bound and/or metabolized to various 
extents by the exterior surface of the tissues, and consequently, in certain preparations
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PAF cannot reach the contractile tissues which may be less accessible (Halonen et a l,
1990). The ET-1 induced contraction of lung parenchymal strips has been shown to be 
associated with an increase in TXA2 formation, (Filep et a l, 1991a) furthermore, it is 
thought that the contractile activity of PAF is dependent on TXA2  formation (Lefort et 
a l,  1984) and it is reasonable to consider that the enhanced formation of TXA% in 
response to stimulation with ET-1 may be in part, a consequence of increased synthesis 
of PAF. However, in this study, it appears that TXA2 is not involved in the ET-1 
induced response, evidenced by the potentiating effect of indomethacin on the 
contractile response to ET-1 (section 4.4.1) and the lack of contractile effect to PAF 
further negates such findings.
The potentiation of the relaxation responses to 0.05-IfiM ET-1 was somewhat 
unexpected. The viability of the PAF antagonist was demonstrated by its inhibitory 
effects on the PAF induced response, therefore, it would seem very unlikely that the 
potentiation of the relaxation responses to ET-1 in the presence of the antagonist were 
due to the ET-1 induced release of PAF itself. It is possible that the PAF antagonist 
inhibits a non-specific contractile factor released by ET-1, the effects of which 
overcome the relaxation responses, however, this seems unlikely as the ET-1 induced 
contractile responses were not attenuated to a significant level.
4.5 EFFECT OF ET-1 INDUCED TACHYPHYLAXIS ON TRACHEAL 
SMOOTH MUSCLE
The term tachyphylaxis is synonymous with desensitization, and both terms are used to 
describe the diminished effect of a drug when given repeatedly or continuously, the 
effects may become apparent within a few minutes. Many different mechanisms can 
give rise to this type of phenomenon including a change in the receptor(s), loss of 
receptors, exhaustion of mediators and physiological adaptation. The response to ET-1
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has been shown to exhibit tachyphylaxis upon repeated administration in anaesthetized 
cats (Le Monnier de Gouville et a i, 1990a) and rats (Le Monnier de Gouville et a i,
1991), therefore, the effects of repeated administration of ET-1 were evaluated with 
respect to its effect on the tracheal smooth muscle of both the rat and guinea-pig.
4.5.1 Effect of Repeat Cumulative Dosing with ET-1
Repeat cumulative dosing with ET-1 on rat tracheal smooth muscle resulted in a marked 
attenuation of the contractile response, indicating that in this tissue preparation repeat 
dosing with ET-1 does induce a tachyphylactic response. Le Monnier de Gouville et 
aLy (1990c), showed that repeated administration of ET-1 to anaesthetized rats resulted 
in a tachyphylactic response to the peptide, evidenced by a progressive decrease in the 
ET-1 induced hypotensive response, furthermore, it was suggested that stimulation of 
the endothelin receptors might liberate a hypotensive substance which is easily 
depletable, thereby accounting for the observed attenuation in response. Whilst it is 
apparent in this study that rat tracheal smooth muscle does display a tachyphylactic 
response to repeat cumulative dosing with ET-1, the explanation for such action is more 
complex. From the studies presented in this thesis, it is apparent that on rat tracheal 
smooth muscle, the action of ET-1 does not involve the induced release of the products 
of the cyclooxygenase and lipoxygenase enzymes nor the action of platelet activating 
factor, therefore, the reduced response observed to repeated ET-1 cannot be accounted 
for by a depletion in secondary mediators. However, the contractile action of ET-1 has 
been shown to involve the influx of extracellular Ca^+ via the dihydropyridine sensitive 
Ca2+ channel (see section 4.3.2). It is possible that the ET-1 receptors undergo 
conformational changes, resulting in binding of ET-1 to its receptor without opening or 
only limited opening of the ion channel, resulting in a reduced response; or that 
membrane internalization of receptors occurs, effectively decreasing the population of 
viable receptors, thus on repeat cumulative dosing with the peptide the number of viable
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receptors capable of mediating a response are reduced, thereby effectively reducing the 
tissue response to the peptide. Direct evidence to support such hypotheses is lacking, 
however, binding studies with [12f>I]ET-l indicate that prolonged exposure of 
membrane preparations to ET-1 results in a decrease of the number of available binding 
sites (Hirata et a l, 1988).
Similarly, the ET-1 induced contractile responses observed on guinea-pig tracheal 
smooth muscle displayed tachyphylaxis upon repeat cumulative dosing with the 
peptide. Interestingly, however, the ET-1 induced relaxation responses did not display 
tachyphylaxis. A similar biphasic response to ET-1 has been observed in anaesthetized 
cats (Le Monnier de Gouville et a i, 1990a), however, repeat administration of ET-1 
induced tachyphylaxis to the ET-1 induced depressor responses only. Such an 
observation is directly contradictory to those made in this study. It has been shown that 
on guinea-pig tracheal smooth muscle, the ET-1 induced contractile responses are 
mediated via the release of the arachidonic acid metabolites of the lipoxygenase enzyme, 
therefore it is possible that repeat cumulative dosing with ET-1 depletes the endogenous 
store of these contractile mediators resulting in tachyphylaxis. However, the degree of 
tachyphylaxis observed on guinea-pig tracheal tissue has been shown to be variable and 
is dependent upon the initial concentration response curve to the peptide. Those tissues 
which exhibited an initial response to ET-1 of < 50% of the maximum contractile 
tension induced by CCh did not display a significant degree of tachyphylaxis upon 
repeat administration, whereas those tissues which displayed an initial response to ET-1 
of > 50% of the contractile tension induced by CCh, exhibited a marked attenuation of 
response upon repeat cumulative dosing with the peptide. In contrast, the ET-1 induced 
relaxation responses in each response group did not vary between the initial and repeat 
administration of the peptide. The reasons for such discrepancies are unclear, but may 
possibly indicate that receptor numbers may vary from one tissue preparation to another 
and that in some tissue preparations ET-1 dissociates more readily from its receptor.
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4.5.2 Effect of Repeat Single Dosing with ET-1
The effects of repeat (x5) single dosing with three different concentrations of ET-1 
were performed on rat tracheal smooth muscle to observe whether the tachyphylaxis 
induced by ET-1 occurred following single concentrations of the peptide, and whether 
the response recovered within the period of exposure to each concentration of the 
peptide. Rat tracheal smooth muscle dosed with 0.05|iM ET-1 displayed an attenuated 
response on the fifth dose of the peptide only, whereas at higher concentrations (0.5 & 
IjiM) an attenuated contractile response was observed on application of the third dose 
and then this level of response was maintained through to the fifth dose. Evidently ET- 
1 induced tachyphylaxis was more prominent at the higher concentrations of the peptide 
possibly suggesting that at these concentrations ET-1 binds more tightly to its receptor 
with only limited dissociation, thus on subsequent application of the peptide the number 
of viable receptors to mediate the contractile response is reduced, furthermore, recovery 
of response did not occur within the experiment. The precise mechanism for such a 
response cannot be evaluated from these studies, but as stated previously, the ET-1 
induced response on rat tracheal smooth muscle does not involve the release of 
secondary mediators and therefore the attenuated response is not due to depletion of 
endogenous stores of such mediators. The maximum response induced by l|iM ET-1 
was not significantly different from the maximum response induced by ET-1 (IjJ-M) 
upon cumulative dosing with the peptide, indicating that within the cumulative 
concentration response curve, the maximum response to the peptide is not affected by 
previous applications of the peptide.
In contrast, guinea-pig tracheal smooth muscle did not display a tachyphylactic 
response to 0.05gM ET-1, neither the contractile nor the relaxant responses to ET-1 
were attenuated despite repeated application of the peptide. At a higher concentration of 
the peptide (0.5|iM) only the ET-1 induced relaxation responses displayed
2 0 7
tachyphylaxis, the response was attenuated on the administration of the second dose of 
the peptide and this reduction in magnitude was then maintained. Such a pattern of 
response is contradictory to the observations of Le Monnier de Gouville et al., (1990a) 
where a progressive reduction in the ET-1 induced depressor response occurred upon 
repeat administration of the peptide. However, in agreement with Le Monnier de 
Gouville et al., (1990a) the contractile responses to ET-1 did not display tachyphylaxis. 
At IpM ET-1 however, the ET-1 induced contractile responses exhibited 
tachyphylaxis, the degree of attenuation of response maintained from the second to the 
fifth application of the peptide. It is interesting to note the disparity in response 
observed between repeat cumulative and repeat single dosing with the peptide with 
respect to the ET-1 induced relaxation responses; no tachyphylaxis was observed with 
repeat cumulative dosing, whereas with single applications of the higher concentrations 
of ET-1 an attenuated response was observed.
Indomethacin has been shown to inhibit the ET-1 induced relaxation responses 
observed on guinea-pig tracheal smooth muscle, whereas on rat tracheal smooth muscle 
preincubation with indomethacin has no effect on the ET-1 induced response (see 
section 4.3.1). The effects of repeat single dosing with ET-1 in the presence of 
indomethacin were examined on guinea-pig tracheal smooth muscle. In the presence of 
indomethacin tachyphylaxis was observed at each concentration of the peptide, whereas 
in the absence of the cyclooxygenase inhibitor, tachyphylaxis of the ET-1 induced 
contractile response was observed at the highest concentration of ET-1 only. At the 
higher concentrations of ET-1 in the presence of indomethacin a progressive attenuation 
of response was observed, whereas at the lowest concentration the degree of 
tachyphylaxis observed upon application of the second dose of ET-1 was maintained 
throughout. As was observed on rat tracheal smooth muscle, no recovery of response 
was apparent. Cardell et a i, (1990) observed marked ET-1 induced tachyphylaxis on 
guinea-pig pulmonary arteries and veins, whereas on tracheal tissue preparations the 
tachyphylaxis reaction upon reapplying ET-1 was shown to be rather weak. Further
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studies revealed that upon reapplication of single concentrations of the peptide on 
guinea-pig pulmonary arteries no or occasionally a small transient contraction was 
observed, whereas on guinea-pig tracheal tissue preparations, reapplication of a single 
concentration of the peptide induced a response which was not significantly different 
from that observed on the initial dose, thereby suggesting that on tracheal tissue, ET-1 
does not induce tachyphylaxis (Cardell et #/., 1992). Such observations appear to be 
directly contradictory to those of this study however, only two applications of the 
peptide were considered by Cardell and coworkers and it is possible that at the 
concentrations studied, the tachyphylactic responses are only observed on further 
application of ET-1, or conversely ET-1 induced tachyphylaxis is only observed at 
higher concentrations of the peptide.
The response to ET-1 in the presence of indomethacin provides further evidence to 
indicate that the ET-1 induced relaxation responses limit the contractile activity of the 
peptide. It is also interesting to note that the maximum response induced by 0.5jiM and 
IpM ET-1 was equivalent and furthermore, the maximum contractile response induced 
by a single application of ET-1 (IpM) was significantly greater than that induced by 
IjiM ET-1 on cumulative dosing in the presence of indomethacin. Therefore, it is 
possible that a degree of tachyphylaxis to the ET-1 induced response occurs on 
cumulative dosing with the peptide. Furthermore, it is possible that the mechanism of 
ET-1 induced tachyphylaxis is multifactorial and that depletion of endogenous 
lipoxygenase metabolites of arachidonic acid are not solely responsible for the 
attenuation in contractile response observed. The variation in the degree of ET-1 
induced tachyphylaxis observed both in the absence and presence of indomethacin 
suggests a more complex mechanism of action.
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4.6 BINDING OF [125i]ET-l TO RAT AND GUINEA-PIG TRACHEAL 
SMOOTH MUSCLE
The protein dilution profiles constructed for both the rat and guinea-pig tracheal smooth 
muscle were inconsistent and gave very little information as to the best concentrations 
of protein to utilize in the subsequent saturation assays. Other researchers (Bolger et 
al.y 1990b) had used 5-10|J,g of tracheal protein throughout experiments, however, in 
view of the limited amount of protein available in this study for binding assays, it was 
decided to use 4|ig and 2|ig of tracheal smooth muscle protein for the rat and guinea- 
pig respectively. It is interesting to note that in those tracheal tissues which had been 
pre-exposed to ET-1, the amount of protein per trachea was significantly reduced, 
suggesting that leeching of available protein occurred.
Saturation assays were performed with concentrations of [125i]ET-l arranged around 
the Kd values obtained from the literature. Total binding increased with an increase in 
[125]]et_i concentration, however,saturablebinding remained very low with the non­
specific binding closely paralleling the total binding. These observations were 
consistent in both the rat and the guinea-pig. Contrary to such observations however, 
the non-specific binding (expressed as a % of the total) varied from only 14-19% for 
lung parenchymal membranes of both the rat and the guinea-pig (Bolger et a l, 1990b). 
Varying the concentrations of ligand used did not improve the saturation plots so 
obtained and although saturablebinding was achieved it was negligible when compared 
with the non-specific binding which remained very high.
Increasing the amount of protein used in the assay to an absolute maximum, 15.6]ig for 
the rat and 10|ig for the guinea-pig limited the number of concentrations of the ligand 
able to be used, therefore the maximum concentration of ligand previously used in 
saturation assays was utilized. However, in doing so, thesaturablebinding of [125%]ET- 
1 to rat tracheal smooth muscle was potentiated indicating that saturablebinding sites for
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ET-1 do exist Furthermore, the non-specific binding was reduced accordingly to ~35% 
of the total binding. Specific binding sites for [125i]ET-l have been identified on 
guinea-pig trachea (Power et a i, 1989; Bolger et a i, 1990b & Henry et a i, 1990) and 
lung (Kanse et al., 1989 & Hemsen et a i, 1990), similarly binding sites have been 
identified on guinea-pig tracheal smooth muscle in this study and it is possible that by 
reducing the non-specific binding to an acceptable level, the saturablebinding would be 
improved. Bolger et al., (1990b) demonstrated that [^^I]ET-1 binding was sensitive 
to the presence of cations in the binding assay. Therefore, it is possible that inclusion of 
cations in the assay would have decreased the non-specific binding to an acceptable 
level. Unfortunately, the lack of radiolabel prevented further experiments with guinea- 
pig tracheal smooth muscle homogenate being undertaken and therefore, the effects of 
further reducing the non-specific binding were unable to be evaluated.
!
It is possible that the lowsaturablebinding observed in this study may correlate with the 
poor response induced by ET-1 in functional assays on guinea-pig tracheal smooth 
muscle. However, others (Turner et ai, 1989b & Bolger et a i, 1990b) have failed to 
observe a correlation between the density of [^^I]ET-1 binding sites and the efficacy 
of ET-1 inducing contractions on rat tissues. Indeed, Turner et a i, (1989b), whilst 
demonstrating the potency of ET-1 on rat tracheal tissue to be in the jxM range, showed 
the Kd of [125i]ET-l binding to the same tissue to be in the nM range. It was intended 
to investigate the effects of preincubation of tracheal smooth muscle with ET-1 on the 
binding of [1^I]ET-1, however, the lack of radioligand prevented such experiments 
being pursued.
4.7 CONCLUSIONS
The wide diversity in potency estimates of the action of endothelin-1 (ET-1), on 
isolated respiratory smooth muscle (Table 12), indicates the variability in the ET-1 
induced response observed between laboratories. In this study, ET-1 has been shown
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to be far less potent on rat and guinea-pig tracheal smooth muscle than that originally 
reported by Uchida et a i, (1988). Although ET-1 induces a consistent contractile 
response on rat tracheal smooth muscle, on guinea-pig tracheal smooth muscle ET-1 
displays great variability in response with contractile responses being preceeded by 
transient, non dose related relaxation responses. The relaxation responses limit the 
constrictor action of the peptide and consequently reduces its potency. Furthermore, the 
presence of two qualitatively distinct responses observed on guinea-pig tracheal smooth 
muscle, further demonstrated the variability in this tissue response to ET-1.
The ET-1 induced response on both rat and guinea-pig tracheal smooth muscle has been 
shown to be unaffected by preincubation with inhibitors of aminopeptidase, angiotensin 
converting and neutral endopeptidase enzymes, indicating that degradation of the 
peptide by these enzymes does not occur within the tracheal smooth muscle. The action 
of ET-1 on guinea-pig tracheal smooth muscle has been shown to be a consequence of 
the ET-1 induced release of secondary mediators. Indomethacin, a cyclooxygenase 
enzyme synthesis inhibitor, abolished the ET-1 induced relaxation responses, indicating 
that such responses are a consequence of the ET-1 induced release of relaxant products 
of cyclooxygenase. Inhibition of the relaxation responses potentiated the ET-1 induced 
contractile responses and thus increased the potency of the peptide on this tissue 
preparation. Furthermore, the contractile activity of the peptide on guinea-pig tracheal 
smooth muscle has been shown to be due to the ET-1 induced release of the 
lipoxygenase metabolites of arachidonic acid, evidenced by the inhibitory effect of the 
lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA). In contrast, the ET-1 
induced response observed on rat tracheal smooth muscle was unaffected by 
preincubation with indomethacin and NDGA, thereby supporting the direct mode of 
action of this peptide on rat tracheal smooth muscle. Removal of the tracheal epithelium 
failed to affect the ET-1 induced response observed on rat tracheal smooth muscle 
indicating that the epithelium does not modulate the peptide induced response. The 
effects of tracheal epithelium removal on the ET-1 induced response on guinea-pig
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tracheal smooth muscle however, were only observed in the presence of indomethacin, 
demonstrating that both the tracheal smooth muscle and epithelium release ET-1 
induced relaxant metabolites of the cyclooxygenase enzyme, although the contribution 
of such metabolites differs between the two.
Some researchers have suggested that the ET-1 induced contractile responses are a 
consequence of the induced release of platelet activating factor (PAF) (Battistini et a i, 
1990b & Filep et a l, 1991a). However, rat tracheal smooth muscle was shown in this 
study to be insensitive to the actions of PAF itself. In contrast, guinea-pig tracheal 
smooth muscle displayed relaxation responses to PAF; preincubation with the PAF 
antagonist however, failed to affect the ET-1 induced contractile response indicating the 
non-involvement of PAF in this response.
ET-1 was originally postulated to be an endogenous agonist of the dihydropyridine 
Ca2+ channel (Yanagisawa et a i, 1988a). The ET-1 induced response on both rat and 
guinea-pig tracheal smooth muscle was unaffected by incubation in a reduced Ca^+ 
containing buffer. In the presence of the Ca^+ channel antagonist nicardipine however, 
an attenuation of the ET-1 induced contractile response was observed on rat tracheal 
smooth muscle indicating the requirement of influx of extracellular Ca2+ via the 
dihydropyridine sensitive Cs?+ channel, for the expression of full constrictor activity 
of the peptide. The ET-1 induced response observed on guinea-pig tracheal smooth 
muscle however, was unaffected by preincubation with nicardipine.
Studies using repeated full cumulative dosing and repeated single dosing techniques 
with 0.05p,M, 0.5|iM and l|iM ET-1 demonstrated tachyphylaxis to ET-1 in both the 
rat and the guinea-pig. However, the degree of tachyphylaxis observed on repeat 
cumulative dosing in the guinea-pig was dependent upon the initial response to the 
peptide. Furthermore, the tachyphylaxis observed on repeat single dosing with the 
peptide in this species was more prominent in the presence of indomethacin. On rat
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tracheal smooth muscle, the degree of ET-1 induced tachyphylaxis was greater at the 
higher concentrations of the peptide.
Binding studies performed with [125i]ET-l indicated the presence of saturable binding 
sites for the peptide on the tracheal smooth muscle of both the rat and the guinea-pig, 
however, such studies were limited by the high degree of non-specific binding. 
Increasing the concentration of protein used potentiated the saturable binding and 
reduced the non-specific binding to an acceptable level with the rat, whereas only a 
slight potentiation of saturablebinding was observed with the guinea-pig, however, the 
lack of radioligand prevented further experimentation.
4.7.1 Further Studies
1. It was intended to investigate the effects of preincubation of tracheal smooth muscle 
with ET-1 on the binding of [^^I]ET-1, however lack of ligand prevented such 
experiments being pursued. However, the rationale behind such intentions may be 
expanded upon. The effects of ET-1 have been shown to be characteristically long 
lasting and resistant to 'wash out' and moreover exhibit tachyphylaxis upon repeat 
dosing. It was intended to observe whether such responses were due to the tight 
association of the peptide with its binding site, thus decreasing the number of available 
sites for further applications of the peptide. Indeed, Hirata et a l, (1988) showed that a 
decrease in the number of available binding sites occurred following prolonged 
exposure to the peptide. Furthermore, pre-exposure of atrial tissue to ET-1 has been 
shown to produce a reduction in [125i]ET-l binding (Bolger et a l, 1990b). Therefore, 
it is possible that pre-exposure of the tracheal tissue to ET-1 could result in a reduction 
of [125i]ET-l binding.
2. Further characterization of the ET-1 induced contractile response observed on 
guinea-pig tracheal smooth muscle with respect to the actions of the lipoxygenase
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enzyme, would further clarify the mechanism of action of the peptide. Henry et a l, 
(1992) have suggested that the attenuation in contractile response to ET-1 observed on 
rat tracheal smooth muscle in the presence of NDGA, is not a consequence of 
leukotriene inhibition as the leukotriene antagonist SKF 104353 was without effect, 
indicating the possible involvement of a novel lipoxygenase sensitve metabolite in the 
ET-1 induced response.
3. Grunstein et a l, (1991b) have indicated that the ET-1 induced response varies 
maturationally in the rabbit airways. It is possible that the wide diversity of responses 
to the peptide observed on both rat and guinea-pig tracheal smooth muscle is a 
conseqence of age-related development in response and therefore, studies looking at the 
ontogeny of the ET-1 induced response represents an area of potential information with 
respect to the mechanism of action of the peptide.
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